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Part 1. Two-step Synthesis of Multi-substituted Amines 
 
Chapter 1. Introduction 
1-1. Features of N-Alkoxyamine Derivatives 
Not only Weinreb amide but other N-alkoxyamine derivatives possess various features 
originated from conflicting nature of “electronegativity” and “unshared electron pair” of the 
oxygen atom in the N-alkoxy group. Herein, the important effects of N-alkoxy group positively 
assisting various type of reaction are summarized (Figure 1-1). For example, while a carbonyl 
oxygen atom is the most nucleophilic site in an ordinary amide 1, a nitrogen atom becomes the 
most nucleophilic in N-methoxyamide 2 (effect A). This is because the inductive electron 
withdrawal of the alkoxy group and the acyl group competes within each other. In addition, the 
electron withdraw effect of the methoxy group also increases the electrophilicity of the carbonyl 
group (effect B).1 Comparing an ordinary N,O-acetal 3, N,O-acetal 4 can be stabilized by 
formation of a five-membered chelation, which plays an important role in Weinreb ketone 
synthesis2 by preventing C-O or N-O bond cleavage (effect C). In addition, a chemoselective 
nucleophilic addition of Grignard reagent to an ester in the presence of an aldehyde or a ketone 
reported by Colby and co-workers also use chelation effect.3 Compared to ordinary iminium ion 
5, the inductive electron withdrawal of the methoxy group also leads to increase in electrophilicity 
of oxyiminium ion 6 (effect D).4 Furthermore, the methoxy group serves as a unique protecting 
group of the nitrogen atom, removable with a mild single electron reducing agent such as SmI2, 
Mo(CO)6, or Zn/acid (compound 7 or compound 8, effect E).5,6,7 Besides the characteristic 
conditions for cleaving N-O bond, the N-methoxy group is sterically the smallest protecting group, 
which would be advantageous for various reactions occurring around nitrogen atom (effect F). 
 
Figure 1-1. Features of N-alkoxyamine derivatives 
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1-2. N-Methoxyamide (Weinreb Amide)8 
Chida-Sato research group has been exploring new synthetic strategies that take advantage of 
a heteroatom-heteroatom bond for the synthesis of biologically active complex natural products. 
The connection of a heteroatom and another heteroatom opens it up to new reactivities as 
represented by -effect of hydroperoxide, 9 and chelation effect of Weinreb amide.2 In 1981, 
Weinreb and co-workers reported a reliable method to access ketone from carboxylic acid 
derivative (Scheme 1-1A, 9→10→11). Treatment of Weinreb amide 9 with organometallic 
reagent ‘R2M’ leads to the formation of the five-membered chelated intermediate 10, which 
prevents the addition of second nucleophile. And sequential workup gives ketone 11 without the 
formation of tertiary alcohol 12. Secondary N-methoxyamide 13 shows a unique reactivity 
originated from the adjacent methoxy group (Scheme 1-1B, 13→14→16→17).10 Treatment of 
N-methoxyamide 13 with PhI(OCOCF3)2 (PIFA) results in formation of N-allylated 
methoxyamide 17 via aziridinium ion 16 generated by concerted insertion of allylsilane to 
acylnitrenium ion 14. Driving forth of producing highly reactive species 14 is the resonance 
stabilization of nitrenium ion (14↔15). 
   
Scheme 1-1. Unique reactivities of N-alkoxyamide 
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1-3. Reductive Nucleophilic Addition to N-Methoxyamide 
The reductive functionalization of amides is one of the greatest methods for synthesizing multi-
substituted amines due to the following two reasons. First, synthetic method to form amide bonds 
have been established. Second, while amines cannot be handled easily due to its strong basicity, 
nucleophilicity, and oxophilicity, amides can be handled because of its low reactivity. Thus 
amides would be a useful nitrogen source for synthesis of alkaloids. However, the stability of 
amides has prevented the late-stage conversion of amides to functionalized amines in the presence 
of more reactive functional groups. Therefore, recently, development of amide-selective 
conversion in the late-stage of natural products and drug syntheses have been desired. 
The proposed mechanism of the reductive nucleophilic addition to N-methoxyamide 2 is 
shown in Scheme 1-2. Treatment of N-methoxyamide 2 with an organometallic reagent (R3M) 
allows the formation of the chelated intermediate 4 at moderate temperatures (Figure 1-1, effects 
B and C). Then, addition of acid promotes the formation of highly electrophilic N-oxyiminium 
ion 18, and subsequent addition of second nucleophile (R4M) would proceed smoothly due to 
high electrophilicity of 18 to give N-methoxyamine 19 in a one-pot process (Figure 1-1, effect 
D). In 2010, Chida-Sato group developed the novel method of the reductive nucleophilic addition 
to N-methoxyamide in using DIBAL-H (Scheme 1-3).1,11 Addition of DIBAL-H to a solution of 
N-methoxyamide 20 in CH2Cl2 at –78 °C, and subsequent one-pot addition of allylstannane (3.0 
equiv) and Sc(OTf)3 (1.1 equiv) afforded the desired amine 21 in 92% yield. Reductive cyanation 
of 20 also proceeded successfully to form α-cyanoamine 22, whose substructure is often seen in 
the bioactive complex alkaloids. 
 
Scheme 1-2. Nucleophilic addition to N-methoxyamide 
 
 
Scheme 1-3. Reductive allylation and cyanation of N-methoxyamide 
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The nucleophilic addition to N-alkoxyamides also enabled access to α-tertiary amine moiety 
in a one-pot reaction (Scheme 1-4).11 Treatment of N-benzyloxyamide 23 with MeLi at –78 °C 
followed by allylation or cyanation afforded tertiary amines 24 or 25 in 92% or 85% yield, 
respectively. The reductive allylation of N-benzyloxyamide 26 afforded 2,6-trans-substituted 
piperidine 27 with complete diastereoselectivity by treatment of DIBAL-H and allylstannane 
(Scheme 1-5-left). Helmchen and co-workers reported Grignard reagent mediated reductive 
nucleophilic addition of N-methoxyamide (Scheme 1-5-right).12 In their method, first nucleophile 
is carbon nucleophile and second nucleophile is hydride reductant such as NaBH4 or Raney nickel, 
and the inverse order of hydride and carbon source resulted in opposite diastereoselectivity. They 
performed the successive addition of EtMgBr and NaBH3CN to N-methoxyamide 28 to afford 
the 2,6-cis-substituted piperidine 29 in 90% yield and >10:1 diastereomeric ratio.  
 
Scheme 1-4. Reductive allylation and cyanation of N-benzyloxyamide 23 
 
 
Scheme 1-5. Control of diastereoselectivity by exchanging the order of nucleophiles 
 
 
To confirm the beneficial effects of N-alkoxy groups, a control experiment between N-
methoxyoctanamide 20 and N-methyloctanamide 32 was conducted (Scheme 1-6). N-
Methoxyamide 20 reacted with DIBAL-H (1.3 equiv) at –78 °C, and subsequent allylation gave 
N-methoxyamine 21 as a single product. In contrast, the reduction of N-methylamide 32 was not 
complete at –78 °C, and the reaction was required to be performed at –50 °C (effect B). 
Furthermore, after completion of the allylation, N-methylamine 35 was obtained in low yield 
along with the undesired over reduced product 36 (35: 20%, 36: 41%). These results indicates 
that N,O-acetal 33 would easily decompose to form iminium ion 34, which would readily be 
converted to over-reduced product 36. Moreover, the chelation effect was crucial for this one-pot 
process.   
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Scheme 1-6. Control experiment with and without N-methoxy group 
 
 
Although various effects of the N-methoxy group enable addition of two different nucleophiles 
to an amide carbonyl group in one-pot process, these methods require the addition of highly 
nucleophilic organometallic reagent such as DIBAL-H, alkyllithium reagent, or Grignard reagent. 
Therefore, more electrophilic functional groups such as ester, nitro, or nitrile groups cannot be 
tolerated under these conditions. For example, ester and amide are embedded in a same molecule, 
the ester group of 37 should be converted to non-reactive ether 38 through reduction and 
protection. Next the nucleophilic addition of amide followed by reconstruction of the ester could 
give the desired product 39 (Scheme 1-7A). These tedious redox reactions and protecting group 
manipulation would decrease synthetic efficiency. However, the Schwartz reagent, which is an 
amide-selective reducing agent, was effective for the development of the amide-selective 
nucleophilic addition (Scheme 1-7B).13 Treatment of N-methoxyamide 40 with the Schwartz 
reagent, and subsequent addition of Sc(OTf)3 and allylstannane afforded N-methoxyamine 41 
without harming more electrophilic methyl ester. 
 
Scheme 1-7. Amide-selective nucleophilic addition by using Schwartz reagent 
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1-4. Total Synthesis of Gephyrotoxin (50) 
In 2014, Chida-Sato group disclosed the total synthesis of gephyrotoxin featuring two-step 
construction of multi-substituted N-methoxypiperidines in highly chemoselective fashion 
(Scheme 1-8).13 Details of the key reactions are depicted in Chapter 2. The synthesis commenced 
with the synthesis of the bicyclic N-methoxylactam 44 taking advantage of the key coupling 
reaction of N-methoxyamide EZ-42 and 4-bromobutyraldehyde. A solution of an amide and an 
aldehyde in CH2Cl2 was treated with BF3·OEt2 at –20 °C to form N-methoxypiperidone 43. The 
key bicyclic intermediate 44 was prepared by several transformations from 43, and then the 
lactam-selective nucleophilic addition was performed. The reduction of 44 with 1.1 equiv of 
Cp2ZrHCl led to formation of the five-membered chelated intermediate 45 (Figure 1-1, effect C). 
Then treatment with Sc(OTf)3 (30 mol%) and allylstannane (2.0 equiv) achieved reductive 
allylation via oxyiminium intermediate 46 in completely lactam-selective fashion. Surprisingly, 
this allylation proceeded at –78 °C due to the increased electrophilicity of 46 (Figure 1-1, effect 
D), and favorably produced the desired compound 47 with 4.6:1 diastereoselectivity. The 
resulting decahydroquinoline 47 was then converted to enoate 48. Reductive cleavage of N-O 
bond of 48 was achieved by addition of activated Zn powder in the presence of AcOH at 60 °C, 
and subsequent aza-Michael reaction proceeded to give 49 in 98% yield and with moderate 
diastereoselectivity (Figure 1-1, effect E). Finally, introduction of the enyne side-chain and 
reduction of tert-butyl ester accomplished the total synthesis of gephyrotoxin (50). 
 
Scheme 1-8. Total Synthesis of Gephyrotoxin (50) 
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1-5. Cleavage of N-O Bond14 
  Heteroatom-heteroatom bonds, for instance N=N, N-N, N-O, O-O, are known to be cleaved 
under reductive-, radical-, or oxidative conditions. To cleave the N-O bond of N-alkoxyamides, 
two representative methods have been commonly used. The first method is single-electron 
reduction with low valent metals (Scheme 1-9A, 1-9C).5-7,15 The other is Pd or Ni catalyzed 
hydrogenation (Scheme 1-9B).16 
 
Scheme 1-9. Reductive cleavage of N-O bond of N-alkoxyamides 
 
 
  The required conditions to cleave the N-O bonds of amines are different from those of amides. 
In case to cleave the N-O bond of N-alkoxyamines, the basicity and electrophilicity of the amine 
are important. For example, treatment of bicyclic compound 57 with mCPBA provoked oxidative 
N-O bond cleavage to give nitrone 58 (Scheme 1-10A).17 N-Methoxyamine 59 was converted to 
secondary amine 60 by treatment with Zn/AcOH (Scheme 1-9B).4 These reactions proceeded via 
onium intermediates such as 61 and 62. 
 
Scheme 1-10. Oxidative and reductive cleavage of N-O bond of N-alkoxyamines 
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Chapter 2. Two-step Synthesis of Multi-substituted N-Methoxypiperidine 
2-1. Piperidine Alkaloids 
The secondary metabolites generated from plants or animals possess a variety of bioactivities. 
In general, most of medicinal drugs contain nitrogen atom in its structure. Therefore various 
scientists have been interested in the development of synthetic method for alkaloids and 
heterocyclic compounds including nitrogen atom. Piperidines are one of the most common and 
important structural motifs seen in a number of natural products. Some selected examples of 
piperidine alkaloids attracting a number of synthetic chemist are listed in Figure 2-1. 
Gephyrotoxin (50)1,2 and histrionicotoxin (63)3,4 possesses synthetically attractive structures 
including α-multi-substituted piperidine skeleton and enyne structure. Therefore a number of 
synthetic studies on 50 and 63 have been investigated to date. From the roots of Rauwolfia 
serpentina, several bioactive indole alkaloids were isolated including reserpine (64) and ajmaline 
(65). Reserpine (64) possesses an antihypertensive and antipsychotic activities,5 and ajmaline 
(65) has an antiarrhythmic activity.6 From the Chinese plant Gelsemium (G. elegans), an indole 
alkaloid, koumidine (66) was isolated, which has a structure similar to 64 and 65.7 In fact, the 
biosynthetic route of 64, 65, and 66 were considered through the same intermediate.8 Morphine 
(67) and cocaine (68) are well known as highly addictive drugs due to the strong activity on the 
central nerve.9,10 On the other hand, tiotropium bromide (69: also known as Spiriva®), which 
possesses a structure similar to 68, is utilized as a COPD (Chronic Obstructive Pulmonary 
Disease) drug.11 Synthetic studies of these natural products and drugs shown in Figure 2-1 have 
been contributed to the improvement of organic synthetic chemistry from many aspects. 
 
Figure 2-1. The piperidine alkaloids 
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2-2. Synthetic Plan 
We supposed that N-methoxy amides would be useful for synthesis of highly substituted 
piperidine compounds, including gephyrotoxin (50), ajmaline (65), and koumidine (66). These 
natural products possess the common structural motif; 2,3,6-trisubstituted piperidine skeleton 74. 
A synthetic plan for the two-step access to highly substituted piperidine 74 from N-methoxyamide 
E-42 is described in Scheme 2-1 (E-42→71→74). The success of this process is highly dependent 
on the assistance from the N-methoxy group which acts as a reactivity control element. The first 
step is an acid-mediated direct coupling of N-methoxyamide E-42 with an aldehyde, followed by 
spontaneous intramolecular allylation of the generated N-acyliminium ion 70 to give 2,3-
disubstituted N-methoxy-piperidone 71.12 Intermolecular condensation of an ordinary amide with 
an aldehyde is very challenging due to the poor nucleophilicity of the amide nitrogen atom. 
However, incorporation of a methoxy group on the nitrogen atom results in an increase of the 
nucleophilicity (Figure 1-1, effect A), enabling direct coupling with an aldehyde R1CHO. The 
second step of the two-step sequence is the nucleophilic addition to N-methoxylactam 71, 
affording 2,3,6-multi-substituted N-methoxypiperidine 74.13 This nucleophilic addition takes 
advantage of both the increased electrophilicity of the N-methoxyamide and the chelation effect 
(Figure 1-1, effects B and C), and the increased electrophilicity of the N-methoxyiminium ion 73 
(Figure 1-1, effect D). The addition of the first nucleophile R2M to the N-methoxylactam would 
provide the five-membered chelated intermediate 72. After addition of acid, the generated 
oxocarbenium ion 73 would then react with a mild nucleophile to provide N-methoxypiperidine 
74 in a one-pot process.  
 
Scheme 2-1. Synthetic plan for the two-step synthesis of multi-substituted piperidine 
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2-3. Synthesis of Allylsilanes E-42, Z-42, and EZ-42 
Allylsilane E-42 was synthesized as shown in Scheme 2-2. Mono protection of the 
commercially available 1,4-butanediol (75) with the TBDPS group, followed by oxidation with 
IBX gave aldehyde 76. Next, the resulting aldehyde 76 was converted to allylic ester 77 by 
Grignard reaction followed by trifluoroacetylation of the allylic alcohol. Treatment of 77 with a 
catalytic amount of Pd(dba)2 and (TMS)2 led to the formation of allylsilane 78. Subsequently, the 
TBDPS group of 78 was removed with TBAF, and the resulting alcohol 79 was oxidized by IBX 
(79→80) and Kraus-Pinnick oxidation to afford carboxylic acid 81. Finally, the condensation of 
81 and N-methoxyamine hydrochloride proceeded to give E-42 in 57% total yield over 9 steps. 
 
Scheme 2-2. Synthesis of E-allylsilane E-42 
 
 
 
The allylsilane Z-42 was prepared by using other synthetic route (Scheme 2-3). The 
commercially available 4-pentyn-1-ol (82) was protected as a THP ether, and subsequent 
alkylation of 83 with trimethylsilyl iodomethane gave internal alkyne 84. Subsequently, the 
removal of the THP group (84→85), followed by Z-selective semi-reduction with nickel boride 
afforded the Z-olefin 86. Finally, the primary hydroxy group of 86 was converted to N-
methoxyamide by oxidation (86→87) and condensation, giving Z-42 in 50% total yield over 7 
steps. 
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Scheme 2-3. Synthesis of Z-allylsilane Z-42 
 
 
Although both stereoisomers of allylsilanes E-42 and Z-42 were obtained, the sequence 
required a number of steps due to multiple oxidation and protection/deprotection. Thus, a two-
step synthesis of EZ-allylsilane EZ-42 was developed by utilizing cross metathesis reaction 
between N-methoxyamide 89 and allyltrimethylsilane (Scheme 2-4A). The commercially 
available 4-butenoic acid (88) was converted to N-methoxyamide 89 by condensation with N-
methoxyamine in good yield. In this reaction, the workup with NaHCO3 was necessary due to 
the removal of the side product derived from HOBt, which was inseparable from 89 by silica gel 
chromatography. Then, optimization of the cross metathesis reaction was conducted. The cross 
metathesis reaction with Grubbs 2nd generation catalyst proceeded in moderate yield, despite the 
presumable deactivation of catalyst caused by coordination with nitrogen atom.14 The addition of 
isocyanide 93, which was prepared from 90 by the sequence of reaction sequence depicted in 
Scheme 2-5B (90→91→92→93),15 was effective in order to remove the side product derived 
from ruthenium catalyst. 
 
Scheme 2-4. Two-step synthesis of EZ-allylsilane EZ-42 
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2-4. The First Step: Coupling of N-Methoxyamide and Aldehyde 
With both allylsilanes E-42 and Z-42 in hand, the first coupling reaction was optimized using 
N-methoxyamide E-42 and octanal 94a. No desired product 71a was formed with Sc(OTf)3, TiCl4, 
SnCl4, or TMSOTf (Table 2-1, entries 1-4). However, addition of LiClO4 and a catalytic amount 
of Bi(OTf)316 to a solution of E-42 and octanal 94a in CH2Cl2 initiated the coupling reaction, 
giving 71a in 53% yield (Table 2-1, entry 5). The reaction proceeded in completely cis-
stereoselective fashion with 71a isolated as the single diastereomer. The yield of 71a was 
improved to 85% with 2 equiv of BF3·OEt2 at –20 °C, along with recovery of E-42 in 12% yield 
(Table 2-1, entry 6). To consume the remaining E-42, added 1.0 equivalent of BF3·OEt2 every 30 
minutes, and found that addition of 6 equiv of BF3·OEt2 resulted in complete consumption of E-
42 to give 71a in 90% yield (Table 2-1, entry 7). Even if Z-allylsilane Z-42 was treated with the 
optimized conditions, the reaction proceeded in 93% yield and completely cis-selective fashion 
(Table 2-1, entry 8). This result clearly suggested that the geometry of the double bond had no 
significant effect on either the yield or the diastereoselectivity.  
 
Table 2-1. Optimization of acid and effect of the geometry of double bond 
 
 
With optimal conditions in hand, the substrate scope of the coupling reaction with several 
aldehydes was surveyed (Table 2-2). Despite the strongly acidic conditions using BF3·OEt2, the 
reaction smoothly proceeded in the presence of various functional groups. The coupling reaction 
with E-42 and aldehyde 94b with the hydroxy group protected as a TBDPS ether proceeded in 
92% yield (Table 2-2, entry 2, 71b: 92%). Methyl ester and alkyl bromide moieties did not 
interfere with this transformation (Table 2-2, entries 3 and 4, 71c: 92%, 71d: 80%). The coupling 
reaction of EZ-42 (E:Z = 2.4:1) and aldehyde 94d was used in the total synthesis of gephyrotoxin 
reported by Chida-Sato group, which afforded the desired cis-piperidone 71d with complete cis-
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selectivity (Table 2-2, entry 5, 71d: 79%). Carbamates including acid-sensitive Boc group were 
compatible with these conditions (Table 2-2, entries 6 and 7, 71e: 92%, 71f: 75%). Although 2-
arylacetoaldehyde derivatives 94g and 94h tend to be enolized, the coupling reactions smoothly 
took place, with 71g and 71h isolated in 78% and 92% yields, respectively (Table 2-2, entries 8 
and 9). The sterically hindered iso-butyraldehyde 94i required a longer reaction time (3 hour vs 
2 days), but still gave the cis-cyclized product 71i in 67% yield (Table 2-2, entry 10). The 
coupling reaction using the less electrophilic benzaldehyde 94j resulted in moderate yield 
(Table2-2, entry 11, 71j: 34%). 
 
Table 2-2. Substrate scope of the coupling reaction of N-methoxyamide E-42 and aldehyde 94 
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In order to demonstrate the utility of the N-methoxy group, the coupling reaction of N-
methylamide 95 with octanal 94a was attempted. As a result, the coupling product 98 was not 
produced, but instead, formation of the terminal olefin 99 was observed. This can be rationalized 
by the intramolecular protonation via six-membered intermediate 100 (Scheme 2-5). In this 
coupling reaction, N-methoxy group would increase the nucleophilicity of the nitrogen atom of 
N-methoxyamide 42 and enable the formation of N,O-acetal E-101. The intramolecular 
cyclization would proceed smoothly due to higher electrophilicity of N-acyl-N-oxyiminium ion 
E-70a than that of ordinary N-acyliminium ion. In addition, stabilization of transition state E-
TS1 by through-space interaction between non-bonding electron of oxygen atom and β-cation of 
silyl group would affect the diastereocelectivity.17  
 
Scheme 2-5. The attempt of coupling reaction with N-methylamide 95 and octanal 94a 
 
 
 
Scheme 2-6. Plausible effect of the N-methoxy group in the amide/aldehyde coupling reaction 
 
 
 
Although the through space interaction of N-methoxy group have not been reported, Floreancig 
and co-workers reported a closely related chemistry (Scheme 2-7).17 In their case, the 6-endo-
cyclization of the acyliminium ion 103 gave 2,3-trans-piperidine 106 as a major product. They 
supposed that this stereoselectivity would be determined by the geometry of the iminium ion,18 
 
16 
and through space interaction between acyl group and cationic β-silyl carbon. According to the 
calculation of a model N-acyliminium ion 108a and 108a’, the E-isomer 108a was more stable 
than 108a’ significantly (the Boltzmann population of 108a and 108a’ at 298 K was calculated 
as 98.4:1.6). Therefore, the transition states 104 and 105 would adopt E-acyliminium ion in the 
cyclization reaction. Although 104 seems to be sterically disfavored due to the 1,3-diaxial-like 
interaction, a through-space interaction between oxygen atom of the carbamate and the β-silyl 
cation is overwhelmingly stronger than the sterical effect to give trans-product 107 with highly 
stereoselective fashion. 
 
Scheme 2-7. Example of through-space interaction (reported by Floreancig and co-workers) 
 
 
Based on these context, the stereochemical outcome of our intramolecular cyclization would 
be explained as shown in Scheme 2-8. DFT calculation indicated that N-oxy-N-acyliminium ion 
108b preferred the Z-geometry than the E-geometry.19 Therefore, two possible transition state E-
TS1 and E-TS2 adopt the Z-geometry in the transient iminium ions. In this occasion, while the 
transition state E-TS1 will be transformed to cis-product 71a, the competing E-TS2 will be 
converted to trans-product 109a. In general, E-TS2 considered to be favorable transition state, 
because the alkyl side-chain and the allylsilane occupied the pseudoequatorial positions.20 For 
example, Ito and co-workers reported highly trans-selective intramolecular allylation of 110 and 
114 via favorable transition states 112 and 116 rather than unfavorable 111 and 115 affording the 
2,3-trans product 113 and 117 (Scheme 2-9).20c The favorable transition states 112 and 116, alkyl 
side-chain and allylsilane were placed in pseudoequatorial positions. Despite such sterical 
advantages in E-TS2, our experimental results showed the complete cis-selectivity via transition 
state E-TS1, probably because the strong through-space interaction as shown in Scheme 2-7 
would stabilize the transition state E-TS1.  
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Scheme 2-8. Plausible mechanistic rational for cis-selective intramolecular allylation of E-42 
 
 
Scheme 2-9. Example of trans-selective cyclization (reported by Speckamp and co-workers) 
 
 
To elucidate the role of the amide carbonyl group, the coupling reaction of N-methoxyamine 
118 was attempted instead of N-methoxyamide E-42 (Scheme 2-10). In this case, the Z-geometry 
of iminium ion was dominant, which was supported by the calculation of model iminium ion 
108c and 108c’. Interestingly, although the stereoselectivity was decreased, the cyclization still 
afforded cis-isomer 120 as a major product (120: 64%, 121: 24%). This cyclization would also 
be considered to proceed through TS3 and TS4 derived from the favorable Z-geometrical 
iminium ion. Although the reason is not clear why trans-product 121 was obtained, in this case 
also cis-product 120 was generated as a major product, probably because the through-space 
interaction would be still dominant.  
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Scheme 2-10. The effect of the carbonyl group 
 
 
The next control experiment was the coupling reaction using Z-allylsilane Z-42. As a result, 
the coupling reaction between Z-42 and 94a afforded cis-isomer 71a with perfect 
stereoselectivity in 93% yield (Scheme 2-11). The reaction of Z-42 would proceed via the 
transition state E-42 shown in Scheme 2-8. Although a larger 1,3-diaxial-like repulsion in 
transition state Z-TS1 would be expected than in E-TS1,17 we considered that the electrostatic 
interaction between β-silyl cation and N-methoxy group would still be dominant, resulting in the 
complete cis-cyclization to give 71a. 
 
Scheme 2-11. The effect of the geometry of allylsilane 
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2-5. The second step: Nucleophilic Addition of N-Methoxylactam 
With N-methoxylactam 71 in hand, then the nucleophilic addition of N-methoxylactam 71 was 
attempted using a variety of nucleophiles (Table 2-3). The reductive cyanation of lactam 71a 
successfully proceeded upon treatment with DIBAL-H at –78 °C and subsequent addition of 
TMSCN and SnCl4 to give N-methoxypiperidine 74a, along with the diastereomer 122a in 87% 
combined yield (Table 2-4, entry 1, 74a:122a = 2.2:1). By changing the first and second 
nucleophiles, this nucleophilic addition allowed quick access to various multi-substituted 
piperidines from the identical N-methoxylactam 71a. The reductive allylation proceeded by using 
a combination of DIBAL-H as a first nucleophile (R2M) and allylstannane as a second 
nucleophile (R3M) (Table 2-4, entry 2, 86%, 74b:122b = 4.1:1). Reductive Pictet-Spengler 
reaction with N-methylindole at –40 °C afforded 74c in highly diastereoselective fashion (Table 
2-4, entry 3, 88%, 74c:122c = 14:1). The reductive Mukaiyama Mannich reaction using 
silylenolether gave 74d as a single diastereomer in 65% yield (Table 2-4, entry 4). In this reaction, 
when DIBAL-H was used as the first nucleophile, inseparable unknown side product was 
generated, and the yield of 74d was 51%. Furthermore, if organolithium reagent was employed 
as a first nucleophile, α-tertiary amines were successfully constructed. For instance, the addition 
of MeLi to N-methoxylactam 71a followed by the cyanation and allylation proceeded smoothly 
to give α-tri-substituted N-methoxypiperidines (Table 2-4, entry 5: 83%, 74e:122e = 1:4.0; entry 
6: 57%, 74f:122f = 4.2:1). Nucleophilic addition to N-methoxylactam 71d was more challenging 
because the methyl ester was incompatible with both DIBAL-H and organolithium reagent. 
However, our chemoselective variant of nucleophilic addition using the Schwartz reagent was 
highly effective with substrates bearing sensitive functional groups.21 The reduction of N-
methoxylactam 71d with Cp2ZrHCl at room temperature followed by the addition of TMSCN 
and 20 mol% Sc(OTf)3 furnished a 1:4.3 diastereomeric mixture of 74g and 122g in 86% yield 
(Table 2-4, entry 7). The reaction was completely chemoselective, and proceeded without 
affecting the methyl ester which is more electrophilic than ordinary amide or the terminal olefin. 
The corresponding allylation of 71d gave 74h as a major diastereomer (Table 2-4, entry 8: 74%, 
74h:122h = 4.2:1). Thus, the two-step procedure including N-methoxyamide/aldehyde coupling 
and subsequent nucleophilic addition proved to be highly practical to afford a variety of multi-
substituted piperidines. 
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Table 2-3. Nucleophilic addition of a variety of nucleophiles to N-methoxypiperidine  
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  The stereochemical rationale for the reductive nucleophilic addition to N-methoxylactam 71a 
was shown in Scheme 2-13. NOESY experiment (500 MHz, CDCl3) indicated that N-
methoxylactam 71a mainly existed as a half-chair conformation 123, in which the alkyl side chain 
occupied the pseudoaxial position. We believed that transient N-oxyiminium ion 73a might exist 
mainly as a half-chair conformation 124 similar to 123, and the transition state 125 might exist 
as a minor conformation due to 1,2-allylic strain between the methoxy group and alkyl side-chain. 
The sterically large nucleophile would avoid the steric repulsion with alkyl side-chain of 124. 
Considering the stereoelectronical effect,22 a large nucleophile would be difficult to react at β-
side of 124 (path A), and would react immediately with β-side of 125 to provide 74 as a major 
product (path B). On the other hand, in the case using sterically small nucleophile, the interaction 
with alkyl side-chain would be negligible. Therefore, the small nucleophile relatively favored the 
α-side attack to 124 (path C, cf. Table 2-4, entries 5 and 7). 
 
Scheme 2-13. Plausible mechanistic rationale for reductive nucleophilic addition to 71a  
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Chapter 3. Further Application of the Two-step Synthesis 
3-1. Macroline- and Sarpagine-type Alkaloids 
As a demonstration to show that the developed method was applicable to complex molecules 
relating to natural alkaloids, we took an interest in the quick synthesis of a tetracyclic structure 
embedded in macroline- and sarpagine-type alkaloids (Figure 3-1).1 Macroline (126) and 
sarpagine (127) alkaloids possess an indole-annulated azabicyclo[3.3.1] core structure, and 
koumidine (66) contains the opposite relative stereochemistry between C5 and C16. Macroline-
type alkaloids have the same skeletal connectivity, only that N4-C21 linkage does not exist. On 
the other hand, sarpagine-type alkaloids possesses the N4-C21 linkage and the C16-(R) 
configuration. The skeletal difference between sarpagine (127) and koumidine (66) is the 
configuration at C16. By taking advantage of our two-step synthesis of multi-substituted 
piperidine, the quick access to tetracyclic compound 128 which correspond to the core structure 
of koumidine (66) would be practical. N-Methoxypiperidine 128 would be synthesized by 
amide/aldehyde coupling reaction between E-42 and indole acetaldehyde derivative 130 as the 
first step, followed by intramolecular reductive Pictet-Spengler reaction of N-methoxylactam 129 
as the second step.  
 
Figure 3-1. Synthetic plan of macroline- and sarpagine-type alkaloids  
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3-2. Construction of Tetracyclic Skeleton of Koumidine (66) 
In the first step, the protecting group of the indole nitrogen atom would affect the stability of 
the indole unit because indoles are vulnerable to acidic conditions. In addition, indole 
acetaldehyde 1302 is likely to form benzylic enolate and decompose by dimerization or 
polymerization. As expected, the protecting group of the indole nitrogen atom was crucial in this 
reaction (Table 3-1, entry 1). The N-methyl indole 130b also decomposed under the acidic 
conditions (Table 3-1, entry 2). However, the electron withdrawing Boc group was effective for 
this coupling reaction to give N-methoxylactam 129c in 44% yield in cis-selective fashion (Table 
3-1, entry 3). The Cbz protection of the indole significantly increased the yield of N-
methoxylactam 129d up to 68% (Table 3-1, entry 4). When the more electron withdrawing 
benzene sulfonyl group was used as a protecting group, the coupling reaction proceeded in 65% 
yield comparable to the Cbz group (Table 3-1, entry 5, 129e: 65%).  
 
Table 3-1. Coupling reaction of N-methoxyamide E-42 and indole acetaldehyde 130 
 
 
 
Next, we attempted the intramolecular reductive Pictet-Spengler reaction (Scheme 3-1). 
Treatment of the Cbz-protected N-methoxylactam 129d with the Schwartz reagent, followed by 
addition of a catalytic amount of Sc(OTf)3 induced the reductive intramolecular Pictet-Spengler 
reaction to give the tetracyclic compound 128d in a reasonable yield. It is noteworthy that this 
reductive cyclization was also highly chemoselective without touching the indole carbamate 
despite its similar structure to the N-methoxylactam. The stereochemistries of lactam 129d and 
tetracyclic compound 128d were determined by NOESY experiments (Figure 3-2, 500 MHz, 
CDCl3). In the case using lactam 129e, the cyclization resulted in low yield presumably due to 
the low nucleophilicity of indole moiety.  
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Scheme 3-1. Construction of tetracyclic compound 128  
 
 
Figure 3-2. NOESY experiment of 129d and 128d  
 
 
 
 
3-3. Three-component Coupling Reaction 
All successful examples in the first coupling reaction thus far are two-component reactions 
employing N-methoxyamide 131 that possesses the allylic silane in the same molecule as the 
nucleophilic moiety. In order to render the developed method more general, a three-component 
coupling reaction was attempted by using N-methoxyamide 131, acetaldehyde 132 and 
allylstannane in the presence of BF3·OEt2 (Scheme 3-2). Unfortunately, initial attempts were 
unsuccessful due to the direct allylation of acetaldehyde by allylstannane to form homoallylic 
alcohol 135. 
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Scheme 3-2. Unsuccessful attempt of the three component coupling reaction 
 
 
The issue in the three-component coupling reaction is the unfavorable reactivity of each 
component; the addition of allylstannane to acetaldehyde 132 was much faster than the addition 
of N-methoxyamide 131, and prevented the formation of the N-acyliminium ion 133. In order to 
prevent the formation of 135, utilization of an enol ether was attempted as the aldehyde equivalent 
(Scheme 3-3). First, N-methoxyamide 131 and ethyl vinyl ether 136 were pre-coupled in the 
presence of 1 mol% CSA. The subsequent treatment of resulting N,O-acetal 137 with 
allylstannane and BF3·OEt2 successfully promoted the allylation via iminium ion 133 to give N-
methoxyamide134 in 82% yield in a one-pot process. The reductive cyanation and allylation of 
N-methoxyamide 134 provided 138 and 139 in 72% and 59% yields, respectively. 
 
Scheme 3-3. First attempt of the three component coupling reaction 
 
 
_________________________ 
Reference in Chapter 3 
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Chapter 4. Conclusion 
We have documented a two-step synthesis of multi-substituted N-methoxyamines involving 
an N-methoxyamide/aldehyde coupling reaction and subsequent nucleophilic addition to amide 
carbonyls. The key to success was the utilization of the N-methoxy group as a reactivity control 
element. The first coupling reaction between the amide and aldehyde took place with 
enhancement of the nucleophilicity of the nitrogen atom by assistance of the N-methoxy group 
(effect A). The unusual cis-stereoselectivity was developed by the strong through-space 
interaction between N-methoxy group and transient β-silyl cation (effect C). The next 
nucleophilic addition was achieved by taking advantage of the high electrophilicity of amide 
carbonyls (effect B), the chelation effect of N-methoxyamides (effect C), and the high 
electrophilicity of N-oxyiminium ion (effect D). At every stage of this synthetic method, N-
methoxy group played a role as sterically less hindered protecting group (effect F). The developed 
synthesis enabled quick supply of a set of various 2,3,6-multi-substituted N-methoxypiperidines 
including a substructure of a complex alkaloid. The method was then applied to a three-
component coupling reaction, giving acyclic compounds. Thus, N-alkoxyamine derivatives 
possess a great potential to create practical chemical reactions for synthesis of complex molecules. 
From now on, a variety of new synthetic method using N-alkoxyamine derivatives will be 
discovered. 
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Part 2. Unified Total Synthesis of Stemoamide-type Alkaloids 
 
Chapter 5. Introduction 
5-1. Stemoamide-type Alkaloids 
5-1-1. Isolation and Bioactivity 
Stemona-alkaloids were isolated from the extracts of ‘Stemonaceae’, which have been used in 
folk medicine in East Asia from ancient years. In China, mainly three species of the Stemona 
genus (S. tuberosa, S. japonica, and S. sessilifolia) have been utilized as a cough medicine and 
an insecticide agent.1,2 
For instance, a water extract of S. tuberosa mainly contains five stemona-alkaloids (Figure 5-
1A) that showed anti cough activity. Especially neostenine and neotuberostemonine were 
revealed to possess the strongest anti-cough activity among these five alkaloids.3 
Stemona-alkaloids also show insecticidal activity (Figure 5-1B). Stemofoline and 
didehydrostemofoline possess strong insecticidal and growth inhibitory activity against neonate 
larvae of the cotton leaf worm Spodoptera littoralis Boisduval.4 Protostemonine and 
dehydroprotostemonine showed notable nematicidal bioactivity against panagrellus redivevus.2c 
 
Figure 5-1. Alkaloids extracted from the root of S. tuberosa 
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5-1-2. Classification of the Stemona-alkaloids 
 More than 150 stemona-alkaloids have been reported to date and they can be classified into 
eight groups (Figure 5-2).1,2,5 The alkaloids belonging to group I to VI possess five- and seven-
membered ring system remarked as pyrrolo[1,2-a]azepine skeleton, which is regarded as the most 
common structure of stemona species. While the alkaloids belonging to group VII possess six- 
and seven-membered ring system remarked as pyrido[1,2-a]azepine skeleton. The alkaloids 
belonging to group VIII do not possess these core structures. 
Among stemona-alkaloids, approximately 40 natural products belong to stemoamide group 
(II), which is the largest group of these alkaloids (Figure 5-3). Stemoamide-type alkaloids 
possess the tricyclic core structure of stemoamide comprised of a -lactone, an azepane, and a γ-
lactam. 
 
Figure 5-2. Classification of the stemona-alkaloids 
 
 Figure 5-3. The stemoamide-type alkaloids 
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5-1-3. Synthetic Examples of Stemoamide (1) 
 More than 20 synthetic examples of stemoamide (1) have been reported to date. Examples of 
enantioselective and racemic total syntheses of stemoamide are listed below (Table 5-1, 5-2).6,7 
 
Table 5-1. Enantioselective synthesis of stemoamide (1) 
 
group year LLS total yield quantity of obtained stemoamide 
Williams 1994 25 steps 5.6% N/A 
Mori 1996 13 steps 8.3% 6.3 mg 
Jacobi 2000 7 steps 4.2% 18 mg 
Sibi 2004 14 steps 7.0% N/A 
Olivo 2006 13 steps <14.1%* 25 mg 
Somfai 2007 12 steps 19.6% 6.8 mg 
Honda 2011 9 steps 23.4% 32.2 mg 
Hong 2012 12 steps 18.7% 24.7 mg 
Sato/Chida 2016 22 steps 2.2% 8.9 mg 
* Yields of first three steps are not reported 
 
Table 5-2. Racemic synthesis of stemoamide (1) 
 
group year LLS total yield quantity of obtained stemoamide 
Narasaka 1996 14 steps 1.1% 12 mg 
Jacobi 1997 7 steps 19.9% 438 mg 
Bates 2009 11 steps 5.70% N/A 
Hong 2011 9 steps 30.1%** 166 mg 
Zhang, Qiu 2014 7 steps 5.1% 24 mg 
** They originally counted the steps starting from 4-bromobutyraldehyde, which is not generally 
commercially available. 
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5-1-4. Brief Outline of Representative Total Synthesis of Stemoamide (1) 
5-1-4-1. Williams and co-workers 
The first total synthesis of stemoamide (1) was reported by Williams and co-workers featuring 
Evans diastereoselective aldol reaction and late-stage construction of tricyclic structure from 
acyclic intermediate (15) (Scheme 5-1).6a The synthesis commenced with preparation of 15, 
which contains all carbon atoms of stemoamide (1). A diastereoselective coupling of aldehyde 8 
and amide 9 with chiral auxiliary proceeded by treatment with Bu2BOTf and triethylamine to 
afford oxazolidinone 10. After altering the protecting group of alcohol, lactone 11 was converted 
to ketone 13 by introducing butenyl lithium reagent 12. Then the reduction of ketone, mesylation, 
and azidation were conducted to give azide 14. Following ozonolysis of 14 completed the 
installation of all carbon atoms of stemoamide (1). In the end of this synthesis, the sequential 
multi-step deprotection, oxidation, and cyclization of A, B, and C rings took place to accomplish 
the first concise total synthesis of stemoamide (1). 
 
Scheme 5-1. Total Synthesis Reported by Williams 
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5-1-4-2. Narasaka and co-worker 
Narasaka and co-worker developed oxidative coupling of silyl enol ether and stannyl 
compound, and it was applied to the total synthesis of stemoamide (1) (Scheme 5-2).6b The first 
key coupling reaction was conducted by treatment of silyl enol ether 16 and α-stannyl ester 17 
with tetrabutylammonium nitratocerate (IV) (TBACN, cerium tetrabutylammonium nitrate; 
CTAN) to give γ-ketoester 18 in 85% yield. Second key coupling reaction was the oxidative 
coupling of silyl enol ether 19 and stannyl pyrrolidine 20 with cerium ammonium nitrate (CAN). 
Subsequent reduction of alkyne 21 afforded ketone 22 and epi-22. After construction of A and C 
rings, the treatment of mesylate 23 with sodium hydride led to tricyclic compound 24 in 62% 
yield. Finally, regio- and diastereo-selective methylation of 24 resulted in the second total 
synthesis of stemoamide (1) in 14 total steps. 
 
Scheme 5-2. Total Synthesis Reported by Narasaka 
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5-1-4-3. Mori and co-worker 
Mori and co-worker reported the total synthesis of (–)-stemoamide (1) using a ruthenium 
catalyzed eneyne metathesis developed by the Grubbs group and the Mori group (Scheme 5-3).6c,e 
Eneyne 26 was prepared in 7 steps (6 pots) from 25, and subsequent homologation of terminal 
alkyne provided 27 in 68% yield. The eneyne metathesis of 27 with Grubbs catalyst 1st generation 
proceeded to give a bicyclic compound 28 in 87% yield. 1,4-Reduction of enoate moiety in 28 
followed by hydrolysis of ester and bromolactonization afforded butenolide 32 and tricyclic 
bromide 31, which was successfully converted to 32 by addition of triethylamine. Eventually, the 
total synthesis of (–)-stemoamide (1) was accomplished by nickel boride catalyzed hydrogenation 
of 32 in total 13 total steps and in 8.3% overall yield. 
 
Scheme 5-3. Total Synthesis Reported by Mori 
 
 
 
5-1-4-4. Jacobi and co-worker 
In 2000, Jacobi and co-worker reported an innovative 7-step total synthesis of (–)-stemoamide 
(1) (Scheme 5-4).6d,f The key step of this synthesis was the intramolecular Diels-Alder/retro-
Diels-Alder reaction of oxazole of 36, which would directly form the tricyclic system. The Swern 
oxidation of alcohol 33 prepared from 25, Seyferth-Gilbert reaction of aldehyde 34, and 
methylation of terminal alkyne 35 were sequentially performed to synthesize key intermediate 
36. Then the intramolecular Diels-Alder reaction followed by retro-Diels-Alder reaction of 37 
immediately proceeded to form 2-oxyfuran 38. Subsequent workup gave α,β-unsaturated lactone 
31. Finally, the diastereoselective reduction of 31 with nickel boride afforded stemoamide as a 
major product (73%) along with undesired diastereomer 39 (15%). 
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Scheme 5-4. Total Synthesis Reported by Jacobi 
 
 
5-1-4-5. Somfai and co-workers 
Somfai and co-workers demonstrated a highly efficient total synthesis of stemoamide featuring 
sp2-sp3 Negishi coupling (40+41→42) and ring closing metathesis (42→43) (Scheme 5-5).6i The 
synthesis began with the construction of iododiene 40 taking advantages of alkylation of amide 
and Ohira-Bestmann alkynylation. Treatment of iodide 40 with Pd(PPh3)4 and nucleophile 41 
allowed C-C bond formation to afford the precursor of metathesis 42 in 78% yield. The key ring 
closing metathesis led to construction of the seven-membered ring in excellent yield. Resulting 
ester 43 was converted to tricyclic compound 44 by treatment with modifying hydrolysis and 
bromolactonization of the Mori’s method. Hydrogenation of 44 was performed under similar 
conditions reported by Mori and Jacobi. Finally, the regio- and stereo-selective methylation 
reported by Narasaka accomplished the total synthesis of (–)-stemoamide (1) in 12 total steps in 
19.6% overall yield. 
 
Scheme 5-5. Total Synthesis Reported by Somfai 
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5-1-4-6. Honda and co-workers 
An efficient total synthesis of stemoamide (1) was reported by Honda and co-workers in 2011 
(Scheme 5-6).6k The key step is SmI2-mediated sequential cyclization of seven- and five-
membered ring, which directly provided the tricyclic structure (E-45→48). The aldehyde E-45 
was prepared from commercially available 25 with five-step conversion. The SmI2 mediated 
cyclization had a possibility to produce four diastereomers at C8 and C9 stereocenters. While 
treatment of E-45 with SmI2 (5 equiv) and MeOH (5 equiv) at 0 °C showed only undesired 
diastereoselectivity to form C9-epimers 46 and 47 (60%, 46:47 = 1:1), additional treatment with 
HMPA (20 equiv) realized the complete opposite selectivity at C9 to give diastereomers 48 and 
49 in 55% and 5%, respectively. In addition, it was revealed that the geometry of olefin would 
affect both the yield and diastereoselectivity, and regioisomer Z-45 was converted to 48 and 49 
in 39% and 11%, respectively. The efficient total synthesis of 1 was achieved by methylation of 
48 in 9 total steps and in 23.4% overall yield. 
 
Scheme 5-6. Total Synthesis Reported by Honda 
 
 
5-1-4-7. Hong and co-worker 
A biomimetic total synthesis of stemoamide (1) was reported by Hong and co-workers.6l,m 
Seger, Greger and co-workers suggested a biosynthesis of stemona-alkaloids stemming from a 
spermidine precursor, which couple with an isoprene unit, followed by oxidation and cyclization 
may afford carbon framework of stemoamide (Scheme 5-7A).8 Therefore, Hong and co-workers 
planned to connect the C9-C9a bond by intramolecular allenylation of acyliminium ion (Scheme 
5-7B). Treatment of N,O-acetal 50 with FeCl3 led to formation of bicyclic structure, and TBS 
group was subsequently removed by the addition of TBAF. The late-stage construction of γ-
lactone was accomplished by dynamic ruthenium-catalyzed CO-insertion, which convergently 
transformed the two isomers 52/52’ to a single isomer 31, which was the same intermediate 
reported by Mori and co-workers. 
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Scheme 5-7. Total Synthesis Reported by Hong 
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5-1-5. The First Total Synthesis of Stemonine 
 Stemonine (4) possesses the core-tricyclic structure of stemoamide-type alkaloids. Despite its 
high structural similarity to stemoamide (1), only one synthetic example of stemonine (4) was 
reported by Williams and co-workers (Scheme 5-8).9 The synthetic strategy was identical as their 
first total synthesis of stemoamide (1), featuring the late-stage C and D ring construction from 
acyclic substrate containing all carbon, oxygen, and nitrogen atoms of 4. Their total synthesis 
commenced with the synthesis of a key intermediate 56 through coupling of lactone 53 and 
alkyllithium 54, followed by protection of primary alcohol with TBS group. Then the resulting 
55 was transformed to the key intermediate 56 through deprotection and oxidation of the primary 
alcohol and azidation of the ketone. Removal of benzyl group followed by oxidation of the 
resulting primary alcohol and Staudinger reaction provided aminoaldehyde 57, which was 
immediately converted to azepane 58 by intramolecular cyclization and reduction. Treatment of 
58 with iodine promoted the key cascade cyclization of C and D rings (58→59→60→61). Finally, 
the total synthesis of stemonine (4) was accomplished by the formation of the A-ring. 
 
Scheme 5-8. The landmark total synthesis of stemonine (4) reported by Williams 
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5-1-6. Synthetic Examples of Croomine 
5-1-6-1. Williams and co-workers 
  Croomine (67) belonging to tuberostemospironine group partially shares the common structure 
corresponding to stemonine, such as pyrrolo[1,2-a]azepine skeleton and γ-lactone connected to 
the C3 position. Williams and co-workers reported the first total synthesis of (+)-croomine (67) 
featuring iodine-mediated cascade cyclization (Scheme 5-9).10 At the early stage of the synthesis, 
diastereoselective epoxidation of allylic alcohol 62 led to construction of two consecutive 
stereocenters at C9 and C9a. Treatment of 62 with catalytic amount of D-diisopropyltartrate, 
Ti(Oi-Pr)4, and t-butyl hydroperoxide in the presence of MS4A at –50 °C successfully afforded 
epoxide 63 in 83% yield. After several steps, addition of excess amount of lithium azide to 
epoxide 64 resulted in construction of nitrogen functionality at the less hindered the C9a position 
in complete stereocontrol. Resulting azide 65 was converted to spirolactone 66 in multiple steps 
through deprotection and oxidation. In the last step of this synthesis, the key iodine-mediated 
cascade cyclization of 66 gave (+)-croomine (67) in 25% yield. 
 
Scheme 5-9. The landmark total synthesis of croomine (67) reported by Williams 
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5-1-6-2. Martin and co-workers 
In 1999, Martin and co-workers reported a convergent total synthesis of (+)-croomine by 
taking advantage of two vinylogous Mukaiyama Mannich reaction (Scheme 5-10).11 The first key 
Mannich reaction of siloxyfuran 68 and N,O-acetal 69 proceeded by the treatment of catalytic 
amount of TIPSOTf (5 mol%) to give bicyclic compound 70 in 32% yield. Next, removal of the 
Boc group and hydrogenation of the unsaturated lactone led to the formation of secondary amine 
71, which would serve as a substrate of the seven-membered ring closure. Treatment of 71 with 
N-methylmorpholine in refluxing DMF followed by acidic hydrolysis of the methyl ester gave 
access to tricyclic compound 72 in 74% yield. The second key Mannich reaction of 72 was 
promoted by the addition of phospholic chloride and siloxyfuran 73 to afford two diastereomers 
74 and 75 in combined 47% yield. The total synthesis of (+)-croomine (67) was achieved by a 
Pd/C-catalyzed diastereoselective hydrogenation of the major isomer 75 possessing the desired 
stereochemistry at C13. 
 
Scheme 5-10. Total synthesis of croomine (67) reported by Martin 
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5-2. Chemoselective Reduction of Amides 
5-2-1. Rhodium-catalyzed Amide-selective Hydrosilylation 
  To reduce the amide carbonyl group, LiAlH4 has been frequently used in either the late- or 
early-stage of natural product synthesis. However, the hazardous reductant often tends to be 
avoided, and alternative methods have been extensively investigated. To the best of our 
knowledge, the first example of catalytic chemoselective hydrosilylation of amides was reported 
by Ito and co-workers in 1998.12 Optimization of rhodium-catalyst and hydrosilane reductant 
revealed that the combination of rhodium(I) hydride catalyst and Ph2SiH2 showed quick reduction 
of tertiary amide 76a to give amine 77a (Table 5-3). A remarkable advantage of this reaction is 
high functional group tolerance. For instance, aliphatic and aromatic esters, an aryl bromide, and 
an epoxide were tolerated (Figure 5-4). 
 
Table 5-3. Optimization of catalyst 
 
 
 
Figure 5-4. Substrate scope 
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5-2-2. Iridium-catalyzed Semi-reduction of tert-Amides 
After the first discovery of the catalytic mild reduction of amides by Ito and co-wokers, double-
reduction to give α-primary amine with a variety of organometallic complex have been reported 
to date.13 In contrast to this, the less number of reports regarding a catalytic semi-reduction of 
amides to give enamines have been existed. However, Nagashima and co-workers invented a 
chemoselective semi-reduction of amides taking advantage of the Vaska’s complex and 
(Me2HSi)2O (tetramethyldisiloxane: TMDS) (optimization of catalyst; shown in Table 5-4, 
substrate scope; shown in Figure 5-5).14  
 
Table 5-4. Optimization of catalyst 
 
 
Figure 5-5. Substrate scope 
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5-2-3. Iridium-catalyzed Semi-reduction of sec-Amides 
In 2012, Brookhart and co-workers established an iridium-catalyzed hydrosilylation of 
secondary amides.15 Treatment of secondary amides 81 with 0.5 mol% of [Ir(COE)2Cl]2 and 4 
equiv of Et2SiH2 afforded the corresponding amines 82 or imines 83 with good chemoselectivity. 
While secondary amines 82 were produced by conducting the reduction with 0.5 mol% of 
[Ir(COE)2Cl]2 and 4 equiv of Et2SiH2 at room temperature or 80 °C (Table 5-5), imines 83 were 
obtained by restricting Et2SiH2 to 2 equiv (Table 5-6). 
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5-2-4. Molybdenum-catalyzed Semi-reduction of tert-Amides 
A molybdenum catalyst has been widely used for catalytic oxidation or reduction of carbonyl 
compounds. Adolfsson and co-workers developed a catalytic reduction of tertiary amides 
utilizing Mo(CO)6, which is an inexpensive and a commercially available metal complex.16 The 
expected products were dependent on either the substrate or the corresponding intermediate. α,β-
Unsaturated tertiary amides 84 were converted to allylamines 85 by addition of 5 mol% of 
Mo(CO)6 and (Me2HSi)2O under reflux conditions (Figure 5-6). Under the same conditions, β,γ-
unsaturated amides 86 was converted to dienamines 87 (Figure 5-7). The key of the molybdenum-
catalyzed semi-reduction is the stabilization of enamines due to resonance effect derived from 
the adjacent aromatic ring or stylene unit. Recently, further applications of this synthetic method 
of enamines were reported such as [2+3] cycloaddition with azide17 or nitrile oxide18 (ex., 
88→89→90).  
 
Figure 5-6. Mo(CO)6 catalyzed 1,2-reduction of α,β-unsaturated amides to allylamines 
 
 
Figure 5-7. Mo(CO)6 catalyzed reduction of β,γ-unsaturated amide 
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5-3. Chemoselective Nucleophilic Addition to sec- and tert-Amides 
5-3-1. Amide-selective Nucleophilic Addition by Using the Schwartz Reagent 
In contrast to the reduction of amides to amines, reductive nucleophilic addition to amides 
requires selective semi-reduction. To restrict the over reduction, various methods were developed 
to date. A pioneering work of chemoselective reductive nucleophilic addition to amides was 
reported by Ganem and co-workers (Scheme 5-11).19 The key of chemoselective nucleophilic 
addition was lactam-selective reduction with the Schwartz reagent.20 Secondary lactam 91 was 
treated with Cp2ZrHCl to give imine 92 without harming ethyl ester, and subsequent addition of 
TMSCN led to direct access to α-cyanoamine 93 in 75% yield. 
 
Scheme 5-11. Secondary lactam-selective reductive cyanation using the Schwartz reagent 
 
 
The principle of the amide-selectivity with the Schwartz reagent could be explained by the 
following two reasons. Firstly, the coordination of zirconium to a carbonyl oxygen atom would 
be important for the reduction with the Schwartz reagent, according to the mechanism reported 
by Georg and co-workers (Figure 5-8).21 Secondly, esters also has a potential to react with the 
Schwartz reagent to give alcohols.22 This means reduction of esters with the Schwartz reagent is 
not impossible but slower than reduction of amides. The reaction of amides is faster than that of 
esters due to higher Lewis basicity of amides than esters favorably forming amide-Zr complex 
iii. However, aldehydes and ketones were reduced by the Schwartz reagent even in the presence 
of amides, due to theirs relatively higher electrophilicity than that of amides. 
 
Figure 5-8. Principle of Amide-selectivity with the Schwartz reagent 
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In 2012, Chida-Sato group developed a chemoselective reductive allylation of secondary- and 
tertiary amides using the Schwartz reagent.23 The reduction of tertiary amide 94 with 1.8 equiv 
of Cp2ZrHCl showed complete amide-selectivity to form the four-membered chelated 
intermediate 95 (Scheme 5-12A). Although 95 is less stable than the five-membered chelated 
intermediate like 4 (see p1), the stability is enough to prevent the spontaneous formation of 
iminium ion 96 followed by undesired over-reduction to form amine 98. After treatment of 95 
with TFA, the resulting intermediate 96 was immediately converted to allylated amine 97 by 
treatment of allylstannane without decomposition of the methylester. In the case of secondary 
amide 99 as a substrate, 2.6 equiv of Cp2ZrHCl promoted amide-selective reduction in the 
presence of the ester group (Scheme 5-12B). And subsequent allylation of imine 100 was 
conducted by treatment with allylstannane and TMSOTf to form secondary amine 102 via 
iminium ion 101. 
 
Scheme 5-12. Amide-selective reductive allylation using the Schwartz reagent 
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5-2-6. Iridium-catalyzed Reductive Nucleophilic Addition to tert-Amides 
The key of our previous methods for the reductive nucleophilic addition to amide was 
utilization of N-methoxyamides whose reactivity was controlled by the N-methoxy group. 
However, it would not be applicable for more general tertiary amides due to the lack of positive 
supplementary effect of methoxy group. Very recently, Chida-Sato group found an iridium-
catalyzed highly chemoselective nucleophilic addition to tertiary amides (Table 5-7). Considering 
the Nagashima’s report (Table 5-4 and Figure 5-5), treatment of tertiary amide 103a with a 
catalytic amount of Vaska’s complex and (Me2HSi)2O would allow the formation of enamine 
104a in a highly chemoselective fashion. Next, optimization of acid for the Mannich reaction of 
enamine 104a with silylketenacetal to give α-substituted amine 105a was conducted. After 
extensive investigation of acids, PPTS was revealed to be the optimal acid, which gave the desired 
product 105a in 85% yield and the undesired over reduced product 106a in merely 5% yield. 
 
Table 5-7. Iridium-catalyzed chemoselective reductive nucleophilic addition to tert-amide 
 
 
Next, the tolerance of the functional groups was investigated. The optimized conditions were 
applicable to a variety of substrates, which contain a methyl ester, a nitrile group, a nitro group, 
an aryl bromide, a MOM group, a tosic amide, a carbamate, and a terminal olefin (Figure 5-9).  
The nucleophiles were also investigated. As a result, silyl ketene acetal, TMSCN, allylstannane, 
and 2-siloxyfuran were available under the optimized conditions (Table 5-8).  
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Figure 5-9. Substrate scope 
 
 
Table 5-8. Scope of nucleophiles 
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  Dixon and co-workers reported highly chemoselective reductive functionalization of the amide 
carbonyl group taking advantage of Nagashima’s conditions.24 Firstly, they reported the reductive 
intramolecular nitro Mannich reaction (Scheme 5-13A).24a Moreover, they demonstrated the 
reductive cyanation by using TMSCN (Scheme 5-13B),24c and reductive alkylation by using 
Grignard reagent (Scheme 5-13C).24d 
 
Scheme 5-13. Amide-selective nucleophilic addition reported by Dixon and co-workers 
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Chapter 6. Enantioselective Total Synthesis of Stemoamide 
6-1. Stemoamide-type Alkaloids 
We planned to synthesize a variety of stemona-alkaloids by taking advantage of the late-stage 
chemoselective transformation of γ-lactam and γ-lactone. Especially, we focused on the synthesis 
of stemoamide-type alkaloids (Figure 6-1). Stemoamide (1)1 possesses a tricyclic core structure. 
While saxorumamide (2) and isosaxorumamide (3)2 have an additional γ-lactone on the lactone 
of stemoamide (1), stemonine (4)3 possesses an additional γ-lactone on the lactam of stemoamide 
(1). More than 20 synthetic example of 1 have been reported to date due to its relatively simple 
structure.4 In contrast, the tetracyclic derivatives cannot be synthesized easily because of its 
complex structures. Indeed, only the Williams’ group achieved the total synthesis of stemonine 
(4) by late-stage ring closure from acyclic intermediate with complete stereoselectivity (Chapter 
5, Scheme 5-8).5 
 
Figure 6-1. Stemoamide-type Alkaloids 
 
 
6-2. Chemoselective Assembly of Hetero Five-membered Building Blocks 
For the unified total synthesis of stemoamide-type alkaloids, we devised the following 
synthetic strategy. Stemoamide-type alkaloids possess five-membered hetero cyclic structures, 
and they could be introduced by utilizing α,β-unsaturated lactone 120 and lactam 121. These five-
membered blocks allow for carbon-carbon bond or carbon-heteroatom bond formation at any 
position of each building blocks such as vinylogous addition or Michael addition (Figure 6-2, 
Features). These features would enable an efficient and short step synthesis of natural products 
containing repetitive structures such as stemoamide-type alkaloids 1-4. However, in order to 
accomplish the unified synthesis of these natural products, the precise control of chemoselectivity 
is required (Figure 6-2, Issue). Convergent assembly is not feasible without the differentiation 
between the γ-lactone 120 and the γ-lactam 121. 
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Figure 6-2. The features and issue of the building block strategy 
 
 
6-3. Synthetic Plan for Unified Total Synthesis of Stemoamide-type Alkaloids 
Our actual synthetic plan is outlined in Scheme 6-1. We envisioned that stemoamide (1) could 
serve as a common precursor to the tetracyclic natural products, and incorporated two successive 
coupling reactions of the five-membered building blocks. First coupling reaction is vinylogous 
Michael reaction/reduction sequence of γ-lactam derivatives 123 to α,β-unsaturated lactone 122. 
The second coupling reaction is the chemoselective nucleophilic addition of lactone derivative 
125 to common precursor 1. The lactone-selective nucleophilic addition would afford 
saxorumamide (2) and isosaxorumamide (3), while the lactam-selective nucleophilic addition 
would afford stemonine (4). 
 
Scheme 6-1. Synthetic plan of stemoamide-type alkaloids 
 
 
 
The lactone-selective nucleophilic addition would be easily accomplished than the lactam-
selective nucleophilic addition because of the inherent larger electrophilicity of the lactone. In 
contrast, the lactam-selective nucleophilic addition would be more challenging. If successful, the 
method would enable the pioneering direct synthesis of stemonine (4) from stemoamide (1). 
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6-4. Preparation of Five-membered Building Blocks 
6-4-1. Preparation of Chiral γ-Butenolide 122 
  The unified total synthesis of stemoamide-type alkaloids commenced with synthesis of γ-
butenolide 122, which is the coupling fragment of vinylogous Michael reaction (Scheme 6-2). 
First, the Michael reaction between siloxyfuran 126 and acrolein was examined.6 The Michael 
reaction successfully proceeded upon treatment of siloxyfuran 126 with a catalytic amount of 
dimethylamine hydrochloride. The subsequent one-pot protection of aldehyde (±)-127 
immediately gave acetal (±)-128 in 82% yield. Acetal (±)-128 was then converted to butenolide 
(±)-122 by hydrolysis, reduction of aldehyde (128→129), and the Appel reaction in good yield. 
 
Scheme 6-2. Synthesis of racemic butenolide (±)-78 
 
 
  Then, the enantioselective Michael reaction of siloxyfuran 130 and acrolein to synthesize 
chiral butenolide (–)-129 was investigated (Scheme 6-3). Siloxyfuran 130 was prepared from 
furanone 120 with TIPSCl and NaN(TMS)2. According to the literature reported by Pihko and 
co-workers, we attempted the Michael reaction catalyzed by C2-symmetric pyrrolidine catalyst 
131 followed by Luche reduction of aldehyde 127.7 However, the reaction lacked both the 
reproducibility of yield and enantioselectivity, especially in the large scale. 
 
Scheme 6-3. Failure to provide chiral butenolide 129 
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To improve the reproducibility, an alternative route to synthesize butenolide 122 was 
investigated (Scheme 6-4). The reduction of commercially available ethyl 4-bromobutyrate 132 
with DIBAL-H followed by the nucleophilic addition of lithium acetylide to the resulting 
aldehyde 133 gave propargylic alcohol 134 in 60% yield over two-steps. Next, the semi-reduction 
of alkyne 134 was attempted. Extensive investigation revealed semi-reduction of alkyne cannot 
be achieved by homogeneous palladium catalyst,8a-d homogeneous nickel catalyst,8e-g or 
heterogeneous palladium catalyst,8h and combinations of additives and solvents (entries 1-6). 
However, the palladium catalyst supported on polyethylene imine reported by Sajiki and co-
wokers was effective for the semi-reduction.9 Subsequent one-pot addition of aqueous hydrogen 
chloride afforded (±)-122 along with over-reduced byproduct 136. Under these conditions, the 
combination of solvent was very important. In fact, although the reaction in 1,4-dioxane was not 
effective for this semi-reduction (entry 7), use of MeOH/1,4-dioxane 1:1 resulted in highly 
selective formation of butenolide 122 in 73% yield along with 136 in 5% yield (entry 8).  
 
Scheme 6-4. Alternative route for racemic butenolide 122 
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Once we set the appropriate conditions for the synthesis of racemic butenolide 122, we then 
focused on enantioselective synthesis of butenolide 122 (Scheme 6-5). To achieve the 
enantioselective alkynylation, we decided to employ conditions reported by Trost and co-
workers.10 After reduction of 132 (8.16 g), treatment of resulting aldehyde with 20 mol% of (S,S)-
Prophenol catalyst 137, Me2Zn, and methyl propiolate gave (–)-134 in 78% yield and with 98% 
ee. Following semi-reduction/cyclization under optimized condition in Scheme 6-4 afforded 3.18 
g of (–)-122 in 72% yield with high reproductivity without racemization. 
 
Scheme 6-5. Asymmetric synthesis of butenolide (–)-122 
 
 
6-4-2. Synthesis of 2-Siloxypyrroles 123a-d 
  2-Siloxypyrroles 123a and 123d were synthesized in 2 steps from commercially available 2,5-
dimethoxy-2,5-dihydrofuran 138 and primary amines (Scheme 6-6).11 The reaction between 138 
and N-methoxyamine hydrochloride was conducted at –2 °C for 24 h to prevent the runaway 
reaction due to unavoidable use of excessive amount of acid as the HCl salt (1 equiv HCl, 
condition A). The reaction between 138 and H2NPMB could be conducted under milder acidic 
conditions (0.2 equiv HCl, condition B). In order to keep the pH approximately around 4, the 
H2NPMB should be added dropwise, especially in large scale. 123b and 123c were prepared 
through oxidation of pyrrole 141 followed by Boc- and TIPS-protections.12 
 
Scheme 6-6. Synthesis of siloxypyrrole 123 
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6-5. Vinylogous Michael Reaction 
6-5-1. Initial Investigation of Vinylogous Michael Reaction 
  With butenolide 122 and 2-oxipyrrole 123 in hand, we then attempted the vinylogous Michael 
reaction. In general, α,β-unsaturated lactam 142 and enamide 143, which are plausible product 
of vinylogous Michael reaction of 122 and 123, would tautomerize respectively via 2-oxypyrrole 
144 under basic conditions.13  
 
Figure 6-3. Predictable issue in vinylogous Michael reaction 
 
 
  Taking the above context into account, we optimized the Mukaiyama-type vinylogous Michael 
reaction of butenolide 122 and 2-siloxypyrrole 123a. First we attempted the fluoride ion mediated 
Michael reaction (Scheme 6-7). After investigation, we found that sufficiently dried TBAF was 
essential for C-C bond formation to afford bicyclic compound 145a, which was immediately 
transformed to enolate 146a. Then the protonation of 146a afforded 142a and 143a (142a: 51%, 
dr = 1:1, 143a: 26%). However the intermediate 146a tended to undergo quick oxidation when 
the slight amount of oxygen was present. Therefore, the use of completely degassed solvent and 
careful control of temperature below –78 °C were necessary. Furthermore, hydrogenation of 142a 
and 143a resulted in poor yield and low stereoselectivity at C9a (68%, 124a:epi-124a = 1:1). 
 
Scheme 6-7. TBAF mediated vinylogous Michael reaction 
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  We then investigated the Lewis acid-mediated vinylogous Michael reaction (Table 6-1). 
Interestingly, this reaction did not proceed with acid other than SnCl4 (Table 6-1, entries 1 to 5). 
In addition, in entry 5, hydrated product 147a was produced in 11% yield. Further investigation 
revealed that excess amount of SnCl4 suppressed the coupling reaction and result in significant 
recovery of butenolide 122 (Table 6-1, entry 6). In contrast, 0.5 equivalent of SnCl4 promoted the 
formation of 147a, and decrease recovery of starting material 122 (Table 6-1, entry 7). Moreover, 
the combined yield of coupling products 142a, 143a, and 147a was largest in entry 7 (87%), and 
optimal acid for vinylogous Michael reaction was decided as 0.5 equiv SnCl4.  
 
Table 6-1. Acid mediated vinylogous Michael reaction 
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6-5-2. Plausible Mechanism and Working Hypothesis for the One-pot Reaction 
Based on the results shown in Table 6-1, we postulated the reaction mechanism and proposed 
a working hypothesis (Scheme 6-8). Treating the mixture of butenolide 122 and 2-siloxypyrrole 
123a with SnCl4 would immediately construct the carbon-carbon bond at C9 and C9a position to 
form ketenacetal 148a with complete stereoselectivity at C9. The excess amount of SnCl4 would 
cause deprotection of TIPS group of 148a to form enolate 149a, which would decompose by 
retro-Michael reaction or transform to α,β-unsaturated lactam 142a. Without the excess amount 
of SnCl4, 148a would immediately be converted to the siloxypyrrole 150a via proton transfer.  
We predicted that 150a would be stable under Lewis acidic conditions at low temperature, and 
converted to enamide 143a via protonation at the less hindered α-position of 150a. In fact, 
according to the TLC analysis, enamide 143a was selectively produced at –78 °C. Then, further 
protonation of enamide 143a would form acyliminium ion 151a, which would react with 
hydrosilane to give the desired lactam 124a. In case we employ an alcohol as a proton source, it 
may assist extending the life-span of iminium ion 151a via the formation of N,O-acetal 152a. 
One of the advantages in this strategy was the every intermediate would converge to the iminium 
ion 151a. In other words, the stereoselectivity of reduction at C9a would only rely on the silane 
reagent and protecting group of the nitrogen. In addition this one-pot reaction would allow us to 
evade the isolation of the unstable intermediate 143a. 
 
Scheme 6-8. Proposed reaction mechanism and working hypothesis 
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6-5-3. Acid-Mediated Vinylogous Michael Reaction 
  To demonstrate our working hypothesis, we optimized the reaction conditions for the one-pot 
vinylogous Michael reaction and reduction sequence. After optimization of the reaction between 
butenolide 122 and N-methoxypyrrole 123a, the bicyclic lactam 124 and epi-124 were produced 
in 77% combined yield (Table 6-2, entry 1). However, under these conditions, not only the poor 
stereoselectivity at C9a was observed, but also racemization was slightly observed. To solve these 
problems, we conducted further investigation. The protecting group of nitrogen was essential, 
and no coupling product was obtained with N-H pyrrole (Table 6-2, entry 2). The reaction with 
N-Boc pyrrole 123c resulted in decomposition due to its instability under acidic conditions (Table 
6-2, entry 3). We found that the utilization of N-PMB group would improve the 
diastereoselectivity (124:epi-124 = 2.7:1), and did not cause racemization (Table 6-2, entry 4).  
 
Table 6-2. Optimization of the protecting group on nitrogen 
 
 
  With the appropriate protecting group of the nitrogen in hand, the silane reductant and 
additional acid were then surveyed (Table 6-3). Use of more sterically hindered triphenylsilane 
and less hindered phenylsilane resulted in poor diastereoselectivity (Table 6-3, entries 2, 3). To 
form N-acyliminium ion, TiCl4 was revealed as an optimal Lewis acid (Table 6-3, entries 4, 5). 
The optimized conditions were successfully applied to gram-scale reaction between chiral 
butenolide 122 (3.11 g, 98% ee) and N-PMB-siloxypyrrole 123d to afford the bicyclic compound 
124 and epi-124 in 73% combined yield with 3.7:1 diastereoselectivity as an inseparable mixture 
(Table 6-3, entry 6).  
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Table 6-3. Optimization of silane reductant and acid 
 
 
The racemization of the product 124a was rationalized when using N-methoxypyrrole 123a 
(Scheme 6-9). First, the coupling reaction gave spiroacetal 157a as an important side product. 
The deprotonation of acyliminium ion 151a could form tetra-substituted enamide 153a. Then, 
the chirality of the C8 position would disappear via the elimination of the carboxylate 154a. 
While reconstruction of γ-lactone 153a would provoke the racemization of 151a, irreversible 
reduction of 154a by silane reagent would form enamide 155a. Protonation of 155a and 
subsequent cyclization of iminium ion 156a led to spiroacetal 157a. The driving forth of these 
reactions would be the increased electrophilicity of N-acyl-N-oxyiminium ion 151a, which 
enables not only the reduction but also the deprotonation to form enamide 153a. 
 
Scheme 6-9. Mechanism of racemization of the N-methoxy substrate 
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6-5-4. Proposed Mechanism of Stereoselectivity 
A proposed mechanism of stereocontrol at the C9 and C9a in vinylogous Michael reaction is 
described in Scheme 6-10A. Firstly, the siloxyfurans would avoid a steric repulsion with bromide 
side chain. Therefore, the C9 stereochemistry was completely controlled, and the C9a 
stereochemistry would depend on the face-selectivity of siloxypyrrole. In transition states TS-1 
and TS-4, the steric repulsion between the substituent of the nitrogen atom and the bromoalkyl 
side-chain would be large. However, transition state TS-2 (Diels-Alder-type) and TS-3 (Open-
type) seems to avoid this steric repulsion.14 Considering the experimental results, the Diels-Alder 
like transition state TS-2 which affords major product α-142 seems to be the most dominant 
transition state.  
In the one-pot reduction, the stereoselectivity at the C9a stereocenter yet to be clarified, the 
selectivity would be explained as shown in Scheme 6-10B. The PMB group would point out the 
opposite direction to the bromide side-chain. Thus, the conformer 151’ would be more dominant 
than 151. The reduction of iminium ion 151’ with triethylsilane would proceed to avoid the 
bromide side-chain affording 124d as a major product. 
 
Scheme 6-10. Plausible mechanism of vinylogous Michael reaction and reduction sequence 
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6-6. Gram-scale Total Synthesis of (–)-Stemoamide 
  Having a practical method for supplying bicyclic compound 124 and epi-124 established on 
multi-gram scale, the next subject is the total synthesis of stemoamide (1) (Scheme 6-11). 
Oxidative removal of N-PMB group using cerium ammonium nitrate gave secondary lactam 158 
and epi-158 in 94% yield (158:epi-158 = 3.7:1). Then, treatment with sodium hydride in the 
presence of catalytic amount of TMSOTf and tetrabutylammonium iodide led to the formation of 
a separable mixture 48 and epi-48 (48: 57%, epi-48: 19%). During the construction of the seven-
membered ring, residual sodium hydroxide induced the hydrolysis of γ-lactone of 1 and formed 
undesired side product 161 (Scheme 6-12). If sodium hydride reacts with slight amount of water, 
sodium hydroxide would easily hydrolyze the γ-lactone 158, giving γ-hydroxy carboxylate 48. 
Then, intramolecular cyclization of the secondary alcohol with alkyl bromide would produce 
furan carboxylic acid 161. Therefore, to avoid this side reaction, we treated the suspension of 
sodium hydride and DMF with TMSOTf to remove the residual sodium hydroxide in advance. 
The total synthesis of stemoamide (1) was accomplished by the site- and stereo-selective 
methylation of tricyclic compound 48 in 84% yield.15 Our enantioselective route enabled the 
gram-scale supply of stemoamide (1: 1.07 g) from a single path in 7 steps and 19.2% total yield, 
which represents one of the most efficient enantioselective synthesis to date. 
 
Scheme 6-11. Total Synthesis of Stemoamide (1) 
 
 
Scheme 6-12. Reaction mechanism from secondary lactam 158 to side product 161 
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Chapter 7. Total Syntheses of Tetracyclic Natural Products 
7-1. Strategies for Lactone-selective Nucleophilic Addition 
  With stemoamide (1) in hand, we embarked on the total syntheses of saxorumamide and 
isosaxorumamide featuring the lactone-selective nucleophilic addition. This chemoselectivity 
could be achieved with classic transformations by taking advantages of the inherent 
electrophilicity: γ-lactone > γ-lactam (Figure 7-1A). In addition, the stereocenter at C11 could be 
constructed with the addition of second nucleophile to an oxocarbenium ion, which is equally 
important as chemoselectivity (Figure 7-1B). To construct desired stereochemistry at C11, we 
proposed two reaction pathway in terms of the order of introduction of reductant (H○― ) and lactone 
equivalent (R○― ).  
 
Figure 7-1. Synthetic plan of saxorumamide (2) and isosaxorumamide (3) 
 
 
  To construct the desired stereochemistry at C11, the most stable conformation of 
oxocarbenium intermediate 162 and 163 were calculated and depicted in Figure 7-2.1 
Stereochemical outcome could be predictable based on both steric effect of methyl group and 
stereoelectronical effect proposed by Woerpel and co-workers.2 In “path I”, the sterically large 
lactone equivalent would attack from both faces due to the competition between steric repulsion 
of methyl group and stereoelectronic effect which arise from the eclipse interaction between the 
nucleophile and the hydrogen atom at C10. In “path II”, if the sterically small reductant is 
employed, the steric effect of the methyl group would become negligible. In such case, the 
stereoselectivity may be controlled by stereoelectronic effect to produce the desired isomer 164.  
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Figure 7-2. Prediction of Stereochemistry 
 
 
7-2. Total Syntheses of saxorumamide and isosaxorumamide via “path I” 
  We investigated the “path I” shown above (Scheme 7-1). The lactone-selective reduction of 
stemoamide (1) was accomplished by treatment with DIBAL at –78 °C to form lactol 165. The 
five-membered lactone was successfully introduced to 165 in the presence of BF3·OEt2 via 
oxocarbenium ion 162. However, the stereoselectivity could not be controlled at all, and four 
diastereomers; saxorumamide 2, isosaxorumamide 3, and 11-epimers 166 and 167 were produced 
(2: 12%, 3: 9%, 166: 15%, 167: 12%, two-step yield from 1).  
 
Scheme 7-1. Total Syntheses of Saxorumamide and Isosaxorumamide through “Path I” 
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7-3. Total Syntheses of saxorumamide and isosaxorumamide via “path II” 
  Next we investigated “path II”. Firstly, success of this reaction would rely on a design of the 
lactone equivalent (Figure 7-3). The candidates of lactone equivalent 168 or 169 would react with 
lactone 171, and subsequent reduction of lactol 172 would afford the target structure 174. 
However, 173 could also be converted to dienoate 175 via undesired deprotonation, which might 
be difficult to transform to 174. Therefore, furyllithium 170 would be more practical candidate, 
which would be converted to furan 178 through nucleophilic addition to lactone 171 followed by 
reduction of lactol 176. In addition, the benzylic lactol 176 would be transformed to 
oxocarbenium ion 177 at low temperature, and lead to stereoselective construction of the desired 
structure 178.  
 
Figure 7-3. The candidates of lactone equivalent in “Path II” 
 
 
  Taking these synthetic plan into considering, furyllithium nucleophile 1793 was selected as 
appropriate nucleophile for the concise and efficient synthesis of saxorumamide families 
(Scheme 7-2). The lactone-selective nucleophilic addition of furyllithium 179 to stemoamide (1) 
provided enol ether 180 in 87% yield through concomitant dehydration of lactol via 
oxocarbenium ion 181 probably with the assistance of the adjacent electron donating furan ring. 
Gratifyingly, stereoselective reduction of enol ether 180 was achieved with NaBH3CN in the 
presence of CCl2HCO2H at –78 °C. Two consecutive stereocenters (C10 and C11) were 
established by stereoselective protonation of the enol ether and subsequent reduction of the 
resulting oxocarbenium ion 181,1 giving 182 in 95% yield as a single diastereomer.  
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Scheme 7-2. Construction of C11 stereocenter through “Path II” 
 
 
The mechanistic rational of stereoselective protonation of enol ether 180 and reduction of 
oxocarbenium ion 181 were described in Scheme 7-3. The protonation of enol ether 180 would 
proceed through transition state 183 or 184 in which 183 would be disfavored due to the steric 
repulsion between two hydrogen atom located eclipse relationships. Therefore, protonation at β-
side through transient 184 would be preferable to form oxocarbenium ion 181. As expected, the 
stereoselective reduction took place from β-side of oxocarbenium ion 181 to afford furan 182 as 
a single diastereomer. 
 
Scheme 7-3. Construction of C11 stereocenter through “Path II” 
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The remaining task was the conversion of furan ring to α,β-unsaturated lactone (Scheme 7-4). 
Treatment of furan 182 with mCPBA (1.2 equiv) led to lactone 187 through Meinwald 
rearrangement of epoxy silane 185 with weak acidic condition of m-chlorobenzoic acid derived 
from mCPBA.3 The driving force of the 1,2-migration was the strong cationic character at C14 
due to the β-effect of silyl group and the mesomeric effect (186↔186’). In addition, the remaining 
mCPBA oxidized the resulting enol ether 187 affording 188. Treatment a mixture of 187 and 188 
with TBAF, followed by addition of AcOH and NaBH4 gave saxorumamide (2) and 
isosaxorumamide (3).3a Epoxide 188 was produced by bisepoxidation of furan 182, and converted 
to γ-hydroxy-α,β-unsaturated lactone 189. Therefore treatment of 189 with AcOH and NaBH4 led 
to formation of 2 and 3. Thus, we accomplished the first total synthesis of saxorumamide (2) and 
isosaxorumamide (3) in 11 longest liner steps in 7.3% and 6.2% total yield, respectively. 
 
Scheme 7-4. Total synthesis of saxorumamide (2) and isosaxorumamide (3) 
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7-4. Lactam-selective Nucleophilic Addition Using Schwartz Reagent 
  Lactone is known to be more electrophilic than lactam. On the contrary, the lactam possesses 
higher Lewis basicity than lactone due to the mesomeric effect of nitrogen, which contributes to 
stability of carbonyl group of lactam. Therefore, the high Lewis basicity of lactam have a 
potential to overcome the difficulty to differentiate γ-lactam and γ-lactone. 
  Previously, Chida-Sato group reported the amide-selective reductive functionalization by 
taking advantage of the Schwartz reagent [Cp2ZrHCl], which is reliable amide-selective reducing 
agent even in presence of ester (Scheme 7-5).4,5 Treatment of N-methoxyamide 190 with 1.1 
equivalent of Cp2ZrHCl gave five-membered chelate intermediate 191. Subsequent addition of 
siloxyfuran 130 and a catalytic amount of Sc(OTf)3 to the chelated intermediate 191 provided α-
substituted N-methoxyamine 193 via iminium ion 192 in 78% yield.  
 
Scheme 7-5. Amide-selective nucleophilic addition with the Schwartz reagent 
 
 
Thus, this method was adopted to the γ-lactam-selective reductive nucleophilic addition of 
siloxyfuran 73 to N-methoxylactam 194 (Scheme 7-6). The reductive nucleophilic addition of 
194 proceeded in 39% combined yield and the four diastereomers were obtained in poor 
diastereoselectivity at C3 and C13 stereocenters, along with recover of the starting material 194 
in 39% yield. In addition, when we attempted the reductive nucleophilic addition to stemoamide 
(1) using the Schwartz reagent, the tetracyclic compound 197 was not observed, and instead lactol 
198 was obtained and the starting material 1 was recovered in 26% and 32%, respectively. These 
results indicated that the Schwartz reagent cannot achieve the γ-lactam-selective reduction of the 
substrate that include γ-lactone moiety such as 194 or 1. 
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Scheme 7-6. The attempt of γ-lactam-selective nucleophilic addition with Schwartz reagent 
 
 
7-5. Total Synthesis of Stemonine 
Since the Schwartz reagent was not effective for the lactam-selective functionalization of 
stemoamide (1), other γ-lactam-selective reducing agent was explored. Buchwald reduction with 
Ti(OiPr)4 and Ph2SiH2,6 Brookhart method with cat. [Ir(COE)2Cl]2 and Et2SiH2,7 
Tinnis/Adolfsson reduction with cat. Mo(CO)6 and (Me2HSi)2O,8 could not achieve the 
chemoselective semi-reduction of the γ-lactam (Scheme 7-7). 
 
Scheme 7-7. Investigation of lactam-selective reducing agent 
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However, we solved this problem by utilizing Nagashima’s conditions for an iridium-catalyzed 
hydrosilylation (Table 7-1).9,10 Treatment of stemoamide (1) with the Vaska complex 
[IrCl(CO)(PPh3)2] (1 mol%) and (Me2HSi)2O (1.5 equiv)11 initiated hydrosilylation of the γ-
lactam carbonyl and subsequent elimination of the siloxy group to form enamine 200. Next, the 
optimization of acid was conducted. Treatment of enamine 200 with 2-siloxyfuran 73, MeCN 
and a Brønsted acid in a one-pot process generated the transient iminium ion 201, which 
underwent the vinylogous Mannich reaction to give tetracyclic compounds 197 and epi-197. The 
optimal acid was proved to be 2-nitrobenzoic acid whose pKa is 2.19 (entry 3, 92%, dr = 1.4:1). 
Both reduction of the γ-lactam and the subsequent addition of 73 took place in highly 
chemoselective fashion without affecting the reactive γ-lactone even in 20 mg scale, giving the 
products 197 in 43% and epi-197 in 30% isolated yield, respectively (entry 9). The addition of 2-
siloxyfuran 73 resulted in complete stereocontrol at the C3 carbon center. In contrast, a slight 
diastereoselectivity at C13 (dr = 1.4:1)12,13 was observed favoring the desired product 197 over 
the undesired product epi-197, which could be isomerized to 197 with DBU in CH2Cl2. Thus, we 
achieved the first direct installation of the γ-lactone to stemoamide (1) at the late stage of the 
synthesis. 
 
Table 7-1. Lactam-selective nucleophilic addition to stemoamide (1) 
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The diastereoselectivity at the C3 and C13 stereocenters would be controlled by inherent 
conformation of the substrate. The most stable conformation of stemoamide (1) and iminium 
intermediate 201 were calculated as shown below (Figure 7-4).14 According to this structure, 2-
siloxyfuran 73 approached from the convex side of iminium ion 201, resulting in complete 
stereocontrol at the C3 carbon center. To prove the importance of the rigid tricyclic cage structure, 
nucleophilic addition to bicyclic compound 194 was performed with various nucleophiles (Table 
7-2). As a result, we could not achieve the stereoselective introduction of siloxyfuran to the 
lactam carbonyl group of 194. Therefore, the tricyclic structure of stemoamide was crucial for 
the construction of the desired stereochemistry at C3. In contrast, the stereoselectivity at C13 was 
moderate due to the planarity of the nucleophile.  
 
Figure 7-4. Conformation of stemoamide (1) and iminium ion (201) 
  
 
Table 7-2. Nucleophilic addition to the bicyclic substrate 194 
 
  
Stemoamide (1) iminium ion 201 
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The hydrogenation of α,β-unsaturated lactone 197 was investigated (Table 7-3). The Pd/C 
catalyzed reduction of 197 led to 5.6:1 mixture of diastereomers of stemonine (4) and 15-epi-
stemonine (epi-4) (Table 7-3, entry 2). This hydrogenation of γ-lactone using homogeneous 
catalyst proceeded on the opposite face to the substituent at C13 to give stemonine (4) as a major 
product. The silica gel column chromatography was attempted for the separation of two 
diastereomers 4 and epi-4. However, it resulted in isolation of stemonine (4) in merely 18% yield 
because either 4 or epi-4 would be unstable to air and silica gel (Table 7-3, entry 3). Therefore, 
we had to find a heterogeneous reducing agent, which can achieve perfect chemoselectivity at 
C15 and can be removable by simple filtration. Finally, we revealed that Rh/Al2O3-catalyzed 
reduction could achieve this task, giving stemonine (4) in high yield as the sole product (Table 7-
3, entry 5). Thus, we succeed in establishing the novel method for the direct access to stemonine 
(4) from stemoamide (1) in two steps including chemoselective nucleophilic addition and 
hydrogenation. 
 
Table 7-3. Hydrogenation of α,β-unsaturated lactone 198 
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Chapter 8. Conclusion 
  We accomplished a unified total synthesis of stemoamide-type alkaloids through convergent 
assembly of three five-membered building blocks. The first key reaction was the vinylogous 
Michael reaction/reduction of butenolide 122 and 2-siloxypyrrole 123d. The second key reaction 
was the chemoselective nucleophilic addition to stemoamide (1) as the common precursor to the 
tetracyclic natural products. While the lactone-selective nucleophilic addition led to first total 
synthesis of saxorumamide (2) and isosaxorumamide (3), the lactam-selective reductive 
nucleophilic addition enabled the direct access to stemonine (4) in 2 steps from stemoamide (1). 
Overview of synthetic route is described below (Scheme 8-1, 8-2). The gram-scale total synthesis 
of stemoamide (1) was accomplished from commercially available ethyl 4-bromobutyrate 132 
from a single path in 7 steps and 19.2% total yield. 
 
Scheme 8-1. Overview of unified total synthesis of stemoamide-type alkaloids (Part I) 
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The first total synthesis of saxorumamide (2) and isosaxorumamide (3) in 11 longest liner steps 
in 7.3% and 6.2% total yield, respectively. A concise and efficient total synthesis of stemonine 
(4) was accomplished in 9 steps with an overall yield of 8.1% (10 steps and 11.0% total yield 
including isomerization of epi-197) 
 
Scheme 8-2. Overview of unified total synthesis of stemoamide-type alkaloids (Part II) 
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The lactam-selective reductive nucleophilic addition in the presence of lactones could be 
applicable to total syntheses of other members of the Stemona-alkaloids. 
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A. Experimental Procedures 
General Details. Reactions were performed in oven-dried glassware fitted with rubber septa under an 
argon atmosphere. Toluene, DMSO and (CH2Cl)2 were distilled from CaH2. DMF and MeOH were 
distilled from CaSO4. Pyridine was distilled from sodium hydroxide. All distilled solvents, MeCN, CH2Cl2 
and EtOH were dried over activated 3Å molecular sieves. THF (dehydrated, stabilizer free) was from 
KANTO CHEMICAL CO., INC. Commercial reagents were used without further purification. Thin-layer 
chromatography was performed on Merck 60 F254 precoated silica gel plates, which were visualized by 
exposure to UV (254 nm) or stained by submersion in aquatic cerium- ammonium molybdate, aquatic 
potassium manganate or ethanolic phosphomolybdic acid solution followed by heating on a hot plate. 
Flash column chromatography was performed on silica gel (Silica Gel 60 N; 63‒210 or 40‒50 mesh, 
KANTO CHEMICAL CO., INC.). 1H NMR spectra were recorded at 500 MHz and 13C NMR spectra at 
125 MHz with JEOL ECA-500 spectrometers. Chemical shifts are reported in ppm with reference to 
solvent signals [1H NMR: CDCl3 (7.26), CD3OD (3.31), d-acetone (2.05), C6D6 (7.16); 13C NMR: CDCl3 
(77.16)]. Signal patterns are indicated as brs, broad peak; s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet. MPLC was performed on Yamazen, YFLC AI-580. Infrared spectra were recorded using a 
BRUKER ALPHA FT-IR spectrometer. Mass spectra (EI and FAB) were measured with a JEOL GC-Mate 
spectrometer. Mass spectra (ESI-TOF) were measured with a Waters, LCT Premier XE. Melting points 
were measured with a Mitamura-Riken microhot stage or Yanaco MODEL MP-S3. 
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Two-step Synthesis of Multi-substituted Amines 
 
A-1. Two-step Synthesis of Multi-substituted N-Methoxypiperidine 
Preparation of aldehydes 94e, 94f 
 
 
 
 
benzyl (6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (141e) 
tert-Butyldimethylsilyl chloride (300 mg, 1.99 mmol) was added to a solution of alcohol 140e (414 mg, 
1.65 mmol),1 triethylamine (280 L, 2.0 mmol) and CH2Cl2 (8.2 mL) at room temperature. The solution 
was maintained for 24 h at room temperature, and quenched with H2O (10 mL). The resulting mixture 
was extracted with chloroform (2 x 10 mL). The combined organic extracts were washed with brine (10 
mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:20 to 1:10) to give 585 mg of 141e (97%): a colorless oil; IR (film) 3337, 2932, 2858, 
1700, 1540, 1457, 1255, 1098, 836 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.38‒7.29 (m, 5H), 5.09 (s, 2H), 
4.71 (bs, 1H), 3.59 (t, J = 6.6 Hz, 2H), 3.19 (dt, J = 6.6, 6.6 Hz, 2H), 1.54‒1.46 (m, 4H), 1.37‒1.29 (m, 
4H), 0.89 (s, 9H), 0.04 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 156.5 (C), 136.8 (C), 128.6 (CH), 128.20 
(CH), 128.15 (CH), 66.6 (CH2), 63.2 (CH2), 41.2 (CH2), 32.8 (CH2), 30.1 (CH2), 26.7 (CH2), 26.1 (CH3), 
25.6 (CH2), 18.5 (C), ‒5.2 (CH3); HRMS (ESI), calcd for C20H35NO3SiNa+ (M+Na)+ 388.2284, found 
388.2281. 
 
 
 
tert-butyl (6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (141f) 
tert-Butyldimethylsilyl chloride (310 mg, 2.06 mmol) was added to a solution of alcohol 140f (373 mg, 
1.72 mmol),2 triethylamine (290 L, 2.1 mmol) and CH2Cl2 (8.6 mL) at room temperature. The solution 
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was maintained for 24 h at room temperature, and quenched with H2O (10 mL). The resulting mixture 
was extracted with chloroform (2x10 mL). The combined organic extracts were washed with brine (10 
mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:30 to 1:20) to give 505 mg of 141f (88%): a colorless oil; IR (film) 3360, 2932, 2859, 
1697, 1525, 1366, 1254, 1175, 1100, 837, 776 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.49 (bs, 1H), 3.59 (t, 
J = 6.6 Hz, 2H), 3.10 (dt, J = 7.2, 7.2 Hz, 2H), 1.54‒1.42 (m, 4H), 1.44 (s, 9H), 1.36‒1.29 (m, 4H), 0.89 
(s, 9H), 0.04 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 156.1 (C), 79.0 (C), 63.2 (CH2), 40.7 (CH2), 32.8 
(CH2), 30.2 (CH2), 28.5 (CH3), 26.7 (CH2), 26.1 (CH3), 25.6 (CH2), 18.5 (C), ‒5.2 (CH3); HRMS (ESI), 
calcd for C17H37NO3SiNa+ (M+Na)+ 354.2440, found 354.2437. 
 
 
 
benzyl benzyl(6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (142e) 
Sodium hydride (60 wt%, 71.5 mg, 4.96 mmol) was added to a solution of carbamate 141e (362 mg, 990 
mol) and THF (2.0 mL) at room temperature. After stirring for 20 min, benzyl bromide (240 L, 2.0 
mmol) and tetrabutylammomium iodide (3.7 mg, 9.9 mol) were added to the mixture of 141e at room 
temperature. The resulting mixture was stirred for 24 h, and quenched with H2O (5 mL). The resulting 
mixture was extracted with EtOAc (5 mL). The organic extracts were washed with brine (5 mL), dried 
over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:40) to give 423 mg of 142e (94%): a colorless oil; IR (film) 2932, 2858, 1703, 1472, 
1422, 1248, 1097, 836 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 7.44‒7.12 (m, 10H), 5.18 (s, 2H), 4.50 
(s, 2H), 3.59 (t, J = 6.3 Hz, 2H), 3.30‒3.18 (m, 2H), 1.58‒1.41 (m, 4H), 1.35‒1.20 (m, 4H), 0.89 (s, 9H), 
0.04 (s, 6H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 156.6 (C), 138.3 (C), 137.2 (C), 128.65 (CH), 128.56 
(CH), 128.0 (CH), 128.0 (CH), 127.8 (CH), 127.4 (CH), 67.3 (CH2), 63.2 (CH2), 50.7 (CH2), 47.2 (CH2), 
32.9 (CH2), 28.2 (CH2), 26.8 (CH2), 26.1 (CH3), 25.7 (CH2), 18.5 (C), ‒5.1 (CH3); HRMS (ESI), calcd for 
C27H42NO3Si+ (M+H)+ 456.2934, found 456.2938. 
 
 
 
tert-butyl benzyl(6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (142f) 
Sodium hydride (60 wt%, 71.5 mg, 4.96 mmol) was added to a solution of carbamate 141f (330 mg, 995 
mol) and THF (2.0 mL) at room temperature. After stirring for 20 min, benzyl bromide (240 L, 2.0 
mmol) and tetrabutylammomium iodide (3.7 mg, 9.9 mol) were added to the mixture of 141f at room 
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temperature. The resulting mixture was stirred for 24 h, and quenched with H2O (5 mL), and extracted 
with EtOAc (5 mL). The organic extracts were washed with brine (5 mL), dried over Na2SO4, and 
concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane 1:60) to give 
309 mg of 142f (74%): a colorless oil; IR (film) 2930, 2857, 1697, 1463, 1416, 1365, 1249, 1170, 1099, 
836, 775 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 7.31 (t, J = 7.5 Hz, 2H), 7.27‒7.21 (m, 3H), 4.43 (s, 
2H), 3.58 (t, J = 6.6 Hz, 2H), 3.22‒3.12 (m, 2H), 1.55‒1.43 (m, 4H), 1.47 (s, 9H), 1.36‒1.22 (m, 4H), 
0.90 (s, 9H), 0.04 (s, 6H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 156.0 (C), 139.0 (C), 128.6 (CH), 127.6 
(CH), 127.2 (CH), 79.6 (C), 63.3 (CH2), 50.5 (CH2), 46.9 (CH2), 33.0 (CH2), 28.7 (CH3), 28.3 (CH2), 26.9 
(CH2), 26.1 (CH3), 25.8 (CH2), 18.5 (C), ‒5.1 (CH3) ; HRMS (ESI), calcd for C24H43NO3SiNa+ (M+Na)+ 
444.2910, found 444.2907. 
 
 
 
benzyl benzyl(6-hydroxyhexyl)carbamate (143e) 
Tetrabutylammonium fluoride (1.0 M in THF, 760 L, 760 mol) was added to a solution of 142e (288 
mg, 632 mol) and THF (3.2 mL) at room temperature. The solution was maintained for 2 h at room 
temperature, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:9 to 1:2) to give 206 mg of 143e (95%): a colorless oil; IR (film) 3158, 2937, 2863, 
1701, 1454, 1423, 1236, 733, 699 cm-1; 1H NMR (300 MHz, CDCl3, 1:1 mixture of rotamers) δ 7.41‒7.10 
(m, 10H), 5.18 (s, 1H), 5.17 (s, 1H), 4.49 (s, 2H), 3.27 (t, J = 7.0 Hz, 1H), 3.20 (t, J = 7.0 Hz, 1H), 2.32 
(t, J = 7.0 Hz, 1H), 2.26 (t, J = 7.0 Hz, 1H), 1.70‒1.39 (m, 4H), 1.39‒1.16 (m, 4H); 13C NMR (125 MHz, 
CDCl3, 60 °C) δ 156.7 (C), 138.2 (C), 137.1 (C), 128.65 (CH), 128.56 (CH), 128.03 (CH), 128.00 (CH), 
127.7 (CH), 127.4 (CH), 67.3 (CH2), 62.8 (CH2), 50.7 (CH2), 46.9 (CH2), 32.8 (CH2), 28.1 (CH2), 26.6 
(CH2), 25.5 (CH2); HRMS (ESI), calcd for C21H27NO3Na+ (M+Na)+ 364.1889, found 364.1886. 
 
 
 
tert-butyl benzyl(6-hydroxyhexyl)carbamate (143f) 
Tetrabutylammonium fluoride (1.0 M in THF, 680 L, 680 mol) was added to a solution of 142f (219 
mg, 567 mol) and THF (2.8 mL) at room temperature. The solution was maintained for 2 h at room 
temperature, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:9 to 1:2) to give 168 mg of 143f (97%): a colorless oil; IR (film) 3441, 2932, 2860, 
1693, 1455, 1417, 1366, 1246, 1168, 879, 732, 700 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 7.31 (t, J 
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= 6.9 Hz, 2H), 7.27‒7.21 (m, 3H), 4.43 (s, 2H), 3.62 (t, J = 6.6 Hz, 2H), 3.19 (bs, 2H), 1.58‒1.48 (m, 4H), 
1.47 (s, 9H), 1.40‒1.25 (m, 4H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 156.1 (C), 139.0 (C), 128.6 (CH), 
127.6 (CH), 127.2 (CH), 79.7 (C), 62.9 (CH2), 50.5 (CH2), 46.7 (CH2), 32.9 (CH2), 28.6 (CH3), 28.2 (CH2), 
26.7 (CH2), 25.6 (CH2); HRMS (ESI), calcd for C18H29NO3Na+ (M+Na)+ 330.2045, found 330.2040. 
 
 
 
benzyl benzyl(6-oxohexyl)carbamate (94a) 
2-Iodoxybenzoic acid (223 mg, 795 mol) was added to a solution of alcohol 143e (181 mg, 530 mol) 
and DMSO (5.3 mL) at room temperature. The solution was maintained for 12 h at room temperature, and 
diluted with hexane (5 mL) and H2O (20 mL). The mixture was filtered through a pad of Celite, which 
was washed with hexane (30 mL). The filtrate was extracted with hexane (5 mL). The combined organic 
extracts were washed with brine (2x 30 mL), dried over Na2SO4, and concentrated. The residue was 
purified by silica gel column chromatography (EtOAc/hexane 1:30 to 1:9) to give 162 mg of 94e (90 %): 
a colorless oil; IR (film) 2936, 2861, 2720, 1698, 1454, 1421, 1235, 1125, 734, 699 cm-1; 1H NMR (500 
MHz, CDCl3, 1:1 mixture of rotamers) δ 9.73 (s, 1/2H), 9.68 (s, 1/2H), 7.42‒7.12 (m, 10H) , 5.19 (s, 1H), 
5.17 (s, 1H), 4.50 (s, 1H), 4.49 (s, 1H), 3.27 (t, J = 6.9 Hz, 1H), 3.20 (t, J = 6.9 Hz, 1H), 2.40 (t, J = 6.6 
Hz, 1H), 2.31 (t, J = 6.6 Hz, 1H), 1.65‒1.45 (m, 4H), 1.35‒1.16 (m, 2H); 13C NMR (125 MHz, CDCl3, 
1:1 mixture of rotamers) δ 202.7 (CH), 202.5 (CH), 156.9 (C), 156.4 (C), 138.0 (C), 138.0 (C), 136.95 
(C), 136.85 (C), 128.7 (CH), 128.7 (CH), 128.61 (CH), 128.58 (CH), 128.14 (CH), 128.05 (CH), 128.00 
(CH), 127.97 (CH), 127.48 (CH), 127.44 (CH), 127.3 (CH), 127.3 (CH), 67.36 (CH2), 67.32 (CH2), 50.7 
(CH2), 50.4 (CH2), 47.0 (CH2), 46.1 (CH2), 43.84 (CH2), 43.77 (CH2), 28.0 (CH2), 27.6 (CH2), 26.4 (CH2), 
26.3 (CH2), 21.9 (CH2), 21.7 (CH2); HRMS (ESI), calcd for C21H26NO3+ (M+H)+ 340.1913, found 
340.1903. 
 
 
 
tert-butyl benzyl(6-oxohexyl)carbamate (94f) 
2-Iodoxybenzoic acid (179 mg, 639 mol) was added to a solution of alcohol 143f (131 mg, 426 mol) 
and DMSO (4.3 mL) at room temperature. The solution was maintained for 12 h at room temperature, and 
diluted with hexane (5 mL) and H2O (20 mL). The mixture was filtered through a pad of Celite, which 
was washed with hexane (30 mL). The filtrate was extracted with hexane (5 mL). The combined organic 
extracts were washed with brine (2x 30 mL), dried over Na2SO4, and concentrated. The residue was 
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purified by silica gel column chromatography (EtOAc/hexane 1:30 to 1:9) to give 117 mg of 94f (90 %): 
a colorless oil; IR (film) 2974, 2933, 2864, 2864, 1726, 1693, 1455, 1416, 1366, 1246, 1163, 879, 734, 
700 cm-1; 1H NMR (500 MHz, CDCl3, 1:1 mixture of rotamers) δ 9.74 (t, J = 1.7 Hz, 1H), 7.32 (t, J = 6.9 
Hz, 2H), 7.28‒7.18 (m, 3H), 4.43 (bs, 1H), 4.40 (bs, 1H), 3.27‒3.17 (m, 1H), 3.17‒3.06 (m, 1H) , 2.40 
(td, J = 7.5, 1.7 Hz, 2H) 5, 1.66‒1.56 (m, 2H), 1.56‒1.38 (m, 11H), 1.34‒1.20 (m, 2H); 13C NMR (125 
MHz, CDCl3, 1:1 mixture of rotamers) δ 202.8 (CH), 202.5 (CH), 156.2 (C), 155.8 (C), 138.8 (C), 138.6 
(C), 128.6 (CH), 128.6 (CH), 127.8 (CH), 127.8 (CH), 127.2 (CH), 127.2 (CH), 79.8 (C), 79.8 (C), 50.6 
(CH2), 50.0 (CH2), 46.5 (CH2), 46.3 (CH2), 43.9 (CH2), 43.9 (CH2), 28.6 (CH3), 28.6 (CH3), 28.0 (CH2), 
27.8 (CH2), 26.5 (CH2), 26.5 (CH2), 21.9 (CH2), 21.9 (CH2); HRMS (ESI), calcd for C18H27NO3Na+ 
(M+Na)+ 328.1889, found 328.1883. 
 
 
Preparation of N-methoxyamide E-42 and N-methylamide 95 
 
 
 
 
(E)-6-(trimethylsilyl)hex-4-enoic acid (81) 
2-Iodoxybenzoic acid (924 mg, 3.30 mmol) was added to a solution of alcohol 79 (1.07 g, 6.21 mmol),3 
and DMSO (12 mL) at room temperature. The solution was maintained for 16 h at room temperature, and 
diluted with Et2O (25 mL) and H2O (20 mL). The mixture was filtered through a pad of Celite, which was 
washed with Et2O (15 mL). The filtrate was extracted with Et2O (5 mL). The combined organic extracts 
were washed with brine (30 mL), dried over Na2SO4, and concentrated to give (E)-6-(trimethylsilyl)hex-
4-enal 80, which was immediately used in the next reaction without further purification. 
    A mixture of sodium chlorite (2.24 g, 24.8 mmol), sodium dihydrogenphosphate (1.49 g, 12.4 mmol) 
and H2O (5.2 mL) was quickly added to a mixture of aldehyde 80, 2,3-Dimethyl-2-butene (18 mL, 160 
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mmol) and t-BuOH (110 mL) at room temperature. The resulting mixture was stirred for 2 h at room 
temperature, and extracted with EtOAc (2x 10 mL). The combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:19 to 1:4) to give 1.01 g of 81 (87%, 2 steps): a colorless oil; IR (film) 
3022, 2955, 2670, 1713, 1412, 1249, 1154, 967, 850, 694 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.47 (dt, J 
= 15.2, 8.0 Hz, 1H), 5.24 (dt, J = 15.2, 7.2 Hz, 1H), 2.40 (t, J = 6.9 Hz, 2H), 2.31 (dt, J = 7.2, 6.9 Hz, 2H), 
1.41 (d, J = 8.0 Hz, 2H), 0.03 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 179.9 (C), 128.3 (CH), 126.1 (CH), 
34.7 (CH2), 28.0 (CH2), 22.8 (CH2), ‒1.9 (CH3); LRMS (EI) m/z 186 (M+, 8.1%), 118 (8), 117 (74), 116 
(6), 79 (6), 78 (47), 77 (13), 76 (7), 75 (52), 74 (11), 73 (100), 72 (9), 68 (15), 59 (6); HRMS (EI), calcd 
for C9H18O2 M+ 186.1076, found 186.1068. 
 
 
 
(E)-N-methoxy-6-(trimethylsilyl)hex-4-enamide (E-42) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 3.53 g, 18.4 mmol) was added to 
a solution of carboxylic acid 81 (3.12 g, 16.8 mmol), O-methylhydroxylamine hydrochloride (1.54 g, 18.4 
mmol), HOBt·H2O (2.48 g, 18.4 mmol), triethylamine (5.1 mL, 37 mmol) and CH2Cl2 (170 mL) at room 
temperature. The solution was maintained for 21 h at room temperature, and quenched with saturated 
aqueous NaHCO3 (100 mL). The resulting mixture was extracted with CH2Cl2 (2x 100 mL). The combined 
organic extracts were washed with brine (150 mL), dried over Na2SO4, and concentrated. The residue was 
purified by silica gel column chromatography (EtOAc/hexane 1:4 to 1:2) to give 3.43 g of E-424 (95%): 
a colorless oil; IR (film) 3180, 2955, 1659, 1441, 1248, 1068, 967, 856 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 5.48 (dt, J = 15.2, 8.0 Hz, 1H), 5.29‒5.17 (m, 1H), 3.75 (s, 3H), 2.33 (dt, J = 6.9, 6.9 Hz, 2H), 2.21‒
2.05 (m, 2H), 1.40 (d, J = 8.0 Hz, 2H), ‒0.02 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 170.7 (C), 128.5 
(CH), 126.3 (CH), 64.6 (CH3), 33.9 (CH2), 28.6 (CH2), 22.8 (CH2), ‒1.9 (CH3); HRMS (ESI), calcd for 
C10H22NO2Si+ (M+H)+ 216.1420, found 216.1419. 
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(E)-N-methyl-6-(trimethylsilyl)hex-4-enamide (95) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 9.5 mg, 49.6 mol) was added to 
a solution of carboxylic acid 81 (8.4 mg, 45.1 mmol), N-methylamine hydrochloride (3.4 mg, 49.6 mol), 
HOBt·H2O (6.7 mg, 49.6 mol), triethylamine (14 L, 99 mol) and CH2Cl2 (1.0 mL) at room temperature. 
The solution was maintained for 24 h at room temperature, and quenched with saturated aqueous NaHCO3 
(5 mL). The resulting mixture was extracted with CHCl3 (2x 5 mL). The combined organic extracts were 
washed with brine (5 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel 
column chromatography (EtOAc/hexane 1:3 to 1:1) to give 8.3 mg of 95 (92%): a colorless oil; IR (film) 
3297, 3095, 2954, 1651, 1557, 1411, 1248, 1157, 852, 695 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.47 (bs, 
1H), 5.46 (dtt, J = 14.9, 8.0, 1.2 Hz, 1H), 5.23 (dtt, J = 14.9, 6.6, 1.2 Hz, 1H), 2.79 (d, J = 4.9 Hz, 3H), 
2.31 (td, J = 6.9, 6.6 Hz, 2H), 2.21 (t, J = 6.9 Hz, 2H), 1.40 (dt, J = 8.0, 1.2 Hz, 2H), ‒0.03 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 173.5 (C), 127.7 (CH), 126.8 (CH), 36.9 (CH2), 28.9 (CH2), 26.2 (CH3), 22.7 
(CH2), ‒2.0 (CH3); HRMS (FAB), calcd for C10H22NOSi+ (M+H)+ 200.1471, found 200.1475. 
 
 
Preparation of N-methoxyamide Z-42 
 
 
 
 
(Z)-6-(trimethylsilyl)hex-4-enoic acid (88) 
Sulfur trioxide pyridine complex (55.4 mg, 348 mol) was added to a solution of alcohol 86 (30.0 mg, 
174 mol),5 DMSO (220 L) and CH2Cl2 (660 L) at room temperature. The solution was maintained for 
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2 h at room temperature, and quenched with H2O (5 mL). The resulting mixture was extracted with CH2Cl2 
(2x 5 mL). The combined organic extracts were washed with brine (5 mL), dried over Na2SO4, and 
concentrated. The residue was purified by silica gel column chromatography (CH2Cl2/pentane 1:3) to give 
aldehyde 87. 
    A solution of aldehyde 87 and EtOH (1.5 mL) was added to a mixture of silver nitrate (59.1 mg, 348 
mol), NaOH (27.8 mg, 696 mol) and H2O (3.0 mL) at 0 °C. The resulting mixture was stirred for 30 
min at room temperature, and quenched with saturated aqueous NH4Cl (10 mL). The resulting mixture 
was extracted with Et2O (2x 10 mL). The combined organic extracts were washed with brine (10 mL), 
dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:14) to give 22.4 mg of 88 (69%, 2 steps): a colorless oil; IR (film) 3011, 2956, 2679, 
1714, 1417, 1292, 1249, 1152, 944, 856, 729, 701, 668 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.47 (dtt, J = 
10.6, 8.6, 1.4 Hz, 1H), 5.24 (dtt, J = 10.6, 6.9, 1.4 Hz, 1H), 2.42‒2.37 (m, 2H), 2.37‒2.30 (m, 2H), 1.49 
(d, J = 8.6 Hz, 2H), 0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 179.6 (C), 127.6 (CH), 124.8 (CH), 34.3 
(CH2), 22.5 (CH2), 18.7 (CH2), ‒1.7 (CH3); LRMS (EI) m/z 186 (M+, 2.8%), 118 (6), 117 (56), 75 (64), 
74 (10), 73 (100), 72 (7), 68 (12), 59 (6); HRMS (EI), calcd for C9H18O2Si M+ 186.1076, found 186.1080. 
 
 
 
(Z)-N-methoxy-6-(trimethylsilyl)hex-4-enamide (Z-42) 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 487 mg, 2.54 mmol) was added 
to a solution of carboxylic acid 88 (432 mg, 2.31 mmol), O-methylhydroxylamine hydrochloride (212 mg, 
2.54 mmol), HOBt·H2O (342 mg, 2.54 mmol), triethylamine (670 L, 5.1 mmol) and CH2Cl2 (23 mL) at 
room temperature. The solution was maintained for 21 h at room temperature, and quenched with saturated 
aqueous NaHCO3 (20 mL). The resulting mixture was extracted with chloroform (2x 20 mL). The 
combined organic extracts were washed with brine (40 mL), dried over Na2SO4, and concentrated. The 
residue was purified by silica gel column chromatography (EtOAc/hexane 1:3 to 1:1) to give 470 mg of 
Z-424 (95%): a colorless oil; IR (film) 3183, 2955, 1660, 1423, 1248, 1152, 1078, 856 cm-1; 1H NMR (500 
MHz, CDCl3) δ 5.49 (dt, J = 9.7, 9.7 Hz, 1H), 5.30‒5.18 (m, 1H), 3.76 (s, 3H), 2.35 (dt, J = 7.2, 7.2 Hz, 
2H), 2.19‒2.05 (m, 2H), 1.50 (d, J = 9.7 Hz, 2H), 0.00 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 170.8 (C), 
127.8 (CH), 124.9 (CH), 64.5 (CH3), 33.4 (CH2), 23.0 (CH2), 18.7 (CH2), ‒1.7 (CH3); HRMS (ESI), calcd 
for C10H22NO2Si+ (M+H)+ 216.1420, found 216.1418. 
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Synthesis of N-methoxylactams 71a-j 
 
[General Procedure A] 
(5S,6R)-6-heptyl-1-methoxy-5-vinylpiperidin-2-one (71a) 
Boron trifluoride diethyl ether complex (570 μL, 4.6 mmol) was added to a solution of octanal 94a (540 
μL, 3.5 mmol), E-42 (500 mg, 2.32 mmol) and CH2Cl2 (12 mL) at ‒20 °C. After maintaining at ‒20 °C 
for 20 min, boron trifluoride diethyl ether complex (290 μL, 2.3 mmol) was added to the solution every 
15 min four times. After maintaining at ‒20 °C for 20 min, the solution was quenched with H2O (15 mL), 
and extracted with chloroform (2x 15 mL). The combined organic extracts were washed with brine (15 
mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:3 to 1:2) to give 529 mg of 71a (90%): a colorless oil; IR (film) 2928, 2857, 1673, 1460, 
1072, 999, 918 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.86 (ddd, J = 17.2, 10.6, 7.5 Hz, 1H), 5.19 (ddd, J = 
10.6, 1.2, 1.2 Hz, 1H), 5.17 (ddd, J = 17.2, 1.2, 1.2 Hz, 1H), 3.74 (s, 3H), 3.67 (ddd, J = 6.6, 5.2, 5.2 Hz, 
1H), 2.77‒2.70 (m, 1H), 2.53 (ddd, J = 17.5, 6.0, 6.0 Hz, 1H), 2.44 (ddd, J = 17.5, 6.2, 6.0 Hz, 1H), 1.87‒
1.76 (m, 2H), 1.72‒1.64 (m, 1H), 1.59‒1.50 (m, 1H), 1.43‒1.19 (m, 10H), 0.87 (t, J = 6.9 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 167.1 (C), 136.5 (CH), 117.1 (CH2), 62.6 (CH), 61.4 (CH3), 42.4 (CH), 31.8 
(CH2), 30.9 (CH2), 29.9 (CH2), 29.7 (CH2), 29.1 (CH2), 27.0 (CH2), 23.5 (CH2), 22.7 (CH2), 14.1 (CH3); 
HRMS (ESI), calcd for C15H27NO2Na+ (M+Na)+ 276.1939, found 276.1936. 
 
NOESY experiment for 71a 
 
71a (500 MHz, CDCl3) 
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(5S,6R)-6-(3-((tert-butyldiphenylsilyl)oxy)propyl)-1-methoxy-5-vinylpiperidin-2-one (71b) 
Following the general procedure A using boron trifluoride diethyl ether complex (6x 34 μL, 1.6 mmol), 
4-((tert-butyldiphenylsilyl)oxy)butanal 94b6 (135 mg, 417 mol) and E-42 (60.0 mg, 278 mol) were 
converted to 115 mg of 71b (92%): a colorless oil; IR (film) 2931, 2857, 1672, 1428, 1111, 772, 703, 613 
cm-1; 1H NMR (500 MHz, d-acetone) δ 7.71‒7.68 (m, 4H), 7.49‒7.41 (m, 6H), 5.97 (ddd, J = 17.5, 10.3, 
7.5 Hz, 1H), 5.18 (ddd, J = 17.5, 1.4, 1.4 Hz, 1H), 5.16 (ddd, J = 10.3, 1.4, 1.4 Hz, 1H), 3.77 (ddd, J = 
6.0, 5.7, 4.6 Hz, 1H), 3.74‒3.68 (m, 2H), 3.65 (s, 3H), 2.84‒2.77 (m, 1H), 2.40 (ddd, J = 17.5, 6.3, 6.3 Hz, 
1H), 2.44 (ddd, J = 17.5, 7.5, 7.5 Hz, 1H), 1.84‒1.76 (m, 3H), 1.76‒1.65 (m, 3H), 1.05 (s, 9H); 13C NMR 
(125 MHz, CDCl3) δ 167.1 (C), 136.4 (CH), 135.6 (CH), 133.9 (C), 129.7 (CH), 127.7 (CH), 117.3 (CH2), 
63.6 (CH2), 62.4 (CH), 61.5 (CH3), 42.5 (CH), 30.8 (CH2), 30.0 (CH2), 26.9 (CH3), 26.5 (CH2), 23.5 (CH2), 
19.3 (C); HRMS (ESI), calcd for C27H37NO3Na+ (M+Na)+ 474.2440, found 474.2443.  
 
NOESY experiment for 71b 
 
71b (500 MHz, d-acetone)  
 
 
 
(5S,6R)-6-(3-bromopropyl)-1-methoxy-5-vinylpiperidin-2-one (71c) 
Following the general procedure A using boron trifluoride diethyl ether complex (5x 60 μL, 2.4 mmol), 
4-bromobutanal 94c4 (108 mg, 717 mol) and E-42 (103 mg, 478 mol) were converted to 105 mg of 
71c4 (80%): a colorless oil; IR (film) 3457, 2936, 1667, 1435, 1266, 999, 923 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 5.86 (ddd, J = 17.5, 10.6, 7.2 Hz, 1H), 5.22 (ddd, J = 10.6, 1.2, 1.2 Hz, 1H), 5.19 (ddd, J = 17.5, 
1.4, 1.4 Hz, 1H), 3.75 (s, 3H), 3.71 (ddd, J = 5.8, 5.8, 4.9 Hz, 1H), 3.44‒3.34 (m, 2H), 2.79‒2.71 (m, 1H), 
2.55 (ddd, J = 17.8, 5.7, 5.7 Hz, 1H), 2.46 (ddd, J = 17.8, 8.0, 8.0 Hz, 1H), 2.03 (ddddd, J = 14.3, 14.3, 
6.3, 6.3, 6.3 Hz, 1H), 1.95 (ddddd, J = 14.3, 14.3, 6.9, 6.9, 6.9 Hz, 1H), 1.86‒1.80 (m, 2H), 1.80‒1.74 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 166.9 (C), 136.2 (CH), 117.5 (CH2), 61.7 (CH), 61.4 (CH3), 42.6 
(CH), 33.5 (CH2), 30.9 (CH2), 30.3 (CH2), 28.9 (CH2), 22.9 (CH2); HRMS (ESI), calcd for 
C11H18NO2NaBr+ (M+Na)+ 298.0419, found 298.0419. 
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NOESY experiment for 71c 
 
71c (500 MHz, CDCl3) 
 
 
 
[General Procedure B] 
methyl 3-((2R,3S)-1-methoxy-6-oxo-3-vinylpiperidin-2-yl)propanoate (71d) 
Boron trifluoride diethyl ether complex (68 μL, 550 mol) was added to a solution of methyl 4-
oxobutanoate 94d7 (78.0 mg, 433 mol), E-42 (60.0 mg, 279 mol) and CH2Cl2 (1.4 mL) at ‒20 °C. After 
maintaining at ‒20 °C for 1 h, boron trifluoride diethyl ether complex (36 μL, 290 mol) was added to the 
solution every 1 h four times. After maintaining at ‒20 °C for 12h, the solution was quenched with H2O 
(5 mL), and extracted with chloroform (2x 5 mL). The combined organic extracts were washed with brine 
(5 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:1 to 3:1 to 1:0) to give 61.4 mg of 71d (92%): a colorless oil; IR (film) 
2950, 1737, 1668, 1437, 1174, 1004, 925 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.85 (ddd, J = 17.2, 10.3, 
6.9 Hz, 1H), 5.19 (ddd, J = 10.3, 1.2, 1.2 Hz, 1H), 5.17 (ddd, J = 17.2, 1.2, 1.2 Hz, 1H), 3.80 (ddd, J = 
6.3, 6.3, 4.6 Hz, 1H), 3.74 (s, 3H), 3.65 (s, 3H), 2.78‒2.71 (m, 1H), 2.53 (ddd, J = 17.5, 6.0, 6.0 Hz, 1H), 
2.49 (t, J = 7.7 Hz, 2H), 2.46 (ddd, J = 17.5, 8.3, 8.3 Hz, 1H), 1.93‒1.88 (m, 2H), 1.84‒1.78 (m, 2H); 13C 
NMR (125 MHz, CDCl3) δ 173.6 (C), 166.8 (C), 136.4 (CH), 117.5 (CH2), 61.4 (CH3), 61.1 (CH), 51.7 
(CH3), 42.6 (CH), 31.5 (CH2), 31.0 (CH2), 25.6 (CH2), 22.6 (CH2); HRMS (ESI), calcd for C12H19NO4Na+ 
(M+Na)+ 264.1212, found 264.1199. 
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NOESY experiment for 71d 
 
71d (500 MHz, CDCl3) 
 
 
 
benzyl benzyl(5-((2R,3S)-1-methoxy-6-oxo-3-vinylpiperidin-2-yl)pentyl)carbamate (71e) 
Following the general procedure B using boron trifluoride diethyl ether complex (4x 35 μL, 1.1 mmol), 
benzyl benzyl(6-oxohexyl)carbamate 94e (142 mg, 418 μmol) and E-42 (60.0 mg, 279 μmol) were 
converted to 119 mg of 71e (92%): a colorless oil; IR (film) 2934, 2861, 1699, 1670, 1456, 1421, 1220, 
914, 771, 744, 700 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 7.42‒7.12 (m, 10H), 5.82 (ddd, J = 17.5, 
10.0, 7.5 Hz, 1H), 5.21‒5.12 (m, 4H), 4.49 (s, 2H), 3.72 (s, 3H), 3.62 (ddd, J = 5.4, 5.4, 4.6 Hz, 1H), 3.24 
(t, J = 6.9 Hz, 2H), 2.74‒2.67 (m, 2H), 2.52 (ddd, J = 17.5, 6.0, 6.0 Hz, 1H), 2.43 (ddd, J = 17.5, 7.7, 7.7 
Hz, 1H), 1.82‒1.76 (m, 2H), 1.69‒1.58 (m, 1H), 1.58‒1.45 (m, 3H), 1.42‒1.29 (m, 2H), 1.29‒1.18 (m, 
2H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 167.2 (C), 156.7 (C), 138.2 (C), 137.1 (C), 136.7 (CH), 128.64 
(CH), 128.55 (CH), 128.01 (CH), 127.96 (CH), 127.7 (CH), 127.4 (CH), 117.2 (CH), 67.3 (CH2), 62.8 
(CH), 61.5 (CH3), 50.7 (CH2), 46.8 (CH2), 42.7 (CH), 31.0 (CH2), 30.0 (CH2), 27.03 (CH2), 26.96 (CH2), 
26.7 (CH2), 23.6 (CH2); HRMS (ESI), calcd for C28H37N2O4+ (M+H)+ 465.2753, found 465.2755.  
 
NOESY experiment for 71e 
 
71e (500 MHz, CDCl3) 
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tert-butyl benzyl(5-((2R,3S)-1-methoxy-6-oxo-3-vinylpiperidin-2-yl)pentyl)carbamate (71f) 
Following the general procedure B using boron trifluoride diethyl ether complex (4x 33 μL, 1.1 mmol), 
tert-butyl benzyl(6-oxohexyl)carbamate 94f (117 mg, 383 μmol) and E-42 (57.0 mg, 264 μmol) were 
converted to 85.1 mg of 71f (75%): a colorless oil; IR (film) 2974, 2932, 1687, 1418, 1365, 1170, 914, 
772, 744 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 7.34‒7.18 (m, 5H), 5.84 (ddd, J = 17.5, 10.3, 7.2 Hz, 
1H), 5.18 (d, J = 10.3 Hz, 1H), 5.16 (d, J = 17.5 Hz, 1H), 4.42 (s, 2H), 3.74 (s, 3H), 3.65 (ddd, J = 5.4, 
5.4, 5.4 Hz, 1H), 3.16 (s, 2H), 2.76‒2.68 (m, 1H), 2.52 (ddd, J = 17.5, 6.0, 6.0 Hz, 1H), 2.43 (ddd, J = 
17.5, 7.7, 7.7 Hz, 1H), 1.86‒1.76 (m, 2H), 1.70‒1.62 (m, 1H), 1.60‒1.45 (m, 12H), 1.45‒1.30 (m, 2H), 
1.29‒1.19 (m, 2H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 167.1 (C), 156.0 (C), 138.9 (C), 136.8 (CH), 
128.6 (CH), 127.6 (CH), 127.2 (CH), 117.2 (CH2), 79.7 (C), 62.9 (CH), 61.5 (CH3), 50.6 (CH2), 46.8 
(CH2), 42.8 (CH), 31.1 (CH2), 30.1 (CH2), 28.6 (CH3), 28.1 (CH2), 27.2 (CH2), 27.1 (CH2), 23.7 (CH2); 
HRMS (ESI), calcd for C25H38N2O4Na+ (M+Na)+ 453.2729, found 453.2725. 
 
NOESY experiment for 13f 
 
13f (500 MHz, CDCl3) 
 
 
 
(5S,6R)-6-benzyl-1-methoxy-5-vinylpiperidin-2-one (71g) 
Following the general procedure B using boron trifluoride diethyl ether complex (5x 34 μL, 1.4 mmol), 
2-phenylacetaldehyde 94g (49 L, 420 μmol) and E-42 (60.0 mg, 279 μmol) were converted to 52.9 mg 
of 71g (78%, dr = 11:1). For an analytical sample, 71g was purified by HPLC (PEGASIL Silica 120-5, 
250×20 mm, EtOAc, 10 mL/min, TR = 15.8 min). 71g: a colorless oil; IR (film) 2934, 1672, 1261, 1070, 
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923, 743, 700 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.28 (dd, J = 7.5, 6.9 Hz, 2H), 7.22‒7.18 (m, 3H), 5.82 
(ddd, J = 17.2, 10.3, 7.5 Hz, 1H), 5.25 (ddd, J = 10.3, 1.4, 1.4 Hz, 1H), 5.15 (ddd, J = 17.2, 1.4, 1.4 Hz, 
1H), 4.17 (ddd, J = 7.7, 4.3, 3.7 Hz, 1H), 3.77 (s, 3H), 3.07 (dd, J = 14.0, 3.7 Hz, 1H), 2.93 (dd, J = 14.0, 
7.7 Hz, 2H), 2.71‒2.65 (m, 1H), 2.52 (ddd, J = 17.5, 6.6, 6.6 Hz, 1H), 2.43 (ddd, J = 17.5, 8.0, 6.6 Hz, 
1H), 1.70 (dddd, J = 13.8, 6.6, 6.6, 3.4 Hz, 2H), 1.58 (dddd, J = 13.8, 9.5, 8.0, 6.6 Hz, 1H); 13C NMR (125 
MHz, CDCl3) δ 167.8 (C), 138.3 (C), 136.4 (CH), 129.8 (CH), 128.5 (CH), 126.6 (CH), 118.0 (CH2), 64.0 
(CH), 61.8 (CH3), 42.0 (CH), 35.1 (CH2), 30.9 (CH2), 23.7 (CH2); LRMS (EI) m/z 245 (M+, 10.7%), 118 
(19.9), 117 (74), 126 (13), 124 (6), 123 (29), 122 (5), 117 (19), 107 (8), 96 (9), 95 (17), 94 (11), 91 (50), 
81 (8), 80 (12), 68 (6), 67 (5), 56 (8); HRMS (EI), calcd for C15H19NO2 M+ 245.1416, found 245.1412. 
 
NOESY experiment for 71g 
 
71g (500 MHz, CDCl3) 
 
 
 
(5S,6R)-6-(2,5-dimethoxybenzyl)-1-methoxy-5-vinylpiperidin-2-one (71h) 
Following the general procedure B using boron trifluoride diethyl ether complex (4x 36 μL, 1.2 μmol), 2-
(2,5-dimethoxyphenyl)acetaldehyde 94h8 (78.0 mg, 433 μmol) and E-42 (62.1 mg, 288 μmol) were 
converted to 81.4 mg of 71h (92%, dr = 11:1). For an analytical sample, 71h was purified by HPLC 
(PEGASIL Silica 120-5, 250×20 mm, EtOAc, 10 mL/min, TR = 19.8 min): 71h: a colorless oil; IR (film) 
3074, 2937, 2834, 1670, 1502, 1226, 1047, 923, 807 cm-1; 1H NMR (500 MHz, CDCl3) δ 6.77‒6.70 (m, 
3H), 5.96 (ddd, J = 17.8, 10.6, 7.7 Hz, 1H), 5.18 (ddd, J = 10.3, 1.4, 1.4 Hz, 1H), 5.15 (ddd, J = 17.2, 1.4, 
1.4 Hz, 1H), 4.17 (ddd, J = 8.0, 4.9, 4.0 Hz, 1H), 3.78 (s, 3H), 3.74 (s, 3H), 3.70 (s, 3H), 3.18 (dd, J = 
13.8, 4.9 Hz, 1H), 2.79 (dd, J = 13.8, 8.0 Hz, 1H), 2.68‒2.62 (m, 1H), 2.53 (ddd, J = 17.5, 6.9, 6.9 Hz, 
1H), 2.43 (ddd, J = 17.5, 6.9, 6.9 Hz, 1H), 2.04 (sept-d, J = 7.2, 2.6 Hz, 1H), 1.80‒1.73 (m, 2H); 13C NMR 
(125 MHz, CDCl3) δ 167.6 (C), 153.4 (C), 151.8 (C), 136.6 (CH), 127.6 (CH), 117.6 (CH2), 117.5 (C), 
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112.2 (CH), 111.2 (CH), 62.2 (CH), 61.3 (CH3), 55.82 (CH3), 55.78 (CH3), 42.3 (CH), 30.7 (CH2), 30.3 
(CH2), 24.3 (CH2); HRMS (ESI), calcd for C17H24NO4+ (M+H)+ 306.1705, found 306.1696. 
 
NOESY experiment for 71h 
 
71h (500 MHz, CDCl3) 
 
 
 
(5S,6R)-6-isopropyl-1-methoxy-5-vinylpiperidin-2-one (71i) 
Boron trifluoride diethyl ether complex (68 μL, 550 mol) was added to a solution of 2-methyl propanal 
94i (38 μL, 410mol), E-42 (60.0 mg, 279 mol) and CH2Cl2 (1.4 mL) at ‒20 °C. After maintaining at  
‒20 °C for 1 h, boron trifluoride diethyl ether complex (34 μL, 280 mmol) was added to the solution every 
1 h three times. After maintaining at ‒20 °C for 2 days, the solution was quenched with H2O (5 mL), and 
extracted with chloroform (2x 5 mL). The combined organic extracts were washed with brine (5 mL), 
dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:3 to 1:2 to 1:1) to give 36.8 mg of 71i (67%): a colorless oil; IR (film) 2925, 2932, 1670, 
1072, 913, 772, 745 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.87 (ddd, J = 16.9, 10.3, 6.0 Hz, 1H), 5.18 (ddd, 
J = 10.3, 1.4, 1.4 Hz, 1H), 5.15 (ddd, J = 16.9, 1.4, 1.4 Hz, 1H), 3.74 (s, 3H), 3.65 (dddd, J = 10.3, 6.0, 
5.2, 4.9 Hz, 1H), 2.81‒2.74 (m, 1H), 2.53 (ddd, J = 17.8, 6.0, 4.0 Hz, 1H), 2.43 (ddd, J = 17.8, 9.7, 8.3 
Hz, 1H), 2.04 (sept-d, J = 7.2, 2.6 Hz, 1H), 1.87‒1.76 (m, 2H), 1.05 (d, J = 7.2 Hz, 3H), 0.95 (d, J = 7.2 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 166.8 (C), 137.8 (CH), 116.5 (CH2), 66.6 (CH), 60.3 (CH3), 43.5 
(CH), 31.4 (CH2), 29.0 (CH), 24.3 (CH3), 22.3 (CH2), 19.5 (CH3); LRMS (EI) m/z 197 (M+, 5.9%), 155 
(9), 154 (100), 123 (12), 102 (51), 97 (10), 96 (9.8), 95 (8), 89 (9), 81 (6), 80 (6), 79 (7), 78 (64), 77 (13), 
73 (7), 70 (7), 69 (20), 68 (27), 67 (16), 56 (29); HRMS (EI), calcd for C11H19NO2 M+ 197.1416, found 
197.1408.  
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NOESY experiment for 71i 
 
71i (500 MHz, CDCl3) 
 
 
 
(2S,5S,6R)-6-heptyl-1-methoxy-5-vinylpiperidine-2-carbonitrile (74a) 
Diisobutylalminium hydride (1.5 M in toluene, 110 μL, 170 μmol) was added to a solution of 71a (36.4 
mg, 144 μmol) and CH2Cl2 (1.4 mL) at ‒78 °C. After stirring for 10 min, acetonitlile (480 μL), 
cyanotrimethylsilane (54 L, 430 μmol) and tetrachlorostannane (20 L, 170 μmol) were added to the 
solution. After stirring for 30 min at ‒78 °C, the resulting mixture was allowed to warm to room 
temperature, and maintained for 1 h at room temperature. This mixture was quenched with saturated 
aqueous (+)-potassium sodium tartrate (5 mL), and extracted with chloroform (2x 5 mL). The combined 
organic extracts were washed with brine (10 mL), dried over Na2SO4, and concentrated. The residue was 
purified by silica gel column chromatography (EtOAc/hexane 1:120) to give 22.5 mg of 74a (60%) and 
10.4 mg of 122a (27%): 74a: a colorless oil; IR (film) 2929, 2857, 2234, 1466, 1044, 916 cm-1; 1H NMR 
(500 MHz, CDCl3, 60 °C) δ 5.98 (ddd, J = 17.5, 9.8, 8.0 Hz, 1H), 5.10 (d, J = 9.8 Hz, 1H), 5.08 (d, J = 
17.5 Hz, 1H), 4.28‒4.21 (m, 1H), 3.54 (s, 3H), 3.00‒2.89 (m, 1H), 2.61‒2.52 (m, 1H), 2.05 (dddd, J = 
13.8, 13.2, 4.0, 3.7 Hz, 1H), 1.93‒1.82 (m, 2H), 1.82‒1.71 (m, 1H), 1.63‒1.54 (m, 1H), 1.39‒1.21 (m, 
11H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 137.1 (CH), 117.9 (C), 116.9 (CH2), 64.5 
(CH), 61.2 (CH3), 55.1 (CH), 41.1 (CH), 31.9 (CH2), 29.9 (CH2), 29.4 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 
(CH2), 24.7 (CH2), 22.8 (CH2), 14.2 (CH3); HRMS (ESI), calcd for C16H29N2O+ (M+H)+ 265.2280, found 
265.2279; 122a: a colorless oil; IR (film) 2928, 2857, 2250, 1467, 1040, 1001, 918 cm-1; 1H NMR (500 
MHz, CDCl3, 60 °C) δ 6.07 (ddd, J = 17.8, 9.7, 9.7 Hz, 1H), 5.15 (d, J = 9.7 Hz, 1H), 5.10 (d, J = 17.8 
Hz, 1H), 3.70 (s, 3H), 3.43 (d, J = 11.5 Hz, 1H), 2.53‒2.47 (m, 1H), 2.47‒2.42 (m, 1H), 2.13 (dddd, J = 
13.5, 13.5, 11.5, 3.2 Hz, 1H), 1.95‒1.79 (m, 2H), 1.69 (dddd, J = 13.5, 3.2, 3.2, 3.2 Hz, 1H), 1.53 (dddd, 
J = 13.5, 13.5, 4.3, 4.3 Hz, 1H), 1.46‒1.37 (m, 1H), 1.37‒1.12 (m, 10H), 0.91 (t, J = 6.6 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 136.6 (CH), 119.6 (C), 117.4 (CH2), 69.9 (CH), 63.4 (CH3), 58.5 (CH), 41.5 
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(CH), 31.9 (CH2), 30.0 (CH2), 29.9 (CH2), 29.5 (CH2), 29.4 (CH2), 26.7 (CH2), 25.4 (CH2), 22.8 (CH2), 
14.2 (CH3); HRMS (ESI), calcd for C16H29N2O+ (M+H)+ 265.2280, found 265.2280. 
 
NOESY experiment for 74a and 122a 
            
74a (500 MHz, CDCl3)                122a (500 MHz, CDCl3) 
 
 
 
(2R,3S,6S)-6-allyl-2-heptyl-1-methoxy-3-vinylpiperidine (74b) 
Diisobutylalminium hydride (1.5 M in toluene, 100 μL, 150 μmol) was added to a solution of 71a (29.2 
mg, 115 μmol) and CH2Cl2 (1.2 mL) at ‒78 °C. After stirring for 10 min, allyltributylstannane (110 μL, 
346 μmol) and Sc(OTf)3 (68.1 mg, 138 μmol) were added to the solution. After stirring for 30 min at ‒
78 °C, the resulting mixture was allowed to warm to room temperature, and maintained for 1 h at room 
temperature. This mixture was quenched with saturated aqueous (+)-potassium sodium tartrate (5 mL), 
and extracted with chloroform (2x 5 mL). The combined organic extracts were washed with brine (10 mL), 
dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:120 to 1:100) to give 32.9 mg of a mixture of 74b and 122b (86%, 74b:122b = 4.1:1). 
For analytical samples, two diastereomers were purified by HPLC (PEGASIL Silica 120-5, 250×20 mm, 
EtOAc/hexane 1:80, 10 mL/min) 74b: a colorless oil; IR (film) 2932, 2856, 1639, 1465, 1045, 910 cm-1; 
1H NMR (500 MHz, d-acetone, 55 °C) δ 5.92 (dddd, J = 16.9, 10.0, 7.2, 6.9 Hz, 1H), 5.83 (ddd, J = 16.9, 
9.2, 7.7 Hz, 1H), 5.08‒4.96 (m, 4H), 3.46 (s, 3H), 3.22‒3.15 (m, 1H), 2.87‒2.79 (m, 1H), 2.87‒2.64 (m, 
1H), 2.46 (ddd, J = 14.0, 6.9, 6.9 Hz, 1H), 2.12 (ddd, J = 14.0, 7.2, 7.2 Hz, 1H), 1.61‒1.54 (m, 1H), 1.54‒
1.39 (m, 4H), 1.39‒1.26 (m, 11H), 0.90 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3, mixture of two 
conformers) δ 141.6 (CH), 140.6 (CH), 137.5 (CH), 136.2 (CH), 116.4 (CH2), 115.7 (CH2), 114.2 (CH2), 
113.8 (CH2), 63.5 (CH), 63.1 (CH), 60.5 (CH3), 59.9 (CH3), 58.0 (CH), 56.6 (CH), 44.5 (CH), 38.0 (CH2), 
37.7 (CH2), 36.9 (CH), 32.1 (CH2), 32.1 (CH2), 31.1 (CH2), 30.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.4 
(CH2), 29.4 (CH2), 27.1 (CH2), 26.2 (CH2), 24.7 (CH2), 24.2 (CH2), 23.5 (CH2), 23.5 (CH2), 22.8 (CH2), 
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22.8 (CH2), 14.3 (CH3), 14.3 (CH3); HRMS (ESI), calcd for C18H34NO (M+H)+ 280.2640, found 280.2626; 
122b: a colorless oil; IR (film) 3074, 2926, 2856, 2823, 1640, 1467, 1442, 1047, 998, 912 cm-1; 1H NMR 
(500 MHz, CDCl3, 60 °C) δ 6.13 (ddd, J = 16.6, 9.5, 9.5 Hz, 1H), 5.87 (dddd, J = 16.9, 9.8, 7.5, 7.5 Hz, 
1H), 5.09‒4.98 (m, 4H), 3.55 (s, 3H), 2.65‒2.56 (m, 1H), 2.56‒2.37 (m, 3H), 2.21 (ddd, J = 13.8, 7.7, 7.5 
Hz, 1H), 1.86‒1.76 (m, 1H), 1.65‒1.24 (m, 15H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 138.6 (CH), 136.3 (CH), 116.5 (CH2), 116.0 (CH2), 70.3 (CH), 67.9 (CH), 63.7 (CH3), 42.5 (CH), 38.4 
(CH2), 32.0 (CH2), 31.0 (CH2), 30.2 (CH2), 30.1 (CH2), 29.5 (CH2), 26.9 (CH2), 25.8 (CH2), 22.8 (CH2), 
14.3 (CH3); HRMS (ESI), calcd for C18H34NO (M+H)+ 280.2640, found 280.2626. 
 
NOE experiment for 74b 
                
74b (500 MHz, d-acetone, 55 °C)  
 
 
 
3-((2S,5S,6R)-6-heptyl-1-methoxy-5-vinylpiperidin-2-yl)-1-methyl-1H-indole (74c) 
Diisobutylalminium hydride (1.5 M in toluene, 100 μL, 150 μmol) was added to a solution of 71a (30.0 
mg, 118 μmol) and CH2Cl2 (1.2 mL) at ‒78 °C. After stirring for 10 min, 1-methylindole (44 μL, 355 
μmol) and Sc(OTf)3 (69.8 mg, 142 μmol) were added to the solution. The resulting mixture was then 
allowed to warmed to ‒40 °C. The mixture was stirred for 22 h, quenched with saturated aqueous (+)-
potassium sodium tartrate (5 mL) and extracted with chloroform (2x 5 mL). The combined organic extracts 
were washed with brine (10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica 
gel column chromatography (EtOAc/hexane 1:120 to 1:80) to give 38.3 mg of 74c (88%, dr = 14:1). For 
an analytical sample, 74c was purified by HPLC (P:EGASIL Silica 120-5, 250×20 mm, EtOAc/hexane 
1:20, 10 mL/min, TR = 14.1 min): 74c: a colorless oil; IR (film) 2928, 2856, 1468, 1045, 910, 738 cm-1; 
1H NMR (500 MHz, CDCl3, 60 °C) δ 7.88 (d, J = 7.5 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.21 (dd, J = 8.0, 
7.5 Hz, 1H), 7.10 (dd, J = 7.5, 7.5 Hz, 1H), 6.99 (s, 1H), 5.94‒5.82 (m, 1H), 5.11‒5.03 (m, 2H), 4.24 (d, 
J = 8.0 Hz, 1H), 3.77 (s, 3H), 3.37‒3.27 (m, 1H), 3.10 (s, 3H), 3.00‒2.80 (m, 1H), 2.35‒2.15 (m, 1H), 
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1.89‒1.56 (m, 5H), 1.56‒1.27 (m, 10H), 0.92 (t, J = 6.3 Hz, 3H); 13C NMR (125 MHz, CDCl3, 60 °C) δ 
141.6 (CH), 137.4 (C), 128.0 (C), 127.4 (CH), 121.5 (CH), 120.8 (CH), 118.8 (CH), 116.9 (C), 113.9 
(CH2), 109.1 (CH), 64.0 (CH), 60.4 (CH3), 52.8 (CH), 44.6 (CH2), 37.0 (CH), 32.7 (CH3), 32.1 (CH2), 
30.0 (CH2), 29.5 (CH2), 28.2 (CH2), 26.4 (CH2), 24.7 (CH2), 22.8 (CH2), 14.2 (CH3); HRMS (FAB), calcd 
for C24H37N2O+ (M+H)+ 369.2906, found 369.2921. 
 
NOESY experiment for 74c 
 
74c (500 MHz, CDCl3, 60 °C) 
 
 
 
2-((2S,5S,6R)-6-heptyl-1-methoxy-5-vinylpiperidin-2-yl)-1-phenylethan-1-one (74d) 
Zirconocene chloride hydride (46.0 mg, 178 μmol) was added to a solution of 71a (32.8 mg, 129 μmol) 
and (CH2Cl)2 (1.3 mL) at room temperature. After stirring for 10 min, triisopropyl((1-
phenylvinyl)oxy)silane (45.5 mg, 165 μmol) and Sc(OTf)3 (12.7 mg, 25.8 μmol) were added to the 
solution. After stirring for 1 h at room temperature, this solution was quenched with saturated aqueous 
NaHCO3 (5 mL), and extracted with chloroform (2x 5 mL). The combined organic extracts were washed 
with brine (5 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:120 to 1:100) to give 30.0 mg of 74d (65%, single diastereomer): a 
colorless oil; IR (film) 2937, 2834, 1670, 1503, 1465, 1226, 1047, 923 cm-1; 1H NMR (500 MHz, CDCl3, 
60 °C) δ 7.97 (d, J = 7.5 Hz, 2H), 7.54 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 5.80 (ddd, J = 17.5, 
10.0, 6.9 Hz, 1H), 5.01 (d, J = 17.5 Hz, 1H), 4.99 (d, J = 10.0 Hz, 1H), 3.60‒3.50 (m, 1H), 3.42 (s, 3H), 
3.46‒3.35 (m, 1H), 3.20‒3.08 (m, 1H), 3.02‒2.87 (m, 1H), 2.78‒2.67 (m, 1H), 1.69‒1.40 (m, 5H), 1.40‒
1.19 (m, 11H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 199.7 (C), 141.2 (CH), 137.6 (C), 
133.0 (CH), 128.7 (CH), 128.3 (CH), 114.1 (CH2), 62.9 (CH), 60.4 (CH3), 53.7 (CH), 37.1 (CH), 32.1 
(CH2), 29.8 (CH2), 29.4 (CH2), 27.0 (CH2), 26.4 (CH2), 25.1 (CH2), 24.3 (CH2), 23.5 (CH2), 22.8 (CH2), 
14.3 (CH3); HRMS (ESI), calcd for C23H36NO2+ (M+H)+ 358.2746, found 358.2739.  
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NOESY experiment for 74d 
 
74d (500 MHz, CDCl3) 
 
 
 
(2S,5S,6R)-6-heptyl-1-methoxy-2-methyl-5-vinylpiperidine-2-carbonitrile (14e) 
Methyl lithium (1.14 M in Et2O, 150 μL, 170 μmol) was added to a solution of 13a (36.0 mg, 142 μmol) 
and THF (1.4 mL, freshly distilled from sodium/benzophenone) at ‒78 °C. After stirring for 10 min, 
acetonitlile (470 μL), cyanotrimethylsilane (53 L, 430 μmol) and tetrachlorostannane (20 L, 170 μmol) 
were added to the solution. The resulting mixture was then allowed to warm to room temperature, and 
maintained for 24 h at room temperature. This mixture was quenched with saturated aqueous NaHCO3 (5 
mL), and extracted with chloroform (2x 5 mL). The combined organic extracts were washed with brine 
(10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:80) to give 32.9 mg of a mixture of 14e and 36e (83%, 14e : 36e = 
1:4.1). For analytical samples, two diastereomers was purified by HPLC (PEGASIL Silica 120-5, 250×20 
mm, EtOAc/hexane 1:20, 10 mL/min) 14e: a colorless oil; IR (film) 2928, 2856, 2228, 1452, 1041, 915 
cm-1; 1H NMR (500 MHz, CDCl3) δ 6.03 (ddd, J = 16.9, 10.6, 10.3 Hz, 1H), 5.13‒5.07 (m, 2H), 3.58 (s, 
3H), 2.87 (ddd, J = 10.0, 3.4, 3.4 Hz, 1H), 2.57‒2.51 (m, 1H), 1.93‒1.74 (m, 4H), 1.62, (s, 3H), 1.60‒1.52 
(m, 2H), 1.42‒1.21 (m, 10H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 137.0 (CH), 120.1 
(C), 117.1 (CH2), 66.5 (CH), 64.7 (CH3), 63.8 (C), 41.5 (CH), 33.4 (CH2), 31.9 (CH2), 30.1 (CH2), 29.5 
(CH2), 29.4 (CH2), 28.3 (CH2), 26.1 (CH2), 25.4 (CH2), 22.8 (CH2), 14.3 (CH3); HRMS (ESI), calcd for 
C17H31N2O+ (M+H)+ 279.2436, found 279.2428; 36e: a colorless oil; IR (film) 2928, 2856, 2241, 1457, 
1036, 916, 773 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 6.11‒5.96 (m, 1H), 5.12‒5.04 (m, 2H), 3.64 
(s, 3H), 3.10‒2.89 (m, 1H), 2.49‒2.41 (m, 1H), 2.28‒2.16 (m, 1H), 2.05‒1.86 (m, 1H), 1.74‒1.59 (m, 3H), 
1.55 (s, 3H), 1.44‒1.35 (m, 1H), 1.35‒1.17 (m, 10H), 0.89 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3, 
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60 °C) δ 138.3 (CH), 123.1 (C), 116.0 (CH2), 62.5 (CH3), 62.5 (CH), 58.5 (C), 42.7 (CH), 33.7 (CH2), 
32.0 (CH2), 29.9 (CH2), 29.4 (CH2), 27.5 (CH2), 27.5 (CH3), 27.5 (CH2), 24.3 (CH2), 22.8 (CH2), 14.1 
(CH3); HRMS (ESI), calcd for C17H31N2O+ (M+H)+ 279.2436, found 279.2435 
 
     NOESY experiments for 74e          NOE and NOESY experiments for 122e 
            
74e (500 MHz, CDCl3)      122e (500 MHz, CDCl3, 60 °C) 
 
 
 
methyl 3-((2R,3S,6S)-6-cyano-1-methoxy-3-vinylpiperidin-2-yl)propanoate (74g) 
Zirconocene chloride hydride (39.9 mg, 155 μmol) was added to a solution of 71d (26.1 mg, 108 μmol) 
and (CH2Cl)2 (1.1 mL) at room temperature. After stirring for 10 min, cyanotrimethylsilane (16 μL, 128 
μmol) and Sc(OTf)3 (5.3 mg, 10.8 μmol) were added to the solution. After stirring for 2.5 h at room 
temperature, this solution was quenched with saturated aqueous NaHCO3 (5 mL), and extracted with 
chloroform (2x 5 mL). The combined organic extracts were washed with brine (10 mL), dried over Na2SO4, 
and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane 1:9 to 
1:5) to give 23.4 mg of a mixture of 74g and 122g (86%, 74g:122g = 1:4.3). For analytical samples, two 
diastereomers were separated by HPLC (PEGASIL Silica 120-5, 250×20 mm, i-PrOH/hexane 1:120, 10 
mL/min, 74g: TR = 19.7 min, 122g: TR = 21.0 min); 74g: a colorless oil; IR (film) 2950, 2234, 1737, 1439, 
1169, 1037, 921 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 5.95 (ddd, J = 17.8, 9.2, 8.6 Hz, 1H), 5.16 (d, 
J = 9.2 Hz, 1H), 5.11 (d, J = 17.8 Hz, 1H), 4.27‒4.20 (m, 1H), 3.69 (s, 3H), 3.55 (s, 3H), 3.03‒2.95 (m, 
1H), 2.60‒2.53 (m, 1H), 2.43‒2.30 (m, 2H), 2.12‒1.97 (m, 2H), 1.97‒1.82 (m, 2H), 1.69 (dddd, J = 14.3, 
7.2, 7.2, 7.2 Hz, 1H), 1.58 (dddd, J = 14.0, 4.3, 4.3, 4.3 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 173.9 
(C), 136.7 (CH), 117.8 (C), 117.5 (CH2), 63.7 (CH), 61.1 (CH3), 54.6 (CH), 51.8 (CH3), 41.2 (CH), 30.9 
(CH2), 26.9 (CH2), 24.5 (CH2), 24.5 (CH2); HRMS (ESI), C13H20N2O3Na+ (M+Na)+ 275.1372, found 
275.1366. 122g: a colorless oil; IR (film) 2951, 2857, 2250, 1738, 1439, 1170, 1038, 922 cm-1; 1H NMR 
(500 MHz, CDCl3, 60 °C) δ 6.07 (ddd, J = 17.2, 9.9, 9.6 Hz, 1H), 5.16 (d, J = 9.9 Hz, 1H), 5.11 (d, J = 
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17.2 Hz, 1H), 3.72 (s, 3H), 3.68 (s, 3H), 3.46 (d, J = 10.8 Hz, 1H), 2.55‒2.48 (m, 1H), 2.48‒2.42 (m, 1H), 
2.40 (ddd, J = 15.8, 9.2, 6.6 Hz, 1H), 2.31 (ddd, J = 15.8, 6.9, 6.9 Hz, 1H), 2.24‒2.08 (m, 2H), 1.95‒1.86 
(m, 1H), 1.76‒1.67 (m, 2H), 1.56 (dddd, J = 13.5, 13.5, 4.4, 4.4 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 
173.8 (C), 136.1 (CH), 119.4 (C), 118.0 (CH2), 68.6 (CH), 63.4 (CH3), 58.4 (CH), 51.8 (CH3), 42.2 (CH), 
30.7 (CH2), 29.8 (CH2), 26.6 (CH2), 25.7 (CH2); HRMS (ESI), calcd for C13H20N2O3Na+ (M+Na)+ 
275.1372, found 275.1374 
 
NOESY experiment for 122g 
 
122g (500 MHz, CDCl3) 
 
 
 
methyl 3-((2R,3S,6S)-6-allyl-1-methoxy-3-vinylpiperidin-2-yl)propanoate (74h) 
Zirconocene chloride hydride (37.6 mg, 146 μmol) was added to a solution of 71d (26.0 mg, 108 μmol) 
and (CH2Cl)2 (1.1 mL) at room temperature. After stirring for 10 min, the solution was cooled to ‒30 °C. 
Allyltributylstannane (67 L, 216 mol) and Sc(OTf)3 (15.9 mg, 32.3 mmol) were then added to the 
solution. After maintaining at ‒30 °C for 17 h, the solution was quenched with saturated aqueous NaHCO3 
(5 mL), and extracted with chloroform (3x 10 mL). The combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:80) to give 17.2 mg of 74h (60%) and 4.1 mg of 122h (14%): 74h: a 
colorless oil; IR (film) 3077, 2938, 1740, 1437, 1169, 1043, 912 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) 
δ 5.86 (dddd, J = 17.5, 10.0, 7.5, 7.5 Hz, 1H), 5.78 (ddd, J = 16.9, 10.3, 6.6 Hz, 1H), 5.08‒4.98 (m, 4H), 
3.67 (s, 3H), 3.44 (s, 3H), 3.23‒3.13 (m, 1H), 2.82‒2.64 (m, 2H), 2.50‒2.41 (m, 2H), 2.35 (ddd, J = 16.0, 
8.0, 8.0 Hz, 1H), 2.12 (ddd, J = 14.3, 7.2, 7.2 Hz, 1H), 1.95‒1.65 (m, 2H), 1.65‒1.56 (m, 1H), 1.56‒1.37 
(m, 3H); 13C NMR (125 MHz, CDCl3, mixture of two conformers, signals of the major conformer were 
reported) δ 174.5 (C), 140.9 (CH), 137.2 (CH), 115.9 (CH2), 114.4 (CH2), 62.6 (CH), 60.5 (CH3), 56.4 
(CH), 51.6 (CH3), 37.8 (CH2), 36.7 (CH), 31.7 (CH2), 24.6 (CH2), 24.0 (CH2), 21.3 (CH2); HRMS (ESI), 
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calcd for C15H26NO3+ (M+H)+ 268.1913, found 268.1905; 122h: a colorless oil; IR (film) 2947, 1742, 
1438, 1171, 1045, 914, 772 cm-1; 1H NMR (500 MHz, CDCl3, 60 °C) δ 6.13 (ddd, J = 17.3, 9.5, 9.5 Hz, 
1H), 5.86 (dddd, J = 17.2, 9.7, 6.9, 6.9 Hz, 1H), 5.11‒4.99 (m, 4H), 3.67 (s, 3H), 3.56 (s, 3H), 2.64‒2.56 
(m, 1H), 2.56‒2.47 (m, 2H), 2.45‒2.27 (m, 3H), 2.21 (ddd, J = 14.6, 6.9, 6.6 Hz, 1H), 2.21‒2.12 (m, 1H), 
1.70 (dddd, J = 14.0, 6.6, 6.6, 6.6 Hz, 1H), 1.65‒1.50 (m, 4H); 13C NMR (125 MHz, CDCl3) δ 174.3 (CH), 
138.0 (CH), 136.1 (CH), 116.7 (CH2), 116.6 (CH2), 69.3 (CH), 67.9 (CH), 63.7 (CH3), 51.7 (CH3), 43.2 
(CH), 38.2 (CH2), 31.2 (CH2), 30.9 (CH2), 26.8 (CH2), 26.3 (CH2); HRMS (ESI), C15H26NO3+ (M+H)+ 
268.1913, found 268.1903. 
 
NOESY experiment for 74h 
 
74h (500 MHz, CDCl3) 
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A-2. Intramolecular Reductive Pictet-Spengler Reaction and Three-component Reaction 
Synthesis of indolealdehyde 130d 
 
 
 
benzyl 3-(2-methoxy-2-oxoethyl)-1H-indole-1-carboxylate (145) 
Benzyl alcohol (620 L, 6.0 mmol) was added to a solution of 1,1’-Carbonyldiimidazole (1.14 mg, 9.00 
mmol) and CH2Cl2 (20 mL) at 0 °C. The resulting mixture was gradually allowed to warm to room 
temperature, and maintained for 18 h at room temperature. The mixture was diluted with H2O (10 mL), 
and extracted with CH2Cl2 (2x10 mL). The combined organic extracts were washed with H2O (2x 30 mL), 
dried over Na2SO4, and concentrated to give benzyl 1H-imidazole-1-carboxylate9, which was used in the 
next reaction without further purification. 
1,8-Diazabicyclo[5.4.0]undec-7-ene (150 L, 993 mol) was added to a solution of benzyl 1H-imidazole-
1-carboxylate (1.00 g, 4.97 mmol), methyl 2-(1H-indol-3-yl)acetate 144 (940 mg, 4.97 mmol) and MeCN 
(25 mL) at room tempelature. The solution was maintained for 12 h at room temperature, diluted with 
H2O (30 mL). The resulting mixture was extracted with AcOEt (2x 30 mL). The combined organic extracts 
were washed with brine (30 mL), dried over Na2SO4, and concentrated. The residue was purified by silica 
gel column chromatography (EtOAc/hexane 1:9) to give 1.33 g of 145 (82%): white crystals, mp 59.5‒
60.5 °C; IR (film) 2952, 1733, 1455, 1397, 1358, 1247, 1161, 1082, 745cm-1; 1H NMR (500 MHz, CDCl3) 
δ 8.18 (bs, 1H), 7.62 (s, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.50‒7.46 (m, 2H), 7.44‒7.36 (m, 3H), 7.34 (t, J = 
8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 5.44 (s, 2H), 3.72 (s, 2H), 3.71 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 171.5 (C), 150.9 (C), 135.6 (C), 135.2 (C), 130.2 (C), 128.91 (CH), 128.87 (CH), 128.6 (CH), 125.0 
(CH), 124.2 (CH), 123.2 (CH), 119.2 (CH), 115.5 (CH), 114.2 (C), 68.8 (CH2), 52.3 (CH3), 31.0 (CH2); 
HRMS (ESI), C19H17NO4Na+ (M+Na)+ 346.1055, found 346.1048. 
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benzyl 3-(2-oxoethyl)-1H-indole-1-carboxylate (130d) 
A solution of diisobutylaluminium hydride (1.0 M in hexane, 430 L, 430 mol) and CH2Cl2 (4.0 mL) 
was added dropwise via cannula to a solution of ester 145 (138 mg, 427 mol) and CH2Cl2 (4.5 mL) at ‒
78 °C. The solution was stirred for 20 min, and quenched with saturated aqueous (+)-potassium sodium 
tartrate (10 mL). The resulting mixture was vigorously for 1 h, and extracted with chloroform (2x 10 mL). 
The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, and concentrated. 
The residue was purified by silica gel column chromatography (EtOAc/hexane 1:15) to give 52.5 mg of 
130d (42%): a pale yellow oil; IR (film) 3119, 3065, 3034, 2958, 2824, 2724, 1726, 1455, 1396, 1356, 
1246, 1085, 1027, 746, 697 cm-1; 1H NMR (500 MHz, CDCl3) δ 9.78 (t, J = 2.3 Hz, 1H), 8.20 (bs, 1H), 
7.63 (s, 1H), 7.51‒7.34 (m, 7H), 7.28 (ddd, J = 7.7, 6.9, 0.9 Hz, 1H), 5.46 (s, 2H), 3.76 (d, J = 2.3 Hz, 
2H); 13C NMR (125 MHz, CDCl3) δ 198.4 (CH), 150.7 (C), 135.6 (C), 135.1 (C), 130.2 (C), 128.9 (CH), 
128.9 (CH), 128.6 (CH), 125.3 (CH), 124.5 (CH), 123.3 (CH), 118.9 (CH), 115.5 (CH), 112.1 (C), 68.9 
(CH2), 40.0 (CH2); HRMS (ESI), calcd for C18H16NO3 (M+H)+ 294.1130, found 294.1130. 
 
 
 
benzyl 3-(((2S,3R)-1-methoxy-6-oxo-3-vinylpiperidin-2-yl)methyl)-1H-indole-1-carboxylate (129d) 
Boron trifluoride diethyl ether complex (16 L, 132 mol) was added to a solution of 3-indole 
acetaldehyde 37 (29.0 mg, 98.9 mol), E-42 (14.2 mg, 65.9 mol) and CH2Cl2 (1.0 mL) at ‒20 °C. After 
maintaining at ‒20 °C for 20 min, boron trifluoride diethyl ether complex (290 μL, 2.3 mmol) was added 
to the solution every 15 min twelve times. After maintaining at ‒20 °C for 20 min, the solution was 
quenched with H2O (5 mL), and extracted with chloroform (2x 5 mL). The combined organic extracts 
were washed with brine (5 mL), dried over Na2SO4, and concentrated. The residue was purified by silica 
gel column chromatography (EtOAc/hexane 1:2 to 1:11) to give 18.9 mg of 129d (68%): a colorless oil; 
IR (film) 2928, 1736, 1671, 1455, 1399, 1249, 1090, 750 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.16 (bs, 
1H), 7.56 (ddd, J = 7.7, 1.2, 0.9 Hz, 1H), 7.51‒7.46 (m, 2H), 7.46‒7.36 (m, 4H), 7.33 (ddd, J = 8.3, 7.2, 
1.2 Hz, 1H), 7.28‒7.24 (m, 1H), 5.95 (ddd, J = 17.2, 10.6, 7.5 Hz, 1H), 5.45 (s, 2H), 5.24 (ddd, J = 10.6, 
1.2, 1.2 Hz, 1H), 5.16 (ddd, J = 17.2, 1.2, 1.2 Hz, 1H), 4.11 (ddd, J = 8.0, 4.0, 4.0 Hz, 1H), 3.80 (s, 3H), 
3.20 (dd, J = 14.6, 4.0 Hz, 1H), 2.98 (dd, J = 14.6, 8.0 Hz, 1H), 2.77‒2.70 (m, 1H), 2.53 (ddd, J = 17.5, 
6.6, 6.6 Hz, 1H), 2.44 (ddd, J = 17.5, 7.2, 7.2 Hz, 1H), 1.81‒1.69 (m, 2H); 13C NMR (125 MHz, CDCl3) 
δ 167.9 (C), 150.8 (C), 136.1 (CH), 135.6 (C), 135.3 (C), 130.4 (C), 128.9 (CH), 128.8 (CH), 128.5 (CH), 
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124.9 (CH), 124.2 (CH), 123.0 (CH), 119.3 (CH), 118.2 (CH2), 117.8 (C), 115.4 (CH), 68.7 (CH2), 62.3 
(CH), 62.0 (CH3), 42.0 (CH), 30.8 (CH2), 25.0 (CH2), 23.9 (CH2); HRMS (ESI), calcd for C25H27N2O4+ 
(M+H)+ 419.1971, found 419.1971. 
 
 
 
benzyl (6R,9S,10R)-12-methoxy-9-vinyl-6,7,8,9,10,11-hexahydro-5H-6,10-epiminocycloocta[b]- 
indole-5-carboxylate (128d) 
Zirconocene chloride hydride (23.4 mg, 90.7 μmol) was added to a solution of 129d (33.4 mg, 79.8 μmol) 
and CH2Cl2 (800 L) at room temperature. After stirring for 10 min, Sc(OTf)3 (3.9 mg, 8.0 μmol) were 
added to the solution, and stirred for 1 h at room temperature. This solution was quenched with H2O (5 
mL), and extracted with chloroform (2x 5 mL). The combined organic extracts were washed with brine (5 
mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography 
(EtOAc/hexane 1:30) to give 15.7 mg of 128d (49%): a colorless oil; IR (film) 2929, 1730, 1455, 1392, 
1328, 1215, 1147, 753 cm-1; 1H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 7.7 Hz, 1H), 7.51‒7.47 (m, 2H), 
7.45‒7.35 (m, 4H), 7.26‒7.20 (m, 2H), 5.82 (ddd, J = 16.3, 10.6, 5.4 Hz, 1H), 5.47 (d, J = 12.0, 1H), 5.43 
(d, J = 12.0, 1H), 5.11 (ddd, J = 10.6, 1.7, 1.7 Hz, 1H), 5.05‒5.01 (m, 1H), 5.02 (ddd, J = 16.3, 1.7, 1.7 
Hz, 1H), 3.74 (dd, J = 6.9, 4.0 Hz, 1H), 3.53 (s, 3H), 2.94 (dd, J = 17.2, 6.9 Hz, 1H), 2.72‒2.64 (m, 1H), 
2.50 (d, J = 17.2 Hz, 1H), 1.99‒1.94 (m, 2H), 1.38 (dddd, J = 13.2, 3.4, 3.4, 3.4 Hz, 1H), 1.09 (dddd, J = 
13.2, 13.2, 10.3, 7.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 151.6 (C), 140.2 (CH), 135.8 (C), 135.1 (C), 
133.3 (C), 129.3 (C), 128.93 (CH), 128.89 (CH), 128.83 (CH), 124.1 (CH), 123.0 (CH), 118.2 (CH), 116.8 
(C), 115.9 (CH), 115.5 (CH2), 68.8 (CH2), 59.7 (CH3), 56.8 (CH), 55.6 (CH), 44.7 (CH), 29.0 (CH2), 20.0 
(CH2), 17.7 (CH2); HRMS (ESI), calcd for C25H27N2O3+ (M+H)+ 403.2022, found 403.2022. 
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Synthesis of N-methoxyoctanamide 131 
 
 
 
N-methoxyoctanamide (131) 
Octanoyl chloride 146 (2.4 mL, 14 mmol) was added to a solution of O-methylhydroxylamine 
hydrochloride (1.00 g, 12.0 mmol), pyridine (2.9 mL, 36 mmol) and CH2Cl2 (60 mL) at room temperature. 
The solution was maintained for 1 h at room temperature, poured into 0.5 M HCl (50 mL). The resulting 
mixture was extracted with chloroform (2x 40 mL). The combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:4 to 2:1) to give 2.03 g of 131 (98%): a colorless oil; IR (film) 3182, 
2958, 2930, 2858, 1661, 1521, 1068 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.76 (s, 3H), 2.40 (bs, 1H), 2.07 
(bs, 2H), 1.64 (tt, J = 7.5, 7.5 Hz, 2H), 1.37‒1.20 (m, 8H), 0.87 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 171.4 (C), 64.0 (CH3), 33.2 (CH2), 31.7 (CH2), 29.2 (CH2), 29.0 (CH2), 25.6 (CH2), 22.6 (CH2), 
14.1 (CH3); LRMS (EI) m/z 173 (M+, 3.5%), 128 (14), 127 (89), 109 (13), 102 (14), 89 (65), 84 (5), 83 
(7), 78 (12), 10.3 (10), 59 (29), 58 (100), 56 (22); HRMS (EI), calcd for C9H19NO2 M+ 173.1416, found 
173.1416. 
 
 
N-methoxy-N-(pent-4-en-2-yl)octanamide (134) 
(±)-10-Camphorsulfonic acid (2.7 mg, 12 mol) was added to a solution of N-methoxyoctanamide 131 
(200 mg, 1.15 mmol), ethylvinylether 136 (130 mL, 1.35 mmol) and CH2Cl2 (2.3 mL) at 0 °C. After 
stirring for 3 h, allyltributylstannane (900 L, 2.90 mmol) and boron trifluoride diethyl ether complex 
(280 μL, 2.3 mmol) were added to the solution at 0 °C. The mixture was stirred for 1 h at 0 °C, and allowed 
to warm to room temperature. After maintaining for 30 min at room temperature, the solution was 
quenched with saturated aqueous NaHCO3 (5 mL), and extracted with chloroform (2x 5 mL). The 
combined organic extracts were washed with brine (10 mL) dried over Na2SO4, and concentrated. The 
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residue was purified by silica gel column chromatography (EtOAc/hexane 1:60 to 1:40) to give 229 mg 
of N-methoxyamide 134 (82%): a colorless oil; IR (film) 2930, 2857, 1672, 1456, 1385, 1157, 1027, 916 
cm-1; 1H NMR (500 MHz, CDCl3) δ 5.74 (dddd, J = 17.2, 10.3, 6.9, 6.9 Hz, 1H), 5.07 (ddd, J = 17.2, 1.4, 
1.4 Hz, 1H), 5.02 (ddd, J = 10.3, 1.4, 1.4 Hz, 1H), 4.52 (bs, 1H), 3.75 (s, 3H), 2.48‒2.31 (m, 3H), 2.24 
(ddddd, J = 14.0, 6.9, 6.9, 1.4, 1.4 Hz, 1H), 1.62 (tt, J = 7.5, 7.5 Hz, 2H), 1.35‒1.25 (m, 8H), 1.23 (d, J = 
6.9 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 176.6 (C), 135.3 (CH), 117.2 (CH2), 
64.8 (CH3), 53.4 (CH), 38.5 (CH2), 32.8 (CH2), 31.8 (CH2), 29.5 (CH2), 29.2 (CH2), 24.7 (CH2), 22.7 
(CH2), 18.0 (CH3), 14.2 (CH3); HRMS (ESI), calcd for C14H28NO2+ (M+H)+ 242.2120, found 242.2112. 
 
 
 
2-(methoxy(pent-4-en-2-yl)amino)nonanenitrile (138) 
Zirconocene chloride hydride (54.0 mg, 209 μmol) was added to a solution of 134 (36.0 mg, 150 μmol) 
and (CH2Cl)2 (1.5 mL) at room temperature. After stirring for 10 min, cyanotrimethylsilane (22 μL, 180 
μmol) and Sc(OTf)3 (7.4 mg, 15.0 μmol) were added to the solution. After stirring for 2.5 h at room 
temperature. This solution was quenched with saturated aqueous NaHCO3 (5 mL), and extracted with 
chloroform (2x 5 mL). The combined organic extracts were washed with brine (10 mL), dried over Na2SO4, 
and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane 1:80) to 
give 27.0 mg of 138 (72%, dr = 1.1:1): a colorless oil; IR (film) 2928, 2858, 2234, 1466, 1042, 914 cm-1; 
1H NMR (500 MHz, CDCl3, 1:1 mixture of diastereomers) δ 5.85‒5.74 (m, 1H), 5.13‒5.03 (m, 2H), 3.78 
(dd, J = 13.5, 6.3 Hz, 1/2H), 3.76 (dd, J = 13.5, 6.3 Hz, 1/2H), 3.62 (s, 3/2H), 3.62 (s, 3/2H), 3.11‒3.02 
(m, 1H), 2.56‒2.49 (m, 1/2H), 2.37‒2.49 (m, 1/2H), 2.19 (ddddd, J = 14.0, 6.3, 6.3, 1.2, 1.2 Hz, 1/2H), 
2.13 (ddddd, J = 14.6, 7.4, 7.2, 1.2, 1.2 Hz, 1/2H), 1.96‒1.80 (m, 2H), 1.59‒1.44 (m, 2H), 1.39‒1.23 (m, 
8H), 1.20 (d, J = 6.3 Hz, 3/2H), 1.03 (d, J = 6.3 Hz, 3/2H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, 
CDCl3, 1:1 mixture of diastereomers) δ 135.3 (CH), 134.7 (CH), 118.3 (C), 117.9 (C), 117.47 (CH2), 
117.44 (CH2), 64.24 (CH3), 64.17 (CH3), 60.4 (CH), 60.4 (CH), 56.2 (CH), 56.1 (CH), 38.5 (CH2), 38.4 
(CH2), 31.8 (CH2), 31.8 (CH2), 31.6 (CH2), 31.5 (CH2), 29.2 (CH2), 29.2 (CH2), 29.2 (CH2), 29.2 (CH2), 
26.2 (CH2), 26.1 (CH2), 22.7 (CH2), 22.7 (CH2), 16.7 (CH3), 16.4 (CH3), 14.2 (CH3), 14.2 (CH3); HRMS 
(ESI), calcd for C15H29N2O+ (M+H)+ 253.2280, found 253.2269. 
 
  
 
108 
 
O-methyl-N-(pent-4-en-2-yl)-N-(undec-1-en-4-yl)hydroxylamine (45b) 
Zirconocene chloride hydride (44.4 mg, 172 μmol) was added to a solution of 134 (26.0 mg, 108 μmol) 
and (CH2Cl)2 (1.4 mL) at room temperature. After stirring for 10 min, allyltributylstannane (100 μL, 323 
μmol) and Sc(OTf)3 (63.6 mg, 129 μmol) were added to the solution. After stirring for 20 min at room 
temperature. This solution was quenched with saturated aqueous NaHCO3 (5 mL), and extracted with 
chloroform (2x 5 mL). The combined organic extracts were washed with brine (10 mL) dried over Na2SO4, 
and concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane 1:80 to 
1:60) to give 16.9 mg of 139 (59%, dr = 1:1): a colorless oil; IR (film) 2927, 2855, 1458, 1375, 1043, 911, 
772 cm-1; 1H NMR (500 MHz, CD3OD, 1:1 mixture of diastereomers) δ 5.93‒5.79 (m, 2H), 5.10‒4.06 (m, 
4H), 3.543 (s, 3/2H), 3.538 (s, 3/2H), 3.08‒2.98 (m, 1H), 2.87‒2.79 (m, 1H), 2.48‒2.33 (m, 2H), 2.24‒
2.06 (m, 2H), 1.60‒1.24 (m, 12H), 1.08‒1.03 (m, 3/2H), 1.03‒0.99 (m, 3/2H), 0.95‒0.88 (m, 3H); 13C 
NMR (125 MHz, CDCl3, 1:1 mixture of diastereomers) δ137.3 (CH), 137.1 (CH), 136.7 (CH), 136.6 (CH), 
116.4 (CH2), 116.4 (CH2), 116.1 (CH2), 116.0 (CH2), 64.1 (CH3), 64.1 (CH3), 62.0 (CH), 61.8 (CH), 57.5 
(CH), 57.5 (CH), 39.0 (CH2), 38.8 (CH2), 34.7 (CH2), 33.8 (CH2), 32.0 (CH2), 32.0 (CH2), 30.7 (CH2), 
30.1 (CH2), 30.0 (CH2), 30.0 (CH2), 29.5 (CH2), 29.4 (CH2), 26.5 (CH2), 26.1 (CH2), 22.8 (CH2), 22.8 
(CH2), 14.3 (CH3), 14.3 (CH3), 14.3 (CH3), 14.3 (CH3); HRMS (ESI), calcd for C17H34NO+ (M+H)+ 
268.2640, found 268.2627. 
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Unified Total Synthesis of Stemoamide-type Alkaloids 
 
A-2. Gram-scale Total Synthesis of Stemoamide (1) 
Synthesis of 2-Siloxypyrrole 123d 
 
1-(4-Methoxybenzyl)-2-((triisopropylsilyl)oxy)-1H-pyrrole (123d)1 
4-Methoxybenzylamine (6.5 mL, 50 mmol, 1.0 equiv) was added dropwise over 1 h to a mixture of 2,5-
dihydro-2,5-dimethoxyfuran 30 (6.0 mL, 49 mmol, 1.0 equiv) and aqueous 0.04 M HCl (260 mL, 10 mmol, 
0.2 equiv) at room temperature. The resulting mixture was stirred for 10 min, and extracted with EtOAc 
(3 x 300 mL). The combined organic extracts were dried over Na2SO4, and concentrated. The residue was 
purified by silica gel column chromatography (EtOAc/hexane 2:1) to give 6.10 g of α,β-unsaturated lactam 
139d and enamide 140d (61%, 139d:140d = 1:2.2). For analytical samples, two diastereomers were 
separated by silica gel column chromatography (EtOAc/hexane 1:5 to 2:1); ,-unsaturated lactam 139d: 
a yellow solid; mp 48–49 °C; IR (film) 2837, 1673, 1513, 1455, 1245, 1177, 1032, 801 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 7.20–7.15 (m, 2H), 7.03 (dt, J = 6.0, 1.7 Hz, 1H), 6.88–6.84 (m, 2H), 6.21 (dt, J = 
6.0, 2.0 Hz, 1H), 4.57 (s, 2H), 3.85 (dd, J = 2.0, 1.7 Hz, 2H), 3.79 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 171.3 (C), 159.1 (C), 142.9 (CH), 129.5 (C), 129.4 (CH), 128.1 (CH), 114.2 (CH), 55.3 (CH3), 52.2 
(CH2), 45.4 (CH2); HRMS (ESI), calcd for C12H14NO2+ (M+H)+ 204.1025, found 204.1021. enamide 
140d: a yellow solid; mp 45–46 °C; IR (film) 2934, 2836, 1692, 1514, 1356, 1247, 1176, 1032, 772 cm−1; 
1H NMR (500 MHz, CDCl3) δ 7.20–7.16 (m, 2H), 6.89–6.84 (m, 2H), 6.30 (dt, J = 4.9, 2.0 Hz, 1H), 5.26 
(dt, J = 4.9, 2.3 Hz, 1H), 4.56 (s, 2H), 3.79 (s, 3H), 3.11 (dd, J = 2.3, 2.0 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ 177.0 (C), 159.3 (C), 132.7 (CH), 129.3 (CH), 128.9 (C), 114.3 (CH), 104.6 (CH), 55.4 (CH3), 
45.2 (CH2), 37.6 (CH2); HRMS (ESI), calcd for C12H14NO2+ (M+H)+ 204.1025, found 204.1025. 
Sodium bis(trimethylsilyl)amide (1.9 M in THF, 17 mL, 32 mmol, 1.1 equiv) was added to a solution 
of α,β-unsaturated lactam 139d and enamide 140d (139d:140d = 1:2.2, 6.10 g, 30.0 mmol, 1.0 equiv) and 
THF (60 mL) at –78 °C. After maintaining for 10 min at –78 °C, triisopropylsilyl chloride (6.4 mL, 30 
mmol, 1.0 equiv) was added to the solution at –78 °C. The solution was allowed to warm to room 
temperature, and stirred for 12 h, and diluted with hexane (100 mL). The resulting mixture was filtered 
through a pad of Celite®, and concentrated. The residue was filtered through a pad of basic alumina, and 
washed with hexane. The filtrate was concentrated to give 8.15 g of 2-siloxypyrrole 123d (76%): a pale 
yellow oil; IR (film) 2945, 2867, 1557, 1513, 1462, 1248, 1030, 913, 854, 684 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.09–7.04 (m, 2H), 6.85–6.80 (m, 2H), 6.13 (dd, J = 3.2, 2.1 Hz, 1H), 5.90 (dd, J = 3.4, 3.2 Hz, 
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1H), 5.23 (dd, J = 3.4, 2.1 Hz, 1H), 4.88 (s, 2H), 3.78 (s, 3H), 1.26 (sep, J = 7.3 Hz, 3H), 1.07 (d, J = 7.3 
Hz, 18H); 13C NMR (125 MHz, CDCl3) δ 158.9 (C), 142.4 (C), 130.9 (C), 128.4 (CH), 114.0 (CH), 111.8 
(CH), 105.1 (CH), 87.3 (CH), 55.4 (CH3), 47.5 (CH2), 18.0 (CH3), 12.5 (CH); HRMS (ESI), calcd for 
C21H34NO2Si+ (M+H)+ 360.2359, found 360.2344. 
 
 
 
Methyl-7-bromo-4-hydroxyhept-2-ynoate ((±)-134) 
Diisobutylaluminium hydride (1.0 M in Hexane, 23 mL, 23 mmol, 1.1 equiv) was added to a solution of 
ethyl 4-bromobutyrate 122 (3.0 mL, 21 mmol, 1.0 equiv) and CH2Cl2 (100 mL) at ‒78 °C. After stirring 
at ‒78 °C for 1 h, the solution was quenched with saturated aqueous (+)-potassium sodium tartrate (50 
mL) at ‒78 °C, allowed to warm to room temperature, stirred vigorously for 1 h, and extracted with CH2Cl2 
(3 x 100 mL). The combined organic extracts were washed with brine (200 mL), dried over Na2SO4, and 
concentrated to give 4-bromobutanal 133, which was immediately used in the next reaction without further 
purification. 
n-Butyllithium (1.55 M in hexane, 15 mL, 23 mmol, 1.1 equiv) was added to a solution of 
hexamethyldisilazane (5.0 mL, 23 mmol, 1.1 equiv) at –78 °C. After stirring at –78 °C for 10 min, methyl 
propiolate (2.6 mL, 31 mmol, 1.5 equiv) was added to the solution of LiN(TMS)2 at –78 °C. After stirring 
at –78 °C for 1 h, a solution of the above aldehyde 133 and THF (16 mL) was added to a solution of the 
lithium acetylide via cannula at –78 °C. The resulting solution was stirred for 30 min at –78 °C, and 
quenched with aqueous saturated NH4Cl (40 mL). The mixture was allowed to warm to room temperature, 
filtered, and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine 
(200 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:5) to give 2.94 g of (±)-γ-hydroxypropiolate 134 (60%). The spectral 
data of 134 was identical to chiral γ-hydroxypropiolate 134. 
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Methyl (R)-7-bromo-4-hydroxyhept-2-ynoate (134) 
Diisobutylaluminium hydride (1.0 M solution in hexane, 31 mL, 31 mmol, 1.1 equiv) was added to a 
solution of ethyl 4-bromobutyrate 132 (4.0 mL, 28 mmol, 1.0 equiv) and CH2Cl2 (140 mL) at ‒78 °C. 
After stirring at ‒78 °C for 1 h, the solution was quenched with saturated aqueous (+)-potassium sodium 
tartrate (70 mL) at ‒78 °C, allowed to warm to room temperature, stirred vigorously for 1 h, and extracted 
with CH2Cl2 (3 x 150 mL). The combined organic extracts were washed with brine (400 mL), dried over 
Na2SO4, and concentrated to give 4-bromobutanal 133, which was immediately used in the next reaction 
without further purification. 
Dimethylzinc (1.2 M solution in toluene, 70 mL, 84 mmol, 3.0 equiv) was added dropwise to a 
solution of (S,S)-ProPhenol (3.53 g, 5.56 mmol, 20 mol%) and methyl propiolate (6.9 mL, 83 mmol, 3.0 
equiv) and toluene (90 mL) at 0 °C. The solution was warmed to room temperature and stirred for 30 min. 
A solution of 4-bromobutanal 133 and toluene (90 mL) was added over 24 h at 0 °C using a syringe pump 
to the solution of the catalyst. The solution was stirred for an additional 3 h at 0 °C, and quenched with 
aqueous saturated NH4Cl (120 mL). The mixture was filtered, and extracted with EtOAc (3 x 200 mL). 
The combined organic extracts were washed with brine (500 mL), dried over Na2SO4, and concentrated. 
The residue was purified by silica gel column chromatography (EtOAc/hexane 1:5) to give 5.13 g of γ-
hydroxypropiolate 134 (78%, 98% ee determined by HPLC (CHIRALPAK OD-H, 250×4.6 mm, UV 210 
nm, iPrOH/hexane 1:11 (v/v), 1.0 mL/min, 134: TR= 12.1 min, ent-134: TR= 16.5 min)): a pale yellow oil; 
[]𝐷
22 = +0.76 (c 1.0, CHCl3); IR (film) 3409, 2956, 2239, 1715, 1436, 1255, 1058, 751 cm−1; 1H NMR 
(500 MHz, CDCl3) δ 4.57 (dd, J = 6.6, 6.6 Hz, 1H), 3.70 (s, 3H), 3.46 (dd, J = 6.6, 6.6 Hz, 2H), 2.11–2.03 
(m, 2H), 1.98 (bs, 1H), 1.97–1.91 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 153.8 (C), 87.5 (C), 76.7 (C), 
61.4 (CH), 53.1 (CH3), 35.3 (CH2), 33.1 (CH2), 28.2 (CH2); HRMS (ESI), calcd for C8H12O3Br+ (M+H)+ 
234.9970, found 234.9967. 
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Chiral HPLC chart of 134 (98% ee) 
CHIRALPAK OD-H, 250×4.6 mm, UV 210 nm, iPrOH/hexane 1:11 (v/v), 1.0 mL/min 
 
 
 
 
 
 
 
 
 
 
 
(R)-5-(3-Bromopropyl)furan-2(5H)-one (122) 
A suspension of palladium on polyethyleneimine (4.3 wt% on polyethyleneimine, 101 mg) and MeOH 
(36 mL) was added to a solution of γ-hydroxypropiolate 134 (5.06 g, 21.5 mmol) and 1,4-dioxane (36 
mL) at room temperature using Pasteur pipette. The flask was purged with hydrogen. After stirring under 
hydrogen atmosphere (1 atm) at room temperature for 14 h, 1 M aqueous HCl (70 mL) was added to the 
mixture. The resulting mixture was stirred for 2 h at room temperature, extracted with EtOAc (3 x 70 mL), 
dried over Na2SO4, and concentrated. The residue was diluted with aqueous saturated NaHCO3 and 
extracted with EtOAc (3 x 70 mL), dried over Na2SO4, and concentrated. The residue was filtered through 
a pad of silica gel (EtOAc/Hexane 1:3), and then purified by MPLC (Yamazen Ultra Pack Column B, 
26×300 mm, EtOAc/hexane 24:76 to 45:55, 20 mL/min, TR = 28 min) to give 3.32 g of an inseparable 
mixture of butenolide 122 (3.18 g, 72%) and lactone 136 (0.14 g, 3%). Butenolide 122: 98% ee determined 
by HPLC (CHIRALPAK AS-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:3 (v/v), 1.0 mL/min, ent-122: 
No. TR Area Height Area (%) 
1 12.10 18055812 755803 98.8339 
2 16.54 213034 7256 1.1661 
No. TR Area Height Area (%) 
1 12.28 444358 16586 49.9345 
2 15.39 445524 13284 50.0655 
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TR= 10.1 min, 122: TR= 12.9 min); a pale yellow oil; []𝐷
23 = –77.7 (c 1.0, CHCl3); IR (film) 3087, 2923, 
2850, 1749, 1163, 814 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.45 (dd, J = 5.7, 1.4 Hz, 1H), 6.14 (dd, J = 
5.7, 2.0 Hz, 1H), 5.08 (dddd, J = 8.3, 3.7, 2.0, 1.4 Hz, 1H), 3.51‒3.41 (m, 2H), 2.11–1.96 (m, 3H), 1.80‒
1.69 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 172.9 (C), 155.9 (CH), 122.1 (CH), 82.4 (CH), 32.9 (CH2), 
31.8 (CH2), 28.1 (CH2); HRMS (ESI), calcd for C7H10O2Br+ (M+H)+ 204.9864, found 204.9865. 
 
Chiral HPLC chart of 122 (98% ee) 
CHIRALPAK AS-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:3 (v/v), 1.0 mL/min 
 
 
 
 
 
 
 
 
 
  
No. TR Area Height Area (%) 
1 10.06 173635 12095 0.9764 
2 12.87 17608930 644765 99.0236 
No. TR Area Height Area (%) 
1 9.62 3509745 147434 49.0203 
2 12.37 3650031 104912 50.9797 
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(S)-5-((2R,3R)-2-(3-Bromopropyl)-5-oxotetrahydrofuran-3-yl)-1-(4-methoxybenzyl)-pyrrolidin-2-
one (124) and 
(R)-5-((2R,3R)-2-(3-bromopropyl)-5-oxotetrahydrofuran-3-yl)-1-(4-methoxybenzyl)-pyrrolidin-2-
one (epi-124) 
Tin (IV) tetrachloride (890 L, 7.6 mmol, 0.5 equiv) was added to a solution of a 3.11 g mixture of 
butenolide 122 and lactone 136 (122: 2.98 g, 14.5 mmol, 1.0 equiv, 136: 0.13 g, 0.63 mmol), 2-
siloxypyrrole 123d (6.54 g, 18.2 mmol, 1.2 equiv) and CH2Cl2 (380 mL) at –78 °C. The solution was 
allowed to warm to –60 °C, and stirred for 12 h at –60 °C. The resulting deep green solution was re-cooled 
to –78 °C. Methanol (1.5 mL, 37 mmol, 2.5 equiv) was added to the solution at –78 °C. Then, triethylsilane 
(36 mL, 220 mmol, 14 equiv) and titanium (IV) tetrachloride (5.0 mL, 46 mmol, 3.0 equiv) were added 
dropwise to the solution at –78 °C. The resulting white suspension was allowed to warm to room 
temperature, and stirred vigorously for 35 h at room temperature. The mixture was quenched with 
saturated aqueous NaHCO3 (200 mL), and vigorously stirred for 1 h at room temperature. The resulting 
mixture was filtered through Celite®, washed with CHCl3, and concentrated carefully. The resulting 
mixture was extracted with CHCl3 (5 x 200 mL). The combined organic extracts were washed with brine 
(200 mL), dried over Na2SO4, and concentrated. The residue was filtered through a pad of silica gel 
(EtOAc), and then purified by MPLC (Yamazen Ultra Pack Column D, 26×300 mm, EtOAc/hexane 46:54 
to 67:33, 45 mL/min, TR = 63 min) to give 4.52 g of a mixture of lactams 124 and epi-124 (76%, 124:epi-
124 = 3.7:1). For analytical samples, two diastereomers were separated by HPLC (PEGASIL Silica 120-
5, 250×20 mm, EtOAc/MeCN 4:1, 10 mL/min, 124: TR = 12.3 min, epi-124: TR = 16.0 min); lactam 124: 
a colorless oil; []𝐷
21 = –6.3 (c 1.0, CHCl3); IR (film) 2935, 2838, 1773, 1684, 1513, 1418, 1247, 1177, 
1031 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.17–7.13 (m, 2H), 6.88–6.84 (m, 2H), 4.71 (d, J = 15.2 Hz, 
1H), 4.22 (ddd, J = 10.0, 3.2, 3.2 Hz, 1H), 4.12 (d, J = 15.2 Hz, 1H), 3.79 (s, 3H), 3.60 (ddd, J = 8.0, 6.3, 
3.7 Hz, 1H), 3.36 (ddd, J = 10.0, 6.6, 6.0 Hz, 1H), 3.32 (ddd, J = 10.0, 7.7, 5.7 Hz, 1H), 2.71 (dd, J = 18.0, 
10.0 Hz, 1H), 2.56 (dddd, J = 10.0, 4.0, 3.7, 3.2 Hz, 1H), 2.53 (ddd, J = 17.5, 10.0, 5.7 Hz, 1H), 2.45 (ddd, 
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J = 17.5, 10.0, 7.2 Hz, 1H), 2.19 (dd, J = 18.0, 4.0 Hz, 1H), 2.09 (dddd, J = 13.2, 10.0, 8.0, 5.7 Hz, 1H), 
2.04–1.94 (m, 1H), 1.85–1.76 (m, 1H), 1.72 (dddd, J = 13.2, 10.0, 7.2, 6.3 Hz, 1H), 1.52 (dddd, J = 14.0, 
10.3, 10.0, 4.6 Hz, 1H), 1.19 (dddd, J = 14.0, 10.6, 5.4, 3.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 175.9 
(C), 175.4 (C), 159.5 (C), 129.3 (CH), 128.4 (C), 114.5 (CH), 79.4 (CH), 59.3 (CH), 55.4 (CH3), 45.0 
(CH2), 40.9 (CH), 34.4 (CH2), 32.9 (CH2), 30.9 (CH2), 30.1 (CH2), 28.7 (CH2), 19.6 (CH2); HRMS (ESI), 
calcd for C19H25NO4Br+ (M+H)+ 410.0967, found 410.0963. lactam epi-124: a colorless oil; []𝐷
22 = +5.5 
(c 1.0, CHCl3); IR (film) 2932, 2837, 1176, 1681, 1513, 1246, 1177, 1031 cm−1; 1H NMR (500 MHz, 
CDCl3) δ 7.18–7.13 (m, 2H), 6.89–6.85 (m, 2H), 4.78 (d, J = 14.9 Hz, 1H), 4.11 (ddd, J = 8.6, 5.7, 4.0 Hz, 
1H), 4.01 (d, J = 14.9 Hz, 1H), 3.80 (s, 3H), 3.62 (ddd, J = 8.3, 6.3, 4.0 Hz, 1H), 3.41 (ddd, J = 10.3, 7.2, 
5.4 Hz, 1H), 3.40 (ddd, J = 10.3, 7.2, 5.4 Hz, 1H), 2.62 (dddd, J = 9.5, 7.2, 5.7, 4.0 Hz, 1H), 2.52 (ddd, J 
= 17.5, 10.0, 6.0 Hz, 1H), 2.46 (ddd, J = 17.5, 9.7, 7.2 Hz, 1H), 2.30 (dd, J = 18.6, 9.2 Hz, 1H), 2.24 (dd, 
J = 18.6, 7.5 Hz, 1H), 2.07 (dddd, J = 13.8, 9.7, 8.3, 6.0 Hz, 1H), 2.04–1.95 (m, 1H), 1.89–1.79 (m, 1H), 
1.79–1.64 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 175.2 (C), 175.1 (C), 159.5 (C), 129.5 (CH), 128.1 
(C), 114.5 (CH), 80.5 (CH), 57.3 (CH), 55.4 (CH3), 44.6 (CH2), 41.6 (CH), 34.2 (CH2), 33.0 (CH2), 30.1 
(CH2), 28.6 (CH2), 28.3 (CH2), 18.9 (CH2); HRMS (ESI), calcd for C19H25NO4Br+ (M+H)+ 410.0967, 
found 410.0969. 
 
NOESY experiment for 124 and epi-124 
 
124 and epi-124 (500 MHz, CDCl3)  
 
 
 (S)-5-((2R,3R)-2-(3-Bromopropyl)-5-oxotetrahydrofuran-3-yl)pyrrolidin-2-one (158) and 
(R)-5-((2R,3R)-2-(3-bromopropyl)-5-oxotetrahydrofuran-3-yl)pyrrolidin-2-one (epi-158) 
Cerium ammonium nitrate (18.0 g, 32.8 mmol, 3.0 equiv) was added to a solution of lactam 124 and epi-
124 (4.48 g, 124:epi-124 = 3.7:1, 10.9 mmol, 1.0 equiv), MeCN (550 mL) and H2O (55 mL) at room 
temperature. After stirring at room temperature for 24 h, the solution was concentrated at 0 °C to 1/5 
volume. Then, solid NaHCO3 (ca. 20 g) was added to the solution. The resulting mixture was filtered, and 
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extracted with CHCl3 (5 x 100 mL). The combined organic extracts were dried over Na2SO4, and 
concentrated. The residue was purified by silica gel column chromatography (EtOAc/MeOH 1:0 to 19:1) 
to give 2.97 g of secondary lactams 158 and epi-158 (94%, 158: epi-158 = 3.7:1). For analytical samples, 
two diastereomers were separated by HPLC (PEGASIL Silica 120-5, 250×10 mm, Et2O/MeCN 2:3, 10 
mL/min, 158: TR = 34.0 min, epi-158: TR = 37.5 min). The ee of secondary lactam 158 was determined as 
98% ee by HPLC (CHIRALPAK AD-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:1 (v/v), 1.0 mL/min, 
ent-158: TR= 20.2 min, 158: TR= 29.8 min). The ee of secondary lactam epi-158 was determined as 98% 
ee by HPLC (CHIRALPAK AD-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:1 (v/v), 1.0 mL/min, epi-
158: TR= 11.3 min, ent-epi-158: TR= 15.9 min): lactam 158: a white solid; []𝐷
22 = 33.1 (c 1.0, CHCl3); 
mp 109–110 °C; IR (film) 3216, 2932, 1771, 1693, 1438, 1423, 1268, 1201, 1181 cm−1; 1H NMR (500 
MHz, CDCl3) δ 7.93 (bs, 1H), 4.30 (ddd, J = 9.5, 6.3, 3.2 Hz, 1H), 3.80 (ddd, J = 7.2, 6.6, 6.0 Hz, 1H), 
3.49 (ddd, J = 10.0, 7.2, 5.2 Hz, 1H), 3.45 (ddd, J = 10.0, 6.8, 6.0 Hz, 1H), 2.68 (dd, J = 18.0, 9.2 Hz, 1H), 
2.47 (dd, J = 18.0, 7.7 Hz, 1H), 2.39–2.25 (m, 4H), 2.14–2.03 (m, 1H), 2.03–1.88 (m, 2H), 1.79–1.68 (m, 
2H); 13C NMR (125 MHz, CDCl3) δ 179.4 (C), 175.3 (C), 81.1 (CH), 55.3 (CH), 45.9 (CH), 33.7 (CH2), 
33.2 (CH2), 30.5 (CH2), 30.3 (CH2), 28.5 (CH2), 25.3 (CH2); HRMS (ESI), calcd for C11H17NO3Br+ 
(M+H)+ 290.0392, found 290.0398. lactam epi-158: a colorless oil; []𝐷
19 = 52.4 (c 0.5, CHCl3); IR (film) 
3216, 2927, 1773, 1692, 1262, 1200, 1183 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.71 (bs, 1H), 4.37 (ddd, 
J = 8.3, 4.9, 3.4 Hz, 1H), 3.72 (ddd, J = 7.5, 7.2, 6.6 Hz, 1H), 3.51 (ddd, J = 10.0, 7.2, 5.4 Hz, 1H), 3.45 
(ddd, J = 10.0, 7.2, 5.7 Hz, 1H), 2.77–2.69 (m, 1H), 2.46–2.26 (m, 5H), 2.15–2.06 (m, 1H), 2.06–1.97 (m, 
1H), 1.97–1.89 (m, 1H), 1.79–1.69 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 179.2 (C), 175.1 (C), 82.0 
(CH), 56.7 (CH), 46.2 (CH), 34.7 (CH2), 33.5 (CH2), 31.2 (CH2), 30.0 (CH2), 28.6 (CH2), 25.2 (CH2); 
HRMS (ESI), calcd for C11H17NO3Br+ (M+H)+ 290.0392, found 290.0389. 
 
Chiral HPLC chart of 158 (98% ee) 
CHIRALPAK AD-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:1 (v/v), 1.0 mL/min 
 
 
 
No. TR Area Height Area (%) 
1 20.21 50178 1700 0.9481 
2 29.81 5242525 67533 99.0519 
 
118 
 
 
 
 
 
Chiral HPLC chart of epi-158 (98% ee) 
CHIRALPAK AD-H, 250×4.6 mm, UV 210 nm, EtOH/hexane 1:1 (v/v), 1.0 mL/min 
 
 
 
 
 
 
 
 
 
(3aR,10aS,10bR)-Octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (48) and 
(3aR,10aR,10bR)-octahydro-2H-furo[3,2-c]pyrrolo[1,2-a]azepine-2,8(1H)-dione (epi-48) 
Trimethylsilyl trifluoromethanesulfonate (TMSOTf; 360 L, 2.0 mmol, 20 mol%) was added to a mixture 
of NaH (63% in mineral oil, 570 mg, 15 mmol, 1.5 equiv), tetrabutylammonium iodide (369 mg, 999 
No. TR Area Height Area (%) 
1 16.81 273165 6184 49.7531 
2 25.49 275876 3897 50.2469 
No. TR Area Height Area (%) 
1 11.28 5093292 198311 99.1763 
2 15.88 42304 1596 0.8237 
No. TR Area Height Area (%) 
1 10.51 1555834 66392 49.7829 
2 14.77 1569405 48490 50.2171 
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mol, 10 mol%) and DMF (100 mL) at room temperature. After stirring for 10 min at room temperature, 
the resulting mixture was cooled to 0 °C. A solution of secondary lactams 158 and epi-158 (2.90 g, 
158:epi-158 = 3.7:1, 9.99 mmol, 1.0 equiv) and DMF (90 mL) was added to the mixture at 0 °C via 
cannula. The reaction mixture was stirred for 6 h, quenched with aqueous 1 M HCl (100 mL), and stirred 
for 30 min. Then, solid LiCl was added to the mixture until the mixture was saturated. The resulting 
mixture was filtered and extracted with CHCl3 (6 x 100 mL). The combined organic extracts were dried 
over Na2SO4, and concentrated. The remaining DMF was azeotropically removed with toluene. The 
residue was filtered through a pad of silica gel (EtOAc/MeOH 9:1), and then purified by MPLC (Yamazen 
Ultra Pack Column D, 26×300 mm, EtOAc/MeOH 85:15, 45 mL/min) to give 1.19 g of desired tricyclic 
compound 48 (57%) and 393 mg of undesired tricyclic compound epi-48 (19%); tricyclic compound 48: 
a colorless oil; []𝐷
21 = –122.9 (c 1.0, CHCl3); IR (film) 2937, 1776, 1681, 1418, 1185, 1015 cm−1; 1H 
NMR (500 MHz, CDCl3) δ 4.29 (ddd, J = 10.3, 10.3, 2.9 Hz, 1H), 4.18–4.12 (m, 1H), 3.99 (ddd, J = 10.6, 
6.3, 6.3 Hz, 1H), 2.85 (dddd, J = 12.6, 10.3, 8.6, 6.3 Hz, 1H), 2.71–2.63 (m, 1H), 2.65 (dd, J = 17.5, 8.6 
Hz, 1H), 2.51 (dd, J = 17.5, 12.6 Hz, 1H), 2.45–2.37 (m, 3H), 2.07 (dddd, J = 12.0, 6.3, 5.7, 4.0 Hz, 1H), 
1.91-1.81 (m, 1H), 1.71 (dddd, J = 12.0, 10.9, 10.6, 10.6 Hz, 1H), 1.63–1.49 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ 174.8 (C), 174.1 (C), 79.9 (CH), 56.1 (CH), 44.9 (CH), 40.2 (CH2), 34.6 (CH2), 31.1 
(CH2), 30.6 (CH2), 25.5 (CH2), 22.7 (CH2); HRMS (ESI), calcd for C11H16NO3+ (M+H)+ 210.1130, found 
210.1128. tricyclic compound epi-48: a white solid; []𝐷
20 = 30.3 (c 1.0, CHCl3); mp 114–115 °C; IR 
(film) 2936, 2870, 1773, 1683, 1290, 1201 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.36 (ddd, J = 10.9, 9.7, 
5.4 Hz, 1H), 3.84 (ddd, J = 14.6, 10.0, 3.2 Hz, 1H), 3.54 (ddd, J = 9.2, 7.5, 7.2 Hz, 1H), 3.18 (ddd, J = 
14.6, 8.9, 3.4 Hz, 1H), 2.64 (dd, J = 16.0, 6.9 Hz, 1H), 2.52–2.25 (m, 5H), 2.20 (dddd, J = 12.9, 8.6, 7.2, 
4.3 Hz, 1H), 1.93–1.81 (m, 2H), 1.75 (dddd, J = 13.2, 10.9, 7.2, 5.7 Hz, 1H), 1.65 (dddd, J = 12.9, 9.5, 
9.5, 7.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 174.5 (C), 174.1 (C), 83.4 (CH), 61.0 (CH), 48.8 (CH), 
40.5 (CH2), 33.1 (CH2), 30.5 (CH2), 30.3 (CH2), 24.3 (CH2), 22.3 (CH2); HRMS (ESI), calcd for 
C11H16NO3+ (M+H)+ 210.1130, found 210.1133. 
 
 
Stemoamide (1) 
n-Butyllithium (1.55 M in hexane, 4.4 mL, 6.8 mmol, 1.2 equiv) was added to a solution of (Me3Si)2NH 
(1.4 mL, 6.7 mmol, 1.2 equiv) and THF (7 mL) at –78 °C. The solution was maintained for 15 min at –
78 °C. The solution of LiN(TMS)2 was added to a solution of tricyclic compound 48 (1.19 g, 5.69 mmol, 
1.0 equiv) and THF (50 mL) via cannula at –78 °C. The resulting white suspension was allowed to warm 
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to –40 °C, stirred for 1 h at –40 °C, and cooled to –78 °C. Methyl iodide (460 L, 7.4 mmol, 1.3 equiv) 
was then added dropwise to the solution at –78 °C. After stirring for 15 min at –78 °C, the mixture was 
allowed to warm to room temperature. After stirring for 2 h at room temperature, the mixture was 
quenched with aqueous 1 M HCl (30 mL). The organic layer was separated, and the aqueous layer was 
extracted with CHCl3 (5 x 50 mL). The combined organic extracts were dried over Na2SO4, and 
concentrated. The residue was purified by silica gel column chromatography (EtOAc/MeOH 1:0 to 19:1) 
to give 1.07 g of (–)-stemoamide (1: 84%): a white solid; []𝐷
20 = –213.1 (c 0.5, MeOH) [lit. []𝐷
26 181 
(c 0.89, MeOH)2a, []𝐷
30 219.3 (c 0.5, MeOH)2b, []𝐷
25 183.5 (c 1.36, MeOH)2c, []𝐷
25 191.6 (c 0.5, 
MeOH)2d]; mp 190–191 °C; [lit. mp 190–191 °C,2a mp 187–188 °C,2b mp 186–187 °C,2c mp 185–
186 °C2d]; IR (film) 2932, 1762, 1683, 1425, 1193, 998 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.20 (ddd, J 
= 10.3, 10.3, 2.9 Hz, 1H), 4.19-4.13 (m, 1H), 3.99 (ddd, J = 10.9, 6.3, 6.3 Hz, 1H), 2.69–2.62 (m, 1H), 
2.60 (dq, J = 12.3, 6.9 Hz, 1H), 2.45–2.36 (m, 4H), 2.08–2.01 (m, 1H), 1.91–1.81 (m, 1H), 1.71 (dddd, J 
= 12.0, 10.9, 10.9, 10.9 Hz, 1H), 1.59–1.49 (m, 2H), 1.31 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
δ 177.5 (C), 174.1 (C), 77.7 (CH), 55.9 (CH), 52.7 (CH), 40.2 (CH2), 37.4 (CH), 34.8 (CH2), 30.7 (CH2), 
25.7 (CH2), 22.6 (CH2), 14.1 (CH3); HRMS (ESI), calcd for C12H18NO3+ (M+H)+ 224.1287, found 
224.1287. 
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A-2. Total Syntheses of Saxorumamide (2) and Isosaxorumamide (3) 
 
Saxorumamide (2), isosaxorumamide (3), 11-epi-saxorumamides (166 and 167) 
Diisobutylalminium hydride (1 M in hexane, 120 L, 120 mol, 3.0 equiv) was added to a solution of 
stemoamide (1: 8.9 mg, 40 mol, 1.0 equiv) and CH2Cl2 at –78 °C. The resulting solution was maintained 
for 1 h at –78 °C, and quenched with aqueous saturated (+)-potassium sodium tertrate (10 mL). The 
mixture was vigorously stirred for 1 h, extracted with CHCl3 (3 x 10 mL). The combined organic extract 
was washed with brine (20 mL), dried over Na2SO4, and concentrated. The crude lactol 165 was used in 
the next reaction without further purification. For analytical sample, the crude mixture was purified by 
silica gel column chromatography (EtOAc/MeOH 1:0 to 9:1) to give two diastereomers of lactol 165 (dr 
= 1.1:1); a colorless oil; 1H NMR (500 MHz, CDCl3, 1.1:1 mixture of C11-diastereomers) 5.25 (d, J = 
4.6 Hz, 1/2H), 5.11 (d, J = 3.4 Hz, 1/2H), 4.09–4.02 (m, 3/2H), 3.95–3.87 (m, 2/2H), 3.83 (ddd, J = 10.3, 
2.3, 2.3 Hz, 1/2H), 2.70–2.58 (m, 2/2H), 2.42 (ddd, J = 12.3, 9.7, 6.9 Hz, 1/2H), 2.40–2.31 (m, 4/2H), 
2.23–2.13 (m, 2/2H), 2.13–2.05 (m, 2/2H), 2.05–1.97 (m, 2/2H), 1.94 (dddd, J = 12.3, 6.3, 6.3, 2.3 Hz, 
1/2H), 1.84 (dddd, J = 12.0, 10.6, 10.6, 10.6 Hz, 1/2H), 1.78–1.70 (m, 2/2H), 1.65 (dddd, J = 12.0, 10.6, 
10.6, 10.6 Hz, 1/2H), 1.58–1.37 (m, 4/2H), 1.13 (d, J = 6.9 Hz, 3/2H), 1.06 (d, J = 6.6 Hz, 3/2H). 
    Boran trifluoride diethylether complex (25 L, 200 mol, 5.0 equiv) was added to a solution of lactol 
165 and 2-siloxyfuran 73 (36 L, 120 mol, 3.0 equiv), and CH2Cl2 (1.3 mL) at room temperature. After 
stirring for 36 h, the reaction mixture was quenched with aqueous saturated NaHCO3 (5 mL) and extracted 
with CHCl3 (4 x 10 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The 
residue was purified by silica gel column chromatography (EtOAc/MeOH 19:1 to 9:1) to give 5.9 mg of 
a mixture of four diastereomers 2, 3, 166, and 167 (2:3:166:167 = 25:19:32:24). For analytical samples, 
four diastereomers were separated by HPLC (PEGASIL Silica 120-5, 250×10 mm, EtOAc/MeOH 4:1, 10 
mL/min, an inseparable mixture of 3 and 166: TR = 12.3 min, 2: TR = 13.4 min, 167: TR = 18.4 min). The 
spectral data of saxorumamide (2) and isosaxorumamide (3) are reported in page 124. 11-epimer 166: 1H 
NMR (500 MHz, CDCl3, an inseparable mixture of 166 and 3, peaks of 166 were reported)  7.28 (dq, J 
= 1.7, 1.4 Hz, 1H), 4.76 (ddq, J = 9.2, 1.7, 1.7 Hz, 1H), 4.13–4.06 (m, 1H), 3.98 (ddd, J = 10.6, 6.3, 6.3 
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Hz, 1H), 3.72 (ddd, J = 10.3, 2.9, 2.9 Hz, 1H), 3.59 (dd, J = 9.2, 7.5 Hz, 1H), 2.68–2.61 (m, 1H), 2.48 
(ddq, J = 9.5, 7.2, 7.2 Hz, 1H), 2.42–2.31 (m, 2H), 2.26–2.19 (m, 1H), 2.15–1.99 (m, 2H), 1.93 (dd, J = 
1.7, 1.4 Hz, 3H), 1.81–1.62 (m, 2H), 1.55–1.33 (m, 2H), 1.23 (d, J = 7.2 Hz, 3H). 11-epimer 167: pale 
yellow crystals; []𝐷
23 = –37.9 (c 0.1, CHCl3); mp 193–194 °C; IR (film) 2925, 2855, 1756, 1667, 1455, 
1261, 1083, 802 cm−1; 1H NMR (500 MHz, CDCl3) 6.97 (dq, J = 1.7, 1.4 Hz, 1H), 4.89–4.86 (m, 1H), 
4.22 (dd, J = 8.3, 0.9 Hz, 1H), 4.07–4.01 (m, 1H), 3.92 (ddd, J = 10.9, 6.9, 6.3 Hz, 1H), 3.73 (ddd, J = 
10.2, 9.7, 2.9 Hz, 1H), 2.72–2.65 (m, 1H), 2.59–2.51 (m, 1H), 2.47 (ddd, J = 12.0, 9.7, 6.9 Hz, 1H), 2.42–
2.31 (m, 2H), 2.00–1.92 (m, 2H), 1.95 (dd, J = 1.7, 1.4 Hz, 3H), 1.74–1.60 (m, 2H), 1.45–1.29 (m, 2H), 
1.24 (d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) 174.7 (C), 174.1 (C), 146.7 (CH), 131.1 (C), 80.6 
(CH), 80.3 (CH), 80.0 (CH), 56.3 (CH), 51.3 (CH), 40.5 (CH2), 38.5 (CH), 35.1 (CH2), 31.0 (CH2), 25.9 
(CH2), 22.1 (CH2), 13.1 (CH3), 10.9 (CH3); HRMS (ESI), calcd for C17H24NO4+ (M+H)+ 306.1705, found 
306.1703. 
 
  
(3aR,10aS,10bR)-2-(5-(Tert-butyldimethylsilyl)-4-methylfuran-2-yl)-1-methyl-
3a,4,5,6,9,10,10a,10b-octahydro-8H-furo[3,2-c]pyrrolo[1,2-a]azepin-8-one (180) 
n-Butyllithium (1.64 M in hexane, 210 L, 340 mol, 1.5 equiv) was added to a solution of tert-
butyldimethyl(3-methylfuran-2-yl)silane 2133 (79 L, 340 mol, 1.5 equiv) and THF (1.1 mL) at –78 °C. 
The resulting solution was allowed to warm to 0 °C, stirred for 30 min at 0 °C, and re-cooled to –78 °C. 
The resulting solution of lithiated furan was added to a suspension of stemoamide (1, 51.0 mg, 228 mol, 
1.0 equiv) and THF (1.2 mL) via cannula at –78 °C. The resulting solution was maintained for 2 h at –
78 °C, quenched with aqueous saturated NH4Cl (5 mL), allowed to warm to room temperature, and stirred 
for 1 h. The mixture was extracted with CHCl3 (5 x 10 mL). The combined organic extracts were washed 
with brine (20 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 1:1 to 4:1) to give 79.5 mg of enol ether 180 (87%); a white solid; []𝐷
21 
= –137.8 (c 1.0, CHCl3); mp 132–133 °C; IR (film) 2929, 2858, 1689, 1419, 823, 731 cm−1; 1H NMR (500 
MHz, CDCl3) 6.28 (s, 1H), 4.25 (ddd, J = 12.0, 10.9, 2.6 Hz, 1H), 4.12–4.05 (m, 2H), 3.46 (ddq, J = 
12.0, 6.9, 1.7 Hz, 1H), 2.71 (ddd, J = 12.6, 12.6, 1.5 Hz, 1H), 2.42 (ddd, J = 16.9, 11.7, 8.9 Hz, 1H), 2.34 
(ddd, J = 16.9, 9.5, 1.7 Hz, 1H), 2.34–2.29 (m, 1H), 2.08 (s, 3H), 2.08–1.92 (m, 2H), 1.97 (d, J = 1.7 Hz, 
3H), 1.80–1.56 (m, 3H), 0.91 (s, 9H), 0.28 (s, 3H), 0.27 (s, 3H); 13C NMR (125 MHz, CDCl3) 174.7 (C), 
154.1 (C), 150.4 (C), 143.6 (C), 132.4 (C), 111.5 (CH), 105.5 (C), 81.0 (CH), 56.9 (CH), 56.7 (CH), 40.5 
(CH2), 34.1 (CH2), 30.9 (CH2), 26.5 (CH3), 25.3 (CH2), 21.2 (CH2), 18.0 (C), 11.4 (CH3), 10.6 (CH3),    
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–5.7 (CH3); HRMS (ESI), calcd for C23H36NO3Si+ (M+H)+ 402.2464, found 402.2460. 
 
 
(1S,2S,3aR,10aS,10bR)-2-(5-(Tert-butyldimethylsilyl)-4-methylfuran-2-yl)-1-methyldecahydro-8H-
furo[3,2-c]pyrrolo[1,2-a]azepin-8-one (182) 
Dichloroacetic acid (44L, 540 mol, 5.0 equiv) was added to a solution of enol ether 180 (42.6 mg, 106 
mol, 1.0 equiv), sodium cyanoborohydride (33.1 mg, 527 mol, 5.0 equiv) and CH2Cl2 (11 mL) at –
78 °C. The resulting suspension was stirred for 14 h at –78 °C, quenched with saturated aqueous NaHCO3 
(10 mL), and extracted with CHCl3 (2 x 10 mL). The combined organic extracts were washed with brine 
(10 mL), dried over Na2SO4, and concentrated. The residue was purified by silica gel column 
chromatography (EtOAc/hexane 2:1 to 1:0) to give 40.5 mg of furan 182 (95%); a white solid; []𝐷
23 = 
–108.2 (c 1.0, MeOH); mp 111–112 °C; IR (film) 2930, 2856, 1692, 1459, 1420, 824 cm−1; 1H NMR (500 
MHz, CDCl3) 6.13 (s, 1H), 4.56 (d, J = 9.2 Hz, 1H), 4.11–4.06 (m, 1H), 4.01–3.95 (m, 1H), 3.95 (ddd, 
J = 10.6, 6.3, 6.3 Hz, 1H), 2.65 (dd, J = 12.8, 12.8 Hz, 1H), 2.43 (ddq, J = 13.2, 9.2, 6.6 Hz, 1H), 2.40–
2.35 (m, 2H), 2.21–2.14 (m, 2H), 2.05 (s, 3H), 2.03–1.95 (m, 1H), 1.82–1.71 (m, 2H), 1.52–1.40 (m, 2H), 
1.07 (d, J = 6.6 Hz, 3H), 0.88 (s, 9H), 0.23 (s, 6H); 13C NMR (125 MHz, CDCl3) 174.3 (C), 157.2 (C), 
153.5 (C), 132.1 (C), 111.0 (CH), 81.0 (CH), 79.2 (CH), 56.4 (CH), 55.7 (CH), 41.2 (CH), 40.6 (CH2), 
36.2 (CH2), 31.0 (CH2), 26.5 (CH3), 26.0 (CH2), 22.4 (CH2), 17.9 (C), 15.5 (CH3), 11.5 (CH3), –5.6 (CH3), 
–5.7 (CH3); HRMS (ESI), calcd for C23H38NO3Si+ (M+H)+ 404.2621, found 404.2619. 
 
NOESY experiment for 182 
 
182 (500 MHz, CDCl3)  
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Saxorumamide (2) and Isosasorumamide (3) 
mChloroperbenzoic acid (69~75 wt% containing H2O, 9.4 mg, 38 mol, 1.2 equiv) was added to a solution 
of furan 182 (9.8 mg, 24 mol, 1.0 equiv) and CH2Cl2 (3.3 mL) at room temperature. The resulting mixture 
was stirred for 2 h at room temperature, filtered through a pad of silica gel (EtOAc/Hexane 1:1 to 1:0), 
and concentrated. The residue was dissolved in THF (3.3 mL), and cooled to –40 °C. Tetrabutylammonium 
fluoride (94 L, 94mol, 3.0 equiv) was added to the solution at –40 °C. After stirring for 30 min at –
40 °C, AcOH (5 L, 90 mol, 3 equiv) and NaBH4 (6.1 mg, 160 mol, 5.0 equiv) were added to the 
solution at –40 °C. The resulting solution was stirred for 30 min, quenched with aqueous 1 M HCl (5 mL), 
and extracted with CHCl3 (4 x 10 mL). The combined organic extracts were dried over Na2SO4, and 
concentrated. The residue was purified by preparative layer chromatography (EtOAc/MeOH 9:1) to give 
4.5 mg of saxorumamide (2: 46%) and 3.8 mg of isosaxorumamide (3: 39%). saxorumamide (2): a white 
amorphous solid; []𝐷
22 = –107.3 (c 0.35, MeOH); IR (film) 3294, 2939, 2872, 1755, 1646, 1461, 1074 
cm−1; 1H NMR (500 MHz, CDCl3)  7.00 (dq, J = 1.7, 1.7 Hz, 1H), 4.93 (ddq, J = 2.3, 1.7, 1.7 Hz, 1H), 
4.08 (ddd, J = 14.3, 2.9, 2.9 Hz, 1H), 3.92 (ddd, J = 10.6, 6.3, 6.3 Hz, 1H), 3.86 (dd, J = 8.6, 2.3 Hz, 1H), 
3.78 (ddd, J = 10.3, 10.3, 2.9 Hz, 1H), 2.60 (ddd, J = 13.9, 12.3, 1.2 Hz, 1H), 2.43–2.33 (m, 3H), 2.15–
2.06 (m, 2H), 2.00 (dddd, J = 12.3, 6.3, 6.3, 2.9 Hz, 1H), 1.95 (dd, J = 1.7, 1.7 Hz, 3H), 1.83–1.69 (m, 
2H), 1.47–1.32 (m, 2H), 1.14 (d, J = 6.6 Hz, 3H); 13C NMR (125 MHz, CDCl3)  174.6 (C), 174.3 (C), 
146.0 (CH), 131.3 (C), 83.7 (CH), 80.3 (CH), 80.2 (CH), 56.3 (CH), 55.2 (CH), 40.6 (CH2), 37.8 (CH), 
36.1 (CH2), 30.9 (CH2), 25.9 (CH2), 22.6 (CH2), 16.0 (CH3), 11.0 (CH3); HRMS (ESI), calcd for 
C17H24NO4+ (M+H)+ 306.1705, found 306.1700. isosaxorumamide (3): a white amorphous solid; []𝐷
22 
= –59.7 (c 0.13, MeOH); IR (film) 3296, 2933, 2872, 1757, 1682, 1456, 1072, 1043, 754 cm−1; 1H NMR 
(500 MHz, CDCl3)  7.17 (dq, J = 1.7, 1.7 Hz, 1H), 4.80 (ddq, J = 6.9, 1.7, 1.7 Hz, 1H), 4.12–4.06 (m, 
1H), 3.92 (ddd, J = 10.6, 6.0, 6.0 Hz, 1H), 3.88 (ddd, J = 10.0, 10.0, 2.9 Hz, 1H), 3.52 (dd, J = 8.0, 6.9 
Hz, 1H), 2.62 (ddd, J = 13.8, 12.0, 1.2 Hz, 1H), 2.38 (dd, J = 10.6, 4.6 Hz, 2H), 2.19–2.08 (m, 3H), 2.06–
1.99 (m, 1H), 1.94 (dd, J = 1.7, 1.7 Hz, 3H), 1.81–1.61 (m, 2H), 1.50–1.35 (m, 2H), 1.14 (d, J = 6.0 Hz, 
3H); 13C NMR (125 MHz, CDCl3)  174.2 (C), 174.1 (C), 147.3 (CH), 130.9 (C), 85.7 (CH), 83.1 (CH), 
79.8 (CH), 56.0 (CH), 55.7 (CH), 40.5 (CH2), 39.8 (CH), 36.1 (CH2), 31.0 (CH2), 26.0 (CH2), 22.7 (CH2), 
16.7 (CH3), 10.9 (CH3); HRMS (ESI), calcd for C17H24NO4+ (M+H)+ 306.1705, found 306.1710. 
 
*The optical rotations for natural samples of saxorumamide (2) and isosaxorumamide (3) were reported 
as []𝐷
20 = –15.4 (c 0.35, MeOH) and []𝐷
20 = –152 (c 0.13, MeOH), respectively.4 Unfortunately, 1H 
NMR spectra of their natural samples apparently contain impurities, see their supporting information. 
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A-3. Total Synthesis of Stemonine (4) 
 
14,15-Dehydrostemonine (197) and 13-epi-14,15-dehydrostemonine (epi-197) 
1,1,3,3-Tetramethyldisiloxane (24 μL, 130 μmol, 1.5 equiv) was added to a mixture of stemoamide (1, 
19.9 mg, 89.1 μmol, 1.0 equiv), IrCl(CO)(PPh3)2 (0.7 mg, 0.9 μmol, 1 mol %) and toluene (6.0 mL), which 
was kept in water bath at 20 °C. The resulting solution was stirred for 1 h at 20 °C. Then, MeCN (30 mL) 
and triisopropyl((3-methylfuran-2-yl)oxy)silane 735 (75 μL, 250 μmol, 2.8 equiv) and 2-nitrobenzoic acid 
(75.0 mg, 449 μmol, 5.0 equiv) were added to the solution at 20 °C. After stirring for 24 h at 20 °C, the 
solution was acidified with aqueous 0.05 M HCl (10 mL). The mixture was extracted with aqueous 0.05 
M HCl (3 x 10 mL). The combined extracts were basified with aqueous saturated NaHCO3 (10 mL), and 
extracted with CHCl3 (3 x 30 mL). The combined organic extracts were dried over Na2SO4, and 
concentrated. The residue was purified by preparative layer chromatography (EtOAc) to give 11.6 mg of 
197 (43%) and 8.3 mg of epi-197 (30%): 14,15-dehydrostemonine (197): a white solid; []𝐷
23 = –202.3 
(c 1.0, MeOH); mp 64–65 °C; IR (film) 2934, 2873, 1759, 1456, 1359, 1324, 1185, 1007, 729 cm−1; 1H 
NMR (500 MHz, CDCl3) δ 6.99 (qd, J = 1.6, 1.4 Hz, 1H), 4.84–4.79 (m, 1H), 4.20 (ddd, J = 10.9, 10.3, 
3.7 Hz, 1H), 3.66–3.60 (m, 1H), 3.43–3.37 (m, 1H), 3.33 (ddd, J = 8.0, 6.6, 6.6 Hz, 1H), 2.92 (ddd, J = 
15.8, 10.6, 1.7 Hz, 1H), 2.42 (dq, J = 12.3, 6.9 Hz, 1H), 2.35–2.29 (m, 1H), 2.25 (ddd, J = 12.3, 10.3, 5.4 
Hz, 1H), 1.99–1.90 (m, 1H), 1.94 (dd, J = 1.6, 1.4 Hz, 3H), 1.87–1.79 (m, 1H), 1.63–1.50 (m, 4H), 1.41 
(dddd, J = 12.6, 12.3, 10.9, 5.4 Hz, 1H), 1.24 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 178.4 
(C), 174.2 (C), 146.5 (CH), 131.4 (C), 85.0 (CH), 79.1 (CH), 63.2 (CH), 58.3 (CH), 53.1 (CH), 46.5 (CH2), 
39.4 (CH), 34.5 (CH2), 27.3 (CH2), 26.8 (CH2), 21.4 (CH2), 14.1 (CH3), 10.9 (CH3); HRMS (ESI), calcd 
for C17H24NO4+ (M+H)+ 306.1705, found 306.1701. 13-epi-14,15-dehydrostemonine (epi-197): a 
colorless oil; []𝐷
23 = –83.7 (c 1.0, MeOH); IR (film) 2934, 2872, 1748, 1455, 1323, 1186, 1097, 1003, 
727 cm−1; 1H NMR (500 MHz, CDCl3) δ 7.01 (dq, J = 2.0, 1.7 Hz, 1H), 5.00–4.96 (m, 1H), 4.26 (ddd, J 
= 10.6, 10.6, 3.4 Hz, 1H), 3.58 (ddd, J = 9.5, 5.7, 5.7 Hz, 1H), 3.47 (ddd, J = 6.9, 6.9, 3.7 Hz, 1H), 3.13–
3.07 (m, 1H), 2.89 (ddd, J = 15.2, 11.5, 0.6 Hz, 1H), 2.43 (dq, J = 12.6, 6.9 Hz, 1H), 2.36–2.30 (m, 1H), 
2.20 (ddd, J = 12.6, 10.6, 5.7 Hz, 1H), 1.94 (dd, J = 2.0, 1.7 Hz, 3H), 1.84–1.75 (m, 2H), 1.63–1.35 (m, 
5H), 1.24 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 178.6 (C), 174.4 (C), 146.8 (CH), 131.2 (C), 
82.1 (CH), 79.0 (CH), 62.8 (CH), 57.9 (CH), 53.0 (CH), 46.0 (CH2), 39.7 (CH), 34.6 (CH2), 27.1 (CH2), 
24.6 (CH2), 23.3 (CH2), 14.2 (CH3), 11.0 (CH3); HRMS (ESI), calcd for C17H24NO4+ (M+H)+ 306.1705, 
found 306.1702. 
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NOESY experiment for 197 and epi-197 
 
197 and epi-197 (500 MHz, CDCl3)  
 
 
Isomerization of 13-epi-14,15-dehydrostemonine (epi-197) 
 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 5 L, 30 mol, 2 equiv) was added to a solution of epi-197 
(4.4 mg, 14.4 mol, 1.0 equiv) and CH2Cl2 (1 mL) at room temperature. After stirring for 3 h, the resulting 
solution was quenched with H2O (5 mL), and extracted with CHCl3 (3 x 5 mL). The combined organic 
extracts were washed with brine, dried over Na2SO4, and concentrated. The residue was purified with 
silica gel column chromatography (EtOAc/Hexane 2:1 to 1:0) to give 4.2 mg of 197 and epi-197 (95%, 
197: epi-197 = 1.2:1). 
 
 
Stemonine (4) 
Rhodium on alumina (5 wt%, 2.9 mg) was added to a solution of butenolide 197 (5.8 mg, 19 mol) and 
EtOH (1.0 mL). The flask was purged with hydrogen. The mixture was stirred under hydrogen atmosphere 
(1 atm) at room temperature for 3 h, filtered through a pad of Celite®, washed with EtOAc, and 
concentrated. The residue was filtered through a pad of basic alumina, and then purified with silica gel 
column chromatography (EtOAc/Hexane 2:1 to 1:0) to give 5.7 mg of stemonine (4) (98%): a white solid; 
[]𝐷
22 = –108.6 (c 0.2, acetone) [lit.6 []𝐷
21 81.1 (c 0.2, acetone)]; mp 53–54 °C; IR (film) 2934, 2874, 
1768, 1455, 1188, 1009, 729 cm−1; 1H NMR (500 MHz, CDCl3) δ 4.22 (ddd, J = 10.9, 10.0, 3.4 Hz, 1H), 
4.18 (ddd, J = 11.2, 7.5, 5.4 Hz, 1H), 3.68 (ddd, J = 11.7, 5.7, 5.2 Hz, 1H), 3.53 (dd, J = 15.8, 4.0 Hz, 1H), 
3.30 (ddd, J = 9.5, 7.5, 6.3 Hz, 1H), 2.89 (dd, J = 15.8, 11.2 Hz, 1H), 2.61 (ddq, J = 12.3, 8.6, 6.9 Hz, 1H), 
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2.42 (dq, J = 12.3, 6.9 Hz, 1H), 2.37 (ddd, J = 12.6, 8.6, 5.4 Hz, 1H), 2.35–2.29 (m, 1H), 2.26 (ddd, J = 
12.3, 10.0, 5.2 Hz, 1H), 1.95 (dddd, J = 13.1, 7.2, 6.3, 1.2 Hz, 1H), 1.85 (dddd, J = 11.7, 7.2, 7.2, 1.2 Hz, 
1H), 1.65 (ddddd, J = 14.9, 13.2, 11.2, 4.0, 1.7 Hz, 1H), 1.60–1.49 (m, 3H), 1.48–1.36 (m, 2H), 1.26 (d, J 
= 6.9 Hz, 3H), 1.24 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 179.6 (C), 178.5 (C), 83.4 (CH), 
79.1 (CH), 64.3 (CH), 58.8 (CH), 53.2 (CH), 46.5 (CH2), 39.4 (CH), 35.0 (CH), 34.54 (CH2), 34.49 (CH2), 
27.3 (CH2), 26.7 (CH2), 20.9 (CH2), 15.1 (CH3), 14.1 (CH3); HRMS (ESI), calcd for C17H26NO4+ (M+H)+ 
308.1862, found 308.1864. 
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B. Comparison of Synthetic Routes for Total Syntheses and Formal Syntheses of Stemoamides  
1. Enantioselective Total Synthesis 
group year starting material LLS total yield scale of stemoamide 
Williams 1994 
(R)-(–)-methyl-3-hydroxy-2-
methyl propionate 
25 steps 5.6% N/A 
Mori 1996 
(5S)-5-(hydroxymethyl)-2-
pyrrolidinone 
13 steps 8.3% 6.3 mg 
Jacobi 2000 
(5S)-5-(hydroxymethyl)-2-
pyrrolidinone 
7 steps 4.2% 18 mg 
Sibi 2004 
(5S)-5-(hydroxymethyl)-2-
pyrrolidinone 
14 steps 7.0% N/A 
Olivo 2006 succiniimide 13 steps <14.1%* 25 mg 
Somfai 2007 
(5S)-5-(hydroxymethyl)-2-
pyrrolidinone 
12 steps 19.6% 6.8 mg 
Honda 2011 
(5S)-5-(hydroxymethyl)-2-
pyrrolidinone 
9 steps 23.4% 32.2 mg 
Hong 2012 4-chlorobutanoyl chloride 12 steps 18.7% 24.7 mg 
Sato/Chida 2016 (+)-dimethyl L-tartrate 22 steps 2.2% 8.9 mg 
Sato/Chida 2017 ethyl 4-bromobutyrate 7 steps 19.2% 1.07 g 
* Yields of first three steps are not reported 
 
2. Racemic Total Synthesis 
group year starting material LLS total yield scale of stemoamide 
Narasaka 1996 4-Methyl-3-penten-2-one 14 steps 1.1% 12 mg 
Jacobi 1997 4-chlorobutanoyl chloride 7 steps 19.9% 438 mg 
Bates 2009 succinimide 11 steps 5.70% N/A 
Hong 2011 propargyl bromide 9 steps 30.1%** 166 mg 
Zhang, Qiu 2014 3-Methyl-2(5H)-furanone 7 steps 5.1% 24 mg 
** They originally counted the steps starting from 4-buromobutanal, which is not generally commercially 
available. 
  
 
130 
3. Enantioselective Formal Synthesis 
group Year starting material possible LLS 
Gurjar 2002 diacetone-D-glucose 22 steps 
Cossy 2006 2,4-pentanedione 11 steps 
Chavan 2012 (–)-methyl Pyroglutamate 18 steps 
 
4. Racemic Formal Synthesis 
group Year starting material possible LLS 
Cossy 2006 dihydrofuran 12 steps 
Rosales/Rodriguez-
Garcia/ Oltra 
2014 succinimide 6 steps 
Pilli 2015 TMS-siloxyfuran 6 steps 
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C. Comparison of Spectral Data with Natural Products 
Comparison of 1H NMR of saxorumamide (2) 
 
 our synthetic sample natural sample 
Proton 1H NMR (500 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) 
13 7.00 (qd, J = 1.7, 1.7 Hz, 1H) 6.99 (m, 1H) 
12 4.92 (ddq, J = 2.3, 1.7, 1.7 Hz, 1H) 4.96 (dd, J = 3.8, 2.0 Hz, 1H) 
5 4.08 (ddd, J = 14.3, 2.9, 2.9 Hz, 1H) 4.08 (dd, J = 14.0, 2.3 Hz, 1H) 
9a 3.92 (ddd, J = 10.9, 6.3, 6.3 Hz, 1H) 3.93 (m, 1H) 
11 3.86 (dd, J = 8.9, 2.3 Hz, 1H) 3.87 (dd, J = 8.8, 2.0 Hz, 1H) 
8 3.78 (ddd, J = 10.3, 10.3, 2.9 Hz, 1H) 3.78 (ddd, J = 13.0, 10.2, 2.7 Hz, 1H) 
5 2.60 (ddd, J = 13.8, 12.3, 1.2 Hz, 1H) 2.60 (dd, J = 14.0, 12.4 Hz, 1H) 
2, 10 2.43–2.33 (m, 3H) 2.38 (m, 1H), 2.37 (m, 2H) 
7, 9 2.15–2.06 (m, 2H) 2.12 (m, 1H), 2.10 (m, 1H) 
1 2.00 (dddd, J = 12.3, 6.3, 6.3, 2.9 Hz, 1H) 2.02 (m, 1H) 
16 1.95 (dd, J = 1.7, 1.7 Hz, 3H) 1.94 (dd, J = 1.7, 1.7 Hz, 3H) 
1, 6 1.83–1.69 (m, 2H) 1.77 (m, 1H), 1.74 (m, 1H) 
6, 7 1.47–1.32 (m, 2H) 1.42 (m, 1H), 1.38 (m, 1H) 
17 1.14 (d, J = 6.6 Hz, 3H) 1.10 (d, J = 6.6 Hz, 3H) 
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Comparison of 13C NMR of saxorumamide (2) 
 
 our synthetic sample natural sample 
Carbon 13C NMR (125 MHz, CDCl3) 13C NMR (100 MHz, CDCl3) 
3, 15 174.6 (C), 174.3 (C) 174.1 (C), 174.1 (C) 
13 146.0 (CH) 145.8 (CH) 
14 131.3 (C) 131.2 (C) 
11 83.7 (CH) 83.6 (CH), 
8, 12 80.3 (CH), 80.2 (CH) 80.1 (CH), 80.1 (CH) 
9a 56.3 (CH) 56.0 (CH) 
9 55.2 (CH) 55.1 (CH) 
5 40.6 (CH2) 40.4 (CH2) 
10 37.8 (CH) 37.6 (CH) 
7 36.1 (CH2) 36.0 (CH2) 
2 30.9 (CH2) 30.7 (CH2) 
6 25.9 (CH2) 25.8 (CH2) 
1 22.6 (CH2) 22.4 (CH2) 
17 16.0 (CH3) 15.9 (CH3) 
16 11.0 (CH3) 10.8 (CH3) 
 
  
 
133 
Comparison of 1H NMR of isosaxorumamide (3) 
 
 our synthetic sample natural sample 
Proton 1H NMR (500 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) 
13 7.17 (dq, J = 1.7, 1.7 Hz, 1H) 7.15 (t, J = 1.6 Hz, 1H) 
12 4.80 (ddq, J = 6.9, 1.7, 1.7 Hz, 1H) 4.78 (ddd, J = 6.9, 3.9, 1.8 Hz, 1H) 
5 4.12–4.06 (m, 1H) 4.08 (m, 1H) 
9a 3.92 (ddd, J = 10.6, 6.0, 6.0 Hz, 1H) 3.92 (m, 1H) 
8 3.88 (ddd, J = 10.0, 10.0, 2.9 Hz, 1H) 3.88 (m, 1H) 
11 3.52 (dd, J = 8.0, 6.9 Hz, 1H) 3.52 (dd, J = 7.9, 6.9 Hz, 1H) 
5 2.62 (ddd, J = 13.8, 12.0, 1.2 Hz, 1H) 2.62 (m, 1H) 
2 2.38 (dd, J = 10.6, 4.6 Hz, 2H) 2.38 (dd, J = 10.5, 4.4 Hz, 2H) 
7, 9, 10 2.19–2.08 (m, 3H) 2.15 (m, 1H), 2.12 (m, 1H), 2.12 (m, 1H) 
1 2.06–1.99 (m, 1H) 2.01 (m, 1H) 
16 1.94 (dd, J = 1.7, 1.7 Hz, 3H) 1.93 (dd, J = 1.9, 1.7 Hz, 3H) 
1, 6 1.81–1.61 (m, 2H) 1.75 (m, 1H), 1.70 (m, 1H) 
6, 7 1.50–1.35 (m, 2H) 1.42 (m, 1H), 1.40 (m, 1H) 
17 1.14 (d, J = 6.0 Hz, 3H) 1.13 (d, J = 8.0 Hz, 3H) 
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Comparison of 13C NMR of isosaxorumamide (3) 
 
 our synthetic sample natural sample 
Carbon 13C NMR (125 MHz, CDCl3) 13C NMR (100 MHz, CDCl3) 
3, 15 174.2 (C), 174.1 (C) 174.0 (C), 174.0 (C) 
13 147.3 (CH) 147.0 (CH) 
14 130.9 (C) 130.8 (C) 
11 85.7 (CH) 85.6 (CH) 
12 83.1 (CH) 82.9 (CH) 
8 79.8 (CH) 79.7 (CH) 
9a 56.0 (CH) 55.9 (CH) 
9 55.7 (CH) 55.6 (CH) 
5 40.5 (CH2) 40.4 (CH2) 
10 39.8 (CH) 39.7 (CH) 
7 36.1 (CH2) 36.0 (CH2) 
2 31.0 (CH2) 30.8 (CH2) 
6 26.0 (CH2) 25.9 (CH2) 
1 22.7 (CH2) 22.6 (CH2) 
17 16.7 (CH3) 16.5 (CH3) 
16 10.9 (CH3) 10.7 (CH3) 
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Comparison of 1H NMR of stemonine (4) 
 
 our synthetic sample Williams’ synthetic sample 
Proton 1H NMR (500 MHz, CDCl3) 1H NMR (400 MHz, CDCl3) 
8 4.22 (ddd, J = 10.9, 10.0, 3.4 Hz, 1H) 
4.24–4.12 (m, 2H) 
13 4.18 (ddd, J = 11.2, 7.5, 5.4 Hz, 1H) 
9a 3.68 (ddd, J = 11.7, 5.7, 5.2 Hz, 1H) 3.67 (dt, J = 10.1, 5.0, 5.0 Hz, 1H) 
5 3.53 (dd, J = 15.8, 4.0 Hz, 1H) 3.53 (dd, J = 15.9, 4.8 Hz, 1H) 
3 3.30 (ddd, J = 9.5, 7.5, 6.3 Hz, 1H) 3.33–3.27 (m, 1H) 
5 2.89 (dd, J = 15.8, 11.2 Hz, 1H) 2.88 (dd, J = 15.8, 11.1 Hz, 1H) 
15 2.61 (ddq, J = 12.3, 8.6, 6.9 Hz, 1H) 2.61 (ddq, J = 12.3, 8.4, 6.9 Hz, 
1H) 10 2.42 (dq, J = 12.3, 6.9 Hz, 1H) 
2.46–2.22 (m, 4H) 
14 2.37 (ddd, J = 12.6, 8.6, 5.4 Hz, 1H) 
7 2.35–2.29 (m, 1H) 
9 2.26 (ddd, J = 12.3, 10.0, 5.2 Hz, 1H) 
2 1.95 (dddd, J = 13.1, 7.2, 6.3, 1.2 Hz, 1H) 1.96–1.90 (m, 1H) 
1 1.85 (dddd, J = 11.7, 7.2, 7.2, 1.2 Hz, 1H) 1.88–1.81 (m, 1H) 
6 1.65 (ddddd, J = 14.9, 13.2, 11.2, 4.0, 1.7 Hz, 
1H) 1.69–1.30 (m, 6H) 1, 6, 14 1.60–1.49 (m, 3H) 
2, 7 1.48–1.36 (m, 2H) 
17 1.26 (d, J = 6.9 Hz, 3H) 1.26 (d, J = 7.1 Hz, 3H) 
12 1.24 (d, J = 6.9 Hz, 3H) 1.23 (d, J = 7.8 Hz, 3H) 
 
*The structure of stemonine was unambiguously determined by X-ray crystallographic analysis by 
Koyama and Oda in 1970.7 However, 1H and 13C NMR data of the natural sample were not reported. The 
Williams’ group compared with an authentic sample of stemonine, as well as 1H NMR, IR, and mass 
spectra of the natural product gifted by Yang Ye, Shanghai Institute of Materia Medica.6 
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Comparison of 13C NMR of stemonine (4) 
 
our synthetic sample Williams’ synthetic sample 
13C NMR (125 MHz, CDCl3) 13C NMR (100 MHz, CDCl3) 
179.6 (C) 179.5 (C) 
178.5 (C) 178.4 (C) 
83.4 (CH) 83.4 (CH) 
79.1 (CH) 78.9 (CH) 
64.3 (CH) 64.1 (CH) 
58.8 (CH) 58.5 (CH) 
53.2 (CH) 53.1 (CH) 
46.5 (CH2) 46.3 (CH2) 
39.4 (CH) 39.2 (CH) 
35.0 (CH) 34.9 (CH) 
34.54 (CH2) 
34.3 (CH2) 
34.49 (CH2) 
27.3 (CH2) 27.2 (CH2) 
26.7 (CH2) 26.6 (CH2) 
20.9 (CH2) 20.7 (CH2) 
15.1 (CH3) 14.9 (CH3) 
14.1 (CH3) 13.9 (CH3) 
 
*The structure of stemonine was unambiguously determined by X-ray crystallographic analysis by 
Koyama and Oda in 1970.7 However, 1H and 13C NMR data of the natural sample were not reported. 
The Williams’ group compared with an authentic sample of stemonine, as well as 1H NMR, IR, and 
mass spectra of the natural product gifted by Yang Ye, Shanghai Institute of Materia Medica.6  
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